Device for removing undesired matter, pathogens, and toxins from a fluid and human blood

Abstract

The present disclosure relates to a device for removing undesired matter, pathogens, and toxins from a fluid and human blood.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a Continuation-In-Part of U.S. patent application Ser. No. 18 / 182,647 filed Mar. 13, 2023 which claims the benefit to U.S. Provisional Application Ser. No. 63 / 319,889, filed Mar. 15, 2022, the contents of the applications cited in the CROSS REFERENCE TO RELATED APPLICATIONS are hereby incorporated by reference herein in their entirety.FIELD

[0002] The present disclosure relates to a device for removing undesired matter, pathogens, and toxins from a fluid and human blood.BACKGROUND

[0003] During the last five years the world's population has suffered a pandemic due to the COVID-19 virus. The virus continues to mutate and has now become an endemic which will persist in the future. In view of the evidence which has been presented in U.S. Congress by Representative Jim Jordan of Ohio on Jun. 29, 2021 which is shown in the following video entitled “Dr. Fauci Wasn't Square With Us,” see https: / / fb.watch / 9g_ofuA2Px / , and by Senator Rand Paul of Kentucky which is shown in the following video: “Rand Paul: Fauci, 15 Agencies KNEW About Wuhan's CORONAVIRUS Research-Interview,” by The Hill, Apr. 11, 2024, https: / / youtu.be / mqbeyB20b9M?si=0ZjSeuBT3Z83Ea28, and in particular, see Representative Paul Gosar's Facebook post on Jan. 10, 2022 entitled: “Jaw dropping report just dropped by Project Veritas. Never before seen military Documents obtained by #ProjectVeritas about Gain of Function . . . ” https: / / www.facebook.com / repgosar / videos / 459786482262168 / , the COVID-19 virus did not originate in nature, but rather was man-made, and Dr. Fauci, the National Institute of Health (NIH), and the company EcoHealth Alliance, were aware of this information in early 2020. The NIH has now admitted that it funded the gain of function research of EcoHealth Alliance and the Wuhan Lab's work in developing the COVID-19 virus, as shown in the following article and website: “NIH Admits to Funding Gain-of-Function Research in Wuhan, Says EcoHealth Violated Reporting Requirements,” by Caroline Downey, National Review, Oct. 21, 2021, https: / / news.yahoo.com / nih-admits-funding-gain-function-125103852.html, and also “Origins of COVID: A Historic Senate Showdown,” by John Leake, Jun. 19, 2024, https: / / open.substack.com / pub / petermcculloughmd / p / origins-of-covid-a-historic-senate?r=ry4ij&utm_campaign=post&utm_medium=web. “Hawley: ‘Bombshell’ Whistleblower Allegations Say That CIA Team Was Paid To Suppress COVID-19 Origins,” Senator Josh Hawley, Senate Hearing, Sep. 15, 2023, https: / / www.youtube.com / watch?v=XhBBAOodRJk&pp=ygUPam9zaCBoYXdsZXkgY2lh.

[0004] There is also considerable evidence to demonstrate and show that Dr. Fauci knew Dr. Peter Daszak who is the CEO of EcoHealth Alliance, and also Mr. Ralph S. Baric who many believe was involved in the creation of the COVID-19 virus, as shown and discussed in the following documents and videos: Why Aren't Daszak and Barid Arrested? by John Leake, May 7, 2024, https: / / petermcculloughmd.substack.com / p / why-arent-daszak-and-baric-arrested; “U.S. Scientists Proposed to Make Viruses with Unique Features of SARS-CoV-2 in Wuhan,” by Emily Kopp, Jan. 18, 2024, https: / / usrtk.org / covid-19-origins / scientists-proposed-making-viruses-with-unique-features-of-sars-cov-2-in-wuhan / ; “The French Connection: Moderna CEO Stephanie Bancel, the Wuhan Lab, and a Curious Gene Patent,” by John Leake, Oct. 28, 2022, https: / / open.substack.com / pub / petermcculloughmd / p / the-french-connection?r=14jb45&utm_campaign=post&utm_medium=web; “The Great SARS-CoV-2 Charade,” by John Leake, May 21, 2023, https: / / petermcculloughmd.substack.com / p / the-great-sars-cov-2-charade; “The Great SARS-CoV-2 Charade: Chapter II,” by John Leake, May 23, 2023, https: / / petermcculloughmd.substack.com / p / the-great-sars-cov-2-charade-chapter-e1e; “The Great SARS-CoV-2 Charade: Chapter III,” by John Leake, https: / / petermcculloughmd.substack.com / p / the-great-sars-cov-2-charade-chapter-4bf: “Inside the risky bat-virus engineering that links America to Wuhan,” MIT Technology Review, by Rowan Jacobsen, Jun. 29, 2021, https: / / www.technologyreview.com / 2021 / 06 / 29 / 1027290 / gain-of-function-risky-bat-virus-engineering-links-America-to-wuhan: “Why did Tony Fauci say under oath he barely knew top coronavirus scientist Ralph Baric—when in fact Fauci hosted a daylong 2013 meeting where Baric laid out his plans for risky research?”, by Alex Barenson, Apr. 12, 2024, https: / / alexberenson.substack.com / p / why-did-tony-fauci-say-under-oath; “Ten years ago, microbiologist Ralph Baric told Tony Fauci and the world he would make coronaviruses more lethal. Them—with Fauci's backing—he did,” by Alex Barenson, Apr. 15, 2024, https: / / alexberenson.substack.com / p / ten-years-ago-microbiologist-ralph / comments; “Military Documents About Gain of Function Contradict Fauci Testimony Under Oath,” Project Veritas, Jan. 10, 2022, https: / / www.projectveritas.com / news / military-documents-about-gain-of-function-contradict-fauci-testimony-under / ; “Major Joseph Murphy's Report,” Project Veritas, Jan. 10, 2022, https: / / www.projectveritas.com / news / military-documents-about-gain-of-function-contradict-fauci-testimony-under / ; “David Martin Presents Hard Evidence Showing COVID-19 Is A Man-Made Bioweapon,” by James Bailey, Feb. 17, 2021, https: / / z3news.com / w / david-martin-presents-evidence-corona-virus-manmade / , and, “Endonuclease Fingerprint Indicates a Synthetic Origin of SARS-CoV-2,” by Bruttel et al., Oct. 20, 2022, https: / / www.biorxiv.org / content / 10.1101 / 2022.10.18.512756v1; “Injuries Caused by COVID 19 Vaccines, Congressional Hearing Led by Marjorie Taylor-Greene,” Nov. 13, 2023, https: / / x.com / i / broadcasts / 1MnGnMVLYmoKO.

[0005] Patents on which Ralph S. Baric is a named inventor include: U.S. Pat. Nos. 6,593,111, 7,279,327, 7,618,802, 9,821,050, 9,884,895, 9,975,923, 10,053,493, 10,117,924, 10,870,682, 11,225,508, and 11,241,491; and, papers on which he is a named author include: “A SARS-like Cluster of Circulating Bat Coronaviruses Shows Potential for Human Emergence,” by Menachery et al. (which includes Baric and also co-author Zhengli-ni Shi of the Wuhan Lab also known as “batlady”), Nat. Med. 2015; 21(12): 1508-1513, Nov. 9, 2015, https: / / www.nature.com / articles / nm.3985; “Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice,” Rokx et al., May 16, 2007, https: / / pubmed.ncbi.nlm.nih.gov / 17507479 / ; “A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice,” Martinez et al., May 28, 2021, https: / / pubmed.ncbi.nlm.nih.gov / 33948590 / ; “Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies,” Zhu et al., Jul. 9, 2007, https: / / pubmed.ncbi.nlm.nih.gov / 17620608 / ; “Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis,” Gralinski et al., Oct. 9, 2018, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC6178621 / ; “Norovirus infectivity in humans and persistence in water.” Seitz et al., Aug. 19, 2011, https: / / pubmed.ncbi.nlm.nih.gov / 21856841 / (which shows that the spike protein can survive for years in water); “A simple strategy to assemble infectious RNA and DNA clones,” Curtis et al., 2021, https: / / pubmed.ncbi.nlm.nih.gov / 11774510 / ; and, “Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture,” Velthuis et al., Nov. 4, 2010, PLoS Pathog. 2010 November; 6(11): e1001176, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC2973827 / . One of the disturbing things about the last two named articles is that Mr. Ralph S. Baric discloses he not only knows how to make such viruses, but that he also knew that Zinc could block its reproduction, and members of the medical profession and American public were not told this by Dr. Fauci or Baric during the COVID-19 pandemic. The development of pathogens which constitute biological weapons is in violation of both U.S. and International Law. See the Biological Weapons Convention which prohibits the development and production of biological and toxic weapons, the Nuremberg Code of ethics relating to medical research, and also the Nuremberg Principle VI relating to “crimes against humanity.”

[0006] On Oct. 18, 2019, Event 201 was conducted with the support of the Bill & Melinda Gates Foundation at the John Hopkins Center For Health Security. The event was supposed to be a dress rehearsal about how to respond to a hypothetical future pandemic. However, it is now known that the COVID-19 virus was infecting people in Wuhan before December, 2019. For more information on Event 201, see PLANDEMIC 2: INDOCTORNATION full documentary, on Rumble. Aug. 18, 2020, https: / / rumble.com / v1mxliy-plandemic-2-indoctornation-full-documentary.html, and Event 201, Oct. 18, 2019: https: / / centerforhealthsecurity.org / event201 / ; and, the remarks of Robert F. Kennedy Jr., (RFK, Jr.) about who hosted and attended the meeting from China in the video: “RFK, Jr. on the Dress Rehearsal for the Covid-19 Epidemic at Event 201.” https: / / www.facebook.com / reel / 1001208377897379?fs=&s=TleQ9V&mibextid=0NULKw Attorney Robert F. Kennedy, Jr., is also the author of a relevant 480 page book entitled: “The Real Anthony Fauci, Bill Gates, Big Pharma, and the Global War on Democracy and Public Health,” published by Simon and Schuster, Nov. 16, 2021, which is a national best seller and available as an e-book through Google, Amazon, and Kindle, e.g., see the website: https: / / amazon.com / Real-Anthony-Fauci-Democracy-Childrens / dp / 1510766804. The Bill & Melinda Gates Foundation has been a contributor to the CDC and WHO. For more information about Bill Gates see: “Bill Gates—The Banned Video,” by StopWorld Control on Rumble, 2022, https: / / rumble.com / v1o6jmf-bill-gates-the-banned-video.html. See also RFK Jr.'s remarks in the following articles and videos: “Full Interview: Robert F. Kennedy, Jr. Talks to Tucker Carlson about Secret Service, Neocons, Assassinations, and More, Ep. 16,” Aug. 14, 2023, and in particular, see the discussion about Dr. Fauci and bioweapons at 33:30, https: / / www.realclearpolitics.com / video / 2023 / 08 / 14 / full_interview_robert_f_kennedyjr_talks__to_tucker_carlson_about_secret_service_neocons_assassinations.html; and, regarding the pharmaceutical companies not performing adequate testing of many vaccines, see the video: “RFK Unloads the Truth about Vaccine Safety on Live TV,” Congressman Chip Roy, Jul. 20, 2023, https: / / fb.watch / m2hOCctrQ- / ?mibextid=aytyXY.

[0007] In this regard, the European Union questioned a representative of Pfizer, J. Small, about whether the Pfizer vaccine had been tested for stopping transmission of the COVID-19 virus before being distributed and administered to members of the public, and her answer was no, e.g., see “Pfizer Did Not Know Whether Covid Vaccine Prevented Transmission Before Rollout,” by news.com.au, Oct. 11, 2022, https: / / youtu.be / mnxlxzxoZx0?si=am_dBn24ai-CY3Hw. It is also apparent that the so-called “vaccines” were in development before the DNA data relating to COVID-19 was provided by China. In this regard, Francesco Donato of Italy raised questions about how could it have been possible for the Pfizer COVID-19 “vaccine” to have been developed so quickly and for their clinical testing to have begun only three days after the Chinese government released the DNA data relating to the COVID-19 virus, e.g., see the “Press conference after Pfizer CEO Albert Bourla refused to answer in front of European Parliament.” by Cristian Terhes, Oct. 11, 2022, https: / / youtu.be / 2jTgDj7uiX8?si=ENTwil_JuMtPn33b.

[0008] In response to the COVID-19 pandemic, members of the executive and legislative branches of the United States Government, Dr. Fauci, the Center for Disease Control, the NIH, and companies in the pharmaceutical industry including Pfizer, Inc., Johnson & Johnson and their subsidiary Janssen Pharmaceuticals, and Moderna quickly developed so-called “vaccines.” Patents of Moderna, Inc. relating to their vaccine are provided on their website: https: / / www.modernatx.com / patents, and include: U.S. Pat. Nos. 8,664,194 B2, 8,999,380 B2, 9,868,692 B2, 10,064,959 B2, 10,266,485 B2, 10,442,756 B2, 10,577,403 B2, 10,702,600 B1, 10,703,789 B2, and 10,933,127 B2. A list of patents of Pfizer, Inc. relating to their COVID-19 vaccine can be found on the website: Pfizer and The Medicines Patent Pool (MPP), Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries, see access the agreement, Appendix 2: https: / / www.pfizer.com / news / press-release / press-release-detail / pfizer-and-medicines-patent-pool-mpp-sign-licensing; and in particular, see U.S. Pat. No. 11,351,149 B2 which is the patent that was licensed for their COVID-19 “vaccine” around the world, and also U.S. 20220017548 A1. The “vaccine” patents of BioNTech include: U.S. Pat. No. 10,729,785 B2, and U.S. 20190321458 A1, and the vaccine patent of Johnson & Johnson is disclosed in WO2021155323A1. Many of these “vaccines” and patents relate to the use of mRNA gene therapy which has a history of causing undesirable inflammatory responses in lab experiments with animals, and now many also believe in humans. Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Medicine in 2023 for their contributions in developing mRNA technology which are disclosed in the following patents: U.S. Pat. Nos. 8,748,089, 9,163,213 B2, 10,808,242 B2, U.S. 20180265848 A1, 20190153425 A1, U.S. 20190274968 A1, U.S. 20200030460 A1, U.S. 20210363172 A1, U.S. 20220218622 A1, U.S. 20220273820 A1, U.S. 20230248818 A1, U.S. 20230312713 A1, and U.S. 20240018486 A1.

[0009] However, the so-called “vaccines” which have been made by Pfizer and Moderna are not vaccines as most people familiar with the normal meaning of the word vaccine over the past 60 years would understand. Their so-called “vaccines” are forms of experimental synthetic gene therapy and are intended to reduce the severity of symptoms experienced when an individual becomes ill with the COVID-19 virus, but these so-called “vaccines” have not prevented individuals from getting ill or spreading the COVID-19 virus. Once again, a representative of Pfizer who testified before the European Union has admitted that their so-called “vaccine” was never even tested for this purpose before it was distributed for public use, e.g., see “European Union BLASTS Pfizer for Hiding Data,” by The Jimmy Dore Show, Oct. 20, 2022, https: / / youtu.be / vsbTeJOEMgo. In this regard, it is well known that many people who have been “vaccinated” have nevertheless become sick with COVID-19, and also communicated the virus to others including members of their own family, e.g., see the following article: “Israel fighting record breaking surge in Covid-19 cases despite high levels of vaccination, by Benedict Brook, Sep. 4, 2021, https: / / www.news.com.au / world / coronavirus / global / israel-fighting-record-breaking-surge-in-covid19-cases-despite-high-levels-of-vaccination / news-story / 3445287a9c46e8712574da2316bd3ee1.

[0010] The following link to the CDC website shows how it defined vaccines until late 2021 which provides the following definitions with the differences shown in red font below: https: / / www.cdc.gov / vaccines / vac-gen / imz-basics.htm.CDC Definitions of Vaccine and Vaccination 2015-2021

[0011] Immunity: Protection from an infectious disease. If you are immune to a disease, you can be exposed to it without becoming infected.

[0012] Vaccine: A product that stimulates a person's immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but some can be administered by mouth or sprayed into the nose.

[0013] Vaccination: The act of introducing a vaccine into the body to produce immunity to a specific disease.

[0014] Immunization: A process by which a person becomes protected against a disease through vaccination. This term is often used interchangeably with vaccination or inoculation.

[0015] An article entitled “The CDC Suddenly Changes the Definition of ‘Vaccine’ and ‘Vaccination’ discloses the CDC's recent changes to the definition of vaccine made on Sep. 1, 2021 which are shown in below: https: / / www.citizensjournal.us / the-cdc-suddenly-changes-the-definition-of-vaccine-and-vaccination / .CDC Definitions of Vaccine and Vaccination Sep. 1, 2021-Present

[0016] Immunity: Protection from an infectious disease. If you are immune to a disease, you can be exposed to it without becoming infected.

[0017] Vaccine: A preparation that is used to stimulate the body's immune response against diseases. Vaccines are usually administered through needle injections, but some can be administered by mouth or sprayed into the nose.

[0018] Vaccination: The act of introducing a vaccine into the body to produce protection from a specific disease.

[0019] Immunization: A process by which a person becomes protected against a disease through vaccination. This term is often used interchangeably with vaccination or inoculation.CDC Definition of Vaccination Pre-2015

[0020] Vaccination: Injection of a killed or weakened infectious organism in order to prevent the disease.

[0021] On Jun. 8, 2024, the 9th Circuit Court of Appeals Acknowledges Plaintiffs' Claim that COVID-19 mRNA injection is NOT a vaccine, but a therapeutic, e.g., see, “9th Circuit Court of Appeals Acknowledges Plaintiffs' Claim that COVID-19 mRNA Jab is NOT a Vaccine, But a Therapeutic,” by Jim Hoft, Jun. 8, 2024, https: / / www.thegatewaypundit.com / 2024 / 06 / breaking-9th-circuit-court-appeals-rules-mrna-covid / .

[0022] Unfortunately, the so-called “vaccines” for COVID-19 are experimental, and have not gone through the same rigorous and lengthy research and approval process that was conducted by the FDA, e.g., in the development of the polio vaccine. In this regard, some of the pharmaceutical companies have also been less than forthright about the testing of their so-called “vaccines,” as disclosed in this video entitled “Bombshell News: Pfizer Lied To You About Their Vaccine!”, by Charlie Kirk, Oct. 8, 2021, https: / / www.facebook.com / realCharlieKirk / videos / 415015263369913 / . Pfizer wished to keep all of its documents relating to the research and development of their “vaccine” sealed for 75 years, but a Court has ordered their release and the following website provides their document listing adverse reactions: https: / / phmpt.org / wp-content / uploads / 2021 / 11 / 5.3.6-postmarketing-experience.pdf. In summary, the so-called “vaccines” are not in reality vaccines as that word has been used and understood over the past 60 years, but the pharmaceutical companies have used the word which created a false impression and illusion in the public mind that they were being protected from becoming infected with and also incapable of spreading COVID-19.

[0023] The use of the word vaccine may also create an impression in the public mind that the pharmaceutical companies are indemnified by the U.S. Government and legally protected from liability for any possible injuries caused by their so-called “vaccine” products. On information and belief, the pharmaceutical industry contributes more money to members of congress than any other lobby in our nation. In 1986, members of the pharmaceutical industry lobbied to get the National Childhood Vaccine Injury Act passed which indemnifies and protects the pharmaceutical companies from being sued by members of the public for their products possibly causing vaccine related injuries. Instead, there is a little-known government program which is supposed to provide benefits to people who can prove they have been seriously injured by a vaccine, but this program rarely pays and has covered less than 50 claims over the last decade. Accordingly, whereas only two or three vaccines were typically administered to children in the United States during 1950-1960's, the number of scheduled vaccines has now increased to over 30, and in part, because the pharmaceutical companies can hide behind the National Childhood Vaccine Injury Act of 1986 with regards to the harm caused by vaccine injuries. For more information, see the webpage for the National Childhood Vaccine Injury Act of 1986: https: / / www.congress.gov / bill / 99th-congress / house-bill / 5546, and also the news video: “You can't sue Pfizer or Moderna if you have severe Covid vaccine side effects. The government likely won't compensate you for damages either” by CNBC, Dec. 17, 2020: https: / / www.cnbc.com / 2020 / 12 / 16 / covid-vaccine-side-effects-compensation-lawsuit.html, and also see the recent newspaper article entitled: “Vaccine Reaction Claims Stalled,” by Jeremy Olson, Minneapolis Star and Tribune, Sunday, Feb. 12, 2023, and the article: “Government Cheapskates: America Has Paid A Total Of $38,893 To Avalanche Of Covid Vaccine Injured Citizens,” by Jeffrey Jaxen, Mar. 29, 2024, https: / / thehighwire.com / editorial / government-cheapskates-America-has-paid-a-total-of-38893-to-avalanche-of-covid-vaccine-injured-citizens / .

[0024] In February, 2021, Health and Human Services Secretary Alex Azar invoked the Public Readiness and Emergency Preparedness (PREP) Act of 2005 which empowered him to provide legal protection to companies making or distributing critical medical supplies such as the so-called COVID-19 “vaccines” and treatments unless there is “willful misconduct” by the company and this protection will last until 2024. For more information, see the webpage for the PREP ACT of 2005: https: / / aspr.hhs.gov / legal / PREPact / Pages / default.aspx. According to Robert F. Kennedy, Jr., who is an attorney and familiar with the relevant body of law, one of the reasons why Dr. Fauci and certain pharmaceutical companies have pushed for having children vaccinated has to do with those companies wanting to thereby obtain a legal shield from possible future litigation.

[0025] Within the scientific and medical community, there are now growing concerns about the nature and contents of the so-called COVID-19 “vaccines.” In this regard, several different researchers have discovered the presence of matter and one or more substances in some of the so-called “vaccines” which have not been listed as ingredients or otherwise revealed to members of the public by the pharmaceutical companies. One of these substances and / or forms of matter has been identified as being a form of graphene such as graphene oxide or graphene hydroxide. It is possible that these substances were included as carriers, adjuvants, and / or as part of the lipid nanoparticles contained in some of the so-called “vaccines,” e.g., see the definition of an immunologic adjuvant which is provided on the following website: https: / / en.m.wikipedia.org / wiki / immunologic_adjuvant. Mercury had been used in the past as an adjuvant in vaccines before this practice was stopped because it was shown to be highly toxic, and instead aluminum nanoparticles have been used as adjuvants in vaccines for the last several decades. However, it is now believed that aluminum is also neurotoxic, e.g., see the book “How to End the Autism Epidemic,” by J. B. Handley, Sep. 19, 2018, https: / / www.amazon.com / How-Autism-Epidemic-J-B-Handley / dp / 1603588248, and the information provided in FIGS. 2.1 and 2.6 therein, which will be provided in an Information Disclosure Statement relating to this patent application, and the following video, Steve Kirsch: “We Can't Find an Autistic Kid Who Was Unvaccinated,” Jun. 29, 2023, Substack https: / / vigilantfox.news / p / steve-kirsch-we-cant-find-an-autistic. One of the main purposes of an adjuvant in a vaccine, as that word was defined prior to Sep. 1, 2021, was to cause an amplified response which is inflammatory in nature because this makes a relatively small payload in the form of a killed or otherwise neutralized pathogen go a long way towards causing an immune system response in an individual, and this also makes vaccines less expensive for pharmaceutical companies to make. However, in view of the undesirable side effects, members of the medical profession may wish to question this practice and suggest more constructive alternatives.

[0026] The following news sources, articles, and websites provide information relating to graphene substances: “Graphene Oxide: Introduction And Market News,” updated Apr. 7, 2024, https: / / www.graphene-info.com / graphene-oxide?amp; “Graphene Oxide: A Carrier For Pharmaceuticals And A Scaffold For Cell Interactions,” by Durán et al., 2015, https: / / pubmed.ncbi.nlm.nih.gov / 25579346; “Magnetic Graphene Oxide: Synthesis Approaches, Physiochemical Characteristics, And Biomedical Applications,” by He et al., 03-xx-2021, https: / / www.sciencedirect.com / science / article / pii / S0165993621000133; “Toxicity of Graphene-Family Nanoparticles: A General Review Of The Origins And Mechanisms,” by Ou et al., Oct. 31, 2016, https: / / particleandfibretoxicology.biomedcentral.com / articles / 10.1186 / s12989-016-0168-y; “Blood exposure to graphene oxide may cause anaphylactic death in non-human primates,” by Lin et al., 12-xx-2020, https: / / www.sciencedirect.com / science / article / pii / S1748013220300918; “Safety Assessment of Graphene-Based Materials: Focus on Human Health and the Environment,” by Fadell et al., Nov. 27, 2018, https: / / pubmed.ncbi.nlm.nih.gov / 30387986 / . The use of some form of graphene oxide in the “vaccines” is considered highly experimental. There are some indications that it can be associated with health risks, and the long-term effects of its presence in the human body are unknown. In this regard, the aforementioned graphene substances can be electrically conductive and responsive to magnetic fields. The following article shows the “Radio-Frequency Characteristics of Graphene Oxide,” by Kim et al., 11-xx-2010, https: / / www.researchgate.net / publication / 234845171_Radio-frequency_characteristics_of_graphene_oxide. The following link and its included videos show magnets sticking to the arms of different individuals at the site where they received their so-called “vaccine” shots: “Vaccine Induced Magnetism,” by Not On The BEEB, No date, https: / / www.notonthebeeb.co.uk / magnetism.

[0027] In the following interview and video with Dr. Zandre' Botha, the blood of a patient is shown under a microscope before and after receiving one of the so-called vaccines. The microscope of the blood sample taken afterwards shows evidence of rouleau, and also what appear to be nano structures and possibly graphene oxide which appears to move and self-assemble, e.g., see “Dr Zandre Botha Reveals Her HORRIFIC Findings After Examining Vaxxed Clients & Then Vials,” The Stew Peters Show, Oct. 12, 2021, https: / / www.bitchute.com / video / AAgOguFMp4Z2 / .

[0028] Karen Kingston, a former Pfizer employee also discusses the origins of the so-called “vaccines” and graphene oxide content, see “DEADLY SHOTS! Former Pfizer Employee Confirms Poison in COVID ‘Vaccine’,” by Stew Peters Network, 2021, https: / / rumble.com / vkgdq7-deadly-shots-former-pfizer-employee-confirms-poison-in-covid-vaccine.html. The late Dr. Andreas Noack was an expert on the subject of graphene oxide substances who sounded an alarm regarding their inclusion in the so-called “vaccines.” In this regard, he discussed that graphene oxide and / or graphene hydroxide is stronger than steel and harder than diamond. Further, he suggested that because these substances can be a single molecule in thickness the combination of their ultra-thin profile, strength, and hardness can make pieces of these substances behave like small razor blades if and when they are introduced into an individual's bloodstream, and so could then cause internal bleeding. As a result, he considered that well-conditioned athletes such as soccer players who do a lot of running and have elevated pulse rates could be at higher risk of suffering injury due to the so-called “vaccines.” The following link which was posted by Marlen Von Isny using Twitter on Nov. 28, 2021 shows four videos of Dr. Andreas Noack discussing the dangers of graphene oxide / graphene hydroxide: https: / / twitter.com / Marlenvonisny / status / 1464992732192067584?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1464992732192067584%7Ctwgr%5E%7Ctwcon%5Es1_c10&ref_url=https%3A%2F%2Fgetindianews.com%2Fwho-was-dr-andreas-noack-and-what-was-his-cause-of-death%2F; and also, “Nanoscale Razor Blades in Vaccine—Dr. Andreas Noack Europe's Leading Carbon Expert,” Nov. 28, 2021, by Blue Cat Media online, https: / / bluecat.media / nanoscale-razor-blades-in-vaccine-dr-andreas-noack-europes-leading-carbon-expert / . Other doctors and researchers have confirmed the presence of graphene oxide in the COVID-19 vaccines: “Detection Of Graphene In COVID19 Vaccines: Research Gate,” by Dr. Pablo Campra, University de Almeria, Micro-Raman Spectroscopy, November, 2021, which provides a pdf copy of his lab report: https: / / www.google.com / url?sa=i&source=web&cd=&ved=2ahUKEwjBsqfXtj1AhXCkYkEHYwBBbQQ3YkBegQIARAD&url=https%3A%2F%2Fwww.researchgate.net%2Fpublication%2F355979001_DETECTION_OF_GRAPHENE_IN_COVID19_VACCINES&psig=AOvVaw0Lkkrj99B6_XNgDzodJrR-&ust=1643045979701437. Further, also see the pdf copy of Dr. Robert Young's lab report which can be found with the article: “American Scientists Confirm Toxic Graphene Oxide, and More, in Covid Injections,” by Rhonda Wilson, Aug. 30, 2021, https: / / rightsfreedoms.wordpress.com / 2021 / 09 / 02 / american-scientists-confirm-toxic-graphene-oxide-and-more-in-covid-injections / . The following article discusses that Japan found metallic particles in the Moderna so-called “vaccines,” and returned 2,600,000 doses to the company: “What Japan found in the Moderna vials is likely to be graphene oxide,” by Fritz Iribar, Sep. 5, 2021, https: / / www.orwell.city / 2021 / 09 / japan.html, and “Japan Finds Black Particles In Moderna's Covid Jabs Days After 1.63 Million Doses Were Suspended,” by CRUX, Sep. 1, 2021, https: / / youtu.be / fXwhQtjV5uw. Also see: “In The Name Of Science: Nobel Prize Winning “Quantum Dots” Cause Irreversible Organ Toxicity To Living Organisms,” by Ana Maria Mihalcea, Jan. 2, 2024, https: / / open.substack.com / pub / anamihalceamdphd / p / in-the-name-of-science-nobel-prize?r=ry4ij&utm_campaign=post&utm_medium=web; “BOMBSHELL NEWS: Do We Still Need Proof? Next Dose 3: Documentary. Must Watch! Electron Microscope Of Nanotechnology Antennas In C19 Vaccinated blood,” by Ana Maria Mihalcea, Jan. 2, 2024, https: / / anamihalceamdphd.substack.com / p / bombshell-news-do-we-still-need-proof.

[0029] Given the findings of Dr. Zandre' Botha under the microscope, and the lab results of Dr. Pablo Campra who performed Micro-Raman Spectroscopy analysis of the Moderna, Pfizer, and Johnson & Johnson so-called “vaccines,” and also the lab results of Dr. Robert Young, it appears that some form of graphene oxide or graphene hydroxide is present in some of the COVID-19 “vaccines.” Some individuals have speculated that it was accidentally introduced during the manufacturing process. At this time, there are many unanswered questions with regards to what the aforementioned graphene substances can do when injected into an individual and patient. How much of the graphene material stays lodged in muscle tissue, and how much enters the bloodstream could depend on whether the injection hit or was proximate to a vein or artery. Does the graphene material migrate and then become lodged in other organs and tissues like the liver and kidneys? Does the graphene material migrate to areas associated with relatively high electrical activity in the body like the heart and brain? Would it be counterproductive to ingest substances which could possibly break down graphene oxide material into small bits which could potentially migrate and lodge in other areas of the body? Does graphene eventually break down and become eliminated? At this time, the answers to many of these questions are not known.

[0030] Senator Ron Johnson of Wisconsin held a Congressional Hearing on Jan. 24, 2020 which included a panel of doctors, researchers, and practitioners who discussed COVID-19, and it was then made clear by several members of the panel that the spike protein associated with the so-called “vaccines” does migrate from the injection site and into multiple human organs where they can cause health problems, e.g., see the testimony of Dr. Peter McCullough at 4:50 minutes in the Congressional Hearing, “Ron Johnson—Senate Hearing—COVID-19: A Second Opinion—Jan. 24, 2022,” by reedr6, https: / / youtu.be / asw_FBipVpg. The pharmaceutical companies have so far denied that graphene substances have been included in their so-called “vaccines.” In this regard, one can either choose to believe what some of the pharmaceutical companies have represented, or what microscopic examination and several other independent laboratory test results have shown.

[0031] If graphene oxide substances, and specific adjuvants are not recited in the relevant patents of the pharmaceutical companies, but they are in fact present in some of their so-called “vaccines” their patents could possibly be held to be invalid because of the pharmaceutical companies' failure to provide a full disclosure. Furthermore, the companies could possibly be held liable for “willful misconduct” by not listing or disclosing the substances to health officials and the general public, and / or later denying that those substances have been and continue to be present in their so-called “vaccines.” As a group, the pharmaceutical companies that made the COVID-19 so-called “vaccines” have not been transparent regarding the contents of their products, nor the findings of their research studies. As a result, the American people and medical doctors do not know what was contained in and known about the side-effects of the so-called “vaccines,” and this is a possible violation of the doctrine of informed consent. Further, despite numerous requests for information, even today members of Congress and the American public are being subjected to censorship at the hands of government agencies, e.g., “Watch: Rand Paul Decries HHS Efforts to Obscure His Document Request On Origin Of COVID-19,” by Forbes Breaking News, Mar. 20, 2024, https: / / youtu.be / 4_Qo8dHsgRk?si=o3VuxhFe4VANo0qD.

[0032] Why would someone want to place nanometals such as aluminum, or graphene oxide, or other conductors of electricity which are sensitive to the influence of electromagnetic fields, radio frequency (RF), and / or microwave radiation which includes 5G wireless communication into the bodies of the world's population? In brief, this practice can be associated with human body and brain hacking which sounds like science fiction, but which is now science fact. For a general introduction to this subject provided by the mainstream media, see, e.g., “Mission Mind Control (1979)” by ABC News, May 30, 2012, https: / / youtu.be / DMH5WgGFxlc?si=9l5fh3Z2XYGAJh2u, “America's Book of Secrets: Darpa's Secret Mind Control Technology (Season 4),” by the History Channel, Jul. 10, 2021, https: / / youtu.be / wZRkfBsTTt8?si=J07MSIDSCUP2Kg9u “Brain Hacking,” by 60 Minutes, Apr. 9, 2017, https: / / youtu.be / awAMTQZmvPE?si=-xwNBDrqrdueRj8O; “U.S. DARPA SMARTDUST,” by Soul.Revolutions, No Date, https: / / www.facebook.com / reel / 356341530422649; “The Effects of Pulsed Microwaved and Extra Low Frequency Electromagnetic Waves on Human Brains?,” by Mojmir Babacek, Nov. 10, 2023, https: / / nexusnewsfeed.com / article / health-healing / the-effects-of-pulsed-microwaves-and-extra-low-frequency-electromagnetic-waves-on-human-brains / ?fbclid=lwZXh0bgNhZW0CMTAAAR0gHG6HWg040D2XueN1mhlKIQVEEE3mLumeNH3A11gfOuYG5MWgRreFF7Qaem_Aami1PcyUOfckKcYBMVyHWY9AYjGHqcVrFK73RDWXR12bTw5GuS-JiixZEFsNf5VD9IleBaDne1aYznECoowxt2; and, EMERGENCY EPISODE: Ex-Google Officer Finally Speaks Out On The Dangers Of AI!—Mo Gawdat|E252, by the Diary of a CEO, Jun. 10, 2023, https: / / youtu.be / bk-nQ7HF6k4?si=9AQVk7YLCOhfVBED. The technology associated with brain hacking can be used to access, influence, and control human behavior. It has and continues to be studied and used by certain government agencies and the military. In this regard, e.g., see “Dr. Charles Morgan on Psycho-Neurobiology and War: CRISPR, technique used to make the Covid Vaccines,” Jun. 14, 2021, 8:53 minutes, https: / / youtu.be / FAnM9XhUdio?si=WOgcl67ZB6hTedZ8; and, Dr. Charles Morgan on “Psycho-Neurobiology and War,” Jun. 14, 2021, see the entire 55:44 minutes and in particular the charts and discussion at 2:43, 28:10 regarding CRISPER, 33:25 regarding stem cells, 35:30 DNA Encoding, and at 43:00 creating and manipulating false memories, https: / / youtu.be / cTtIPBPSv0U?si=Vbrw8N6hQkHFNhbJ. This kind of work relating to wireless communication and mind control has been going on since at least the 1960's. Here are several articles published or about Ross Adey who was a leading expert on this subject, also known as William Ross Adey, who some individuals also believe had the pseudo identity of Hendricus J. Loos: “Biological Effects of Electromagnetic Fields,” by Dr. W. Ross Adey, Apr. 1, 1994, https: / / onlinelibrary.wiley.com / doi / 10.1002 / jcb.2400510405; “William Ross Adey, Obituary,” by John Hanley, University of California, https: / / senate.universityofcalifornia.edu / _files / inmemoriam / html / williamrossadey.htm; “William Ross Adey, Obituary,” by Ivan Oransky, The Lancet, Jul. 17, 2004, https: / / www.thelancet.com / journals / lancet / article / PIIS0140-6736(04)16699-3 / fulltext; “Microwave News, Ross Adey (1922-2004),” May 20, 2004, https: / / microwavenews.com / news-center / ross-adey; “Two Years Ago—DARPA to Resurrect Top-Secret Pandora Project,” Feb. 22, 2017, https: / / inteltoday.org / 2019 / 02 / 22 / two-years-ago-darpa-to-resurrect-top-secret-pandora-project / . Here are the patents of Hendricus J. Loos relating to mind control: e.g., see U.S. Pat. No. 6,506,148, but also U.S. Pat. Nos. 5,782,874, 5,800,481, 5,899,922, 5,935,054, 6,017,302, 6,081,744, 6,091,944, and 6,238,333. Other patents relating to mind control include: U.S. Pat. Nos. 3,951,134, 11,684,304, and U.S. 20220273907 A1. Also see the recent patents by Microsoft and Bank of America which relate to using the body for powering location tracking chips, and other nanodevices for use with digital passports, e.g., U.S. Pat. Nos. 8,064,953, 11,553,311, and WO2020060606 A1. U.S. Pat. No. 11,107,588 relates to wirelessly tracking the location and scoring the health of individuals and / or patients. U.S. Pat. No. 10,786,570 assigned to Rockefeller University relates to wirelessly using nanometals for controlling portions of the endocrine system of the human body. U.S. Pat. No. 9,643,841 by Akyildiz et al. relates to the use of nanographene in future 6G and 7G communications. U.S. Pat. No. 11,801,394 by Norris et al. is entitled: “Systems and Methods of Covertly Creating Adverse Health Effects in Subjects.” U.S. Pat. No. 5,450,859 by Litovitz relates to the protection of living systems from adverse effects of electric, magnetic and electromagnetic fields.

[0033] What these articles, videos, and patents disclose is that it is possible to remotely cause physical events to take place in the human body, and that it is also possible to directly affect the brain and thoughts of sentient beings, that is, to effect mind control, using electric fields, magnetic fields, electromagnetic fields, sound, microwave, RF, and other forms of wireless communication. In this regard, some nanomaterials can function as antennas and be caused to self-assemble because in the presence of an electrical, magnetic, or electromagnetic field their positive and negative poles are attracted to one another and they behave like nanomagnets. The presence of nanometals like aluminum, gold, silver, iron, or electrically sensitive and responsive materials like nanographene, nanochips, nanobots, or other nanodevices when placed inside an individual's body can facilitate and make physical body and / or mind control objectives easier to accomplish. In this regard, if the information and video of Dr. Charles Morgan provided above is not enough to convince, then also see the video: “TRADOC Mad Scientist 2017 Georgetown: Neurotechnology in National Defense with Dr. Giordano,” Aug. 9, 2017, https: / / youtu.be / Ez4m_NqSRCU?si=g98KgRgcw-IY1CJE, and then see the charts and discussion presented at 9:30, 11:25, 18:00, and at 35:50 regarding nanoparticulate matter and causing a stroke; and then at 44:10 neural biohacking; and, “HDIAC Podcast—Weaponizing Brain Science: Neuroweapons—Part 1,” by Dr. James Giordano, Jun. 19, 2020, https: / / youtu.be / DA9QdslZoXs?si=VtYocFoffdNsWGf1; and, “Weaponizing Brain Science: Neuroweapons—Part 2,” by Dr. James Giordano, Jun. 25, 2020, https: / / youtu.be / vFgTmCchkKw?si=xxsQbwwmsCDksUtP; and, “The Battle for Your Mind: Neuroscience, Technology / AI & the OODA Loop w / James Giordano, PhD|Flow,” by AGLX, Aug. 1, 2023, https: / / youtu.be / 1cPWJfjXu7M?si=aqJPPRLeomiu1ei9; and see, “Neurotechnologies as Weapons in National Intelligence and Defense—An Overview,” by James Giordano and Rachel Wurzman, 2011, http: / / www.synesisjournal.com / vol2_no2_t1 / GiordanoWurzman_2011_2_1.pdf; and also see, “Dr. James Giordano: The Brain is the Battlefield of the Future, Lecture at West Point,” Oct. 29, 2018, see in particular the chart and discussion starting at 29:00 minutes, https: / / youtu.be / N02SK9yd60s?si=mwckL3sFZfbAqPSR; and, “Advanced Materials To Enable Wireless Brain-Machine Interface,” by Prannoy Suraneni, Prof. Sakhrat Khizroev, Apr. 28, 2021, https: / / youtu.be / r7LG2Es6YXU?si=pMU9Z8p1jWg2UQPf, and, the paper entitled: “Neurotechnology and International Security, Predicting Commercial and Military Adoption of Brain-Computer Interfaces (BCIs) in the United States and China,” by Margaret Kosal and Joy Putney, Politics and the Life Sciences, Spring 2023, Vol. 42, No. 1, pages 81-103, https: / / www.cambridge.org / core / journals / politics-and-the-life-sciences / article / neurotechnology-and-international security / 29155A74DBB0FDE5CB0CBA4D3DF6AF0C, and see also the cited references. Further, the following video is a leaked Pentagon briefing about the use of gene therapy for behavior modification. It shows evoked potentials in the brain of different individuals in response to key words and includes a discussion about putting and hiding gene therapy in flu shots that can make people, and in particular religious fundamentalists in the Middle East, or elsewhere, more docile: “Leaked Pentagon Video Shows Vaccine Designed to Modify Behavior,” Sep. 20, 2011, https: / / youtu.be / -gfTqfVeLHw_. This video was removed from YouTube for violating community standards, but can still be seen by going to the Internet Archive WaybackMachine website, http: / / wayback.archive.org / , and searching for the link, and then clicking on the capture made, e.g., on Mar. 2, 2016. Further, another copy of this video is still on Youtube and is entitled: “FunVax: Vaccine For Religious Fundamentalism,” by AngryHateMusic, Sep. 19, 2011, https: / / youtu.be / qmQwTinKKZ8?feature=shared. The identity of those individuals in attendance who asked questions could possibly be identified using voice recognition technology. During the presentation, numerous slides are shown and one includes the following information: DOD proj ID—149AZ2, Doc ID—FX36.879.AX.AZ2.17, Submission Date—Apr. 10, 2005, Submission ID—983459.4.05. In addition, see the articles: “How It All Fits Together: Covid, 5G, Nanotech, Transhumanism & Charles Lieber,” by Maryam Henein, Feb. 6, 2022, https: / / vaxxter.com / how-5g-it-all-fits-together-covid-nanotech-transhumanism-charles-lieber / ; “From Espionage to Tax Evasion_Charles Lieber Found Guilty On All Six Counts—The Tenpenny Report,” by Maryam Henein, Dec. 24, 2021, https: / / vaxxter.com / from-espionage-to-tax-evasion-charles-lieber-found-guilty-on-all-six-counts / ; “The Work of Allen H. Frey, by the Cellular Phone Task Force,” No Author, No Date, https: / / cellphonetaskforce.org / the-work-of-allan-h-frey / ; “Modification of Heart Function with Low Intensity Electromagnetic Energy,” by Allan Frey et al., 1986, https: / / www.researchgate.net / publication / 232083331_Modification_of_Heart_Function_with_Low_Intensity_Electromagnetic_Energy; “The Work of Dr. Leif Salford, by the Cellular Phone Task Force,” No Author, No Date, https: / / cellphonetaskforce.org / the-work-of-leif-salford / ; “Mobile-Phone Pulse Triggers Evoked Potentials,” by Carrubba et al., Jan. 18, 2010, https: / / www.sciencedirect.com / science / article / abs / pii / S0304394009015596?via%3Dihub; “Nanowire Brain Networks For Brain Computer Interface—Hydrogels To Create Tissue Engineered Electronic Nerve Interface For Artificial Memory & Nanotechnological Neuromodulation,” by Ana Maria Mihalcea, MD, PhD, May 5, 2024, https: / / anamihalceamdphd.substack.com / p / nanowire-brain-networks-for-brain?utm_source=profile&utm_medium=reader2.

[0034] At this time, few members of the medical profession are aware of the degree to which the field of medicine and vaccines have been potentially and / or actually weaponized. Accordingly, members of the medical profession need to be aware of the possible ramifications of unwittingly or not being used to inject nanomaterials and / or experimental gene therapy into human beings. In view of this information, a valid question can be raised as to whether and to what degree the creation of the COVID-19 virus and resulting pandemic, and unprecedented push to get the world's population “vaccinated” with an experimental form of gene therapy had as one of its objectives the accessing and hacking of human bodies and minds in present and future generations. Americans had never before experienced the kind of pressure to be vaccinated with so-called “vaccines” (which would not prevent the targeted illness nor prevent it from being transmitted), but also the censorship and economic hardship that was imposed during the COVID-19 pandemic. When a disease and the magnitude of the response to it are so out of proportion and don't make any sense, then perhaps it's because we have been looking at the wrong formula or equation, and the actual objectives are not those which have been represented to the American people.

[0035] Some members of the medical profession may be aware of the desire of members of the World Economic Forum (WEF), which typically includes some of the wealthiest individuals in the world, as well as the representatives of many national governments, to direct and control human behavior. This subject area is being called transhumanism and / or BioDigital Convergence. Here are links to four articles and / or publications by the WEF relating to this subject: “Navigating the Industrial Metaverse: A Blueprint for Future Innovation,” Mar. 12, 2024, https: / / www.weforum.org / publications / navigating-the-industrial-metaverse-a-blueprint-for-future-innovations / ; “Metaverse Identity: Defining the Self in a Blended Reality,” Apr. 12, 2024, https: / / www.weforum.org / publications / metaverse-identity-defining-the-self-in-a-blended-reality / ; “Davos 2023—Are you Ready for Brain Transparency?|World Economic Forum,” https: / / www.weforum.org / videos / davos-am23-ready-for-brain-transparency-english / ; “Global Risks Report 2024 / World Economic Forum,” Jan. 10, 2024, https: / / www.weforum.org / publications / global-risks-report-2024 / . Here are documents and websites on BioDigital Convergence by the governments of Canada and the United Kingdom: “Exploring Biodigital Convergence—Policy Horizons Canada,” Feb. 11, 2020, https: / / horizons.service.canada.ca / en / 2020 / 02 / 11 / exploring-biodigital-convergence / index.shtml; “Biodigital Today and Tomorrow,” May 31, 2022, https: / / horizons.service.canada.ca / en / 2022 / 05 / 31 / biodigital-today-and-tomorrow / index.shtml; “Canada at the Forefront of Exploring Biodigital Convergence,” Nov. 23, 2021, https: / / www.scc.ca / en / news-events / news / 2021 / canada-forefront-exploring-biodigital-convergence; “Human Augmentation—The Dawn of a New Paradigm—GOV.UK,” May 13, 2021, https: / / www.gov.uk / government / publications / human-augmentation-the-dawn-of-a-new-paradigm.

[0036] Other articles and videos which relate to the subject of transhumanism and BioDigital Convergence include: “Progress in Convergence: Basic Concepts and Applications,” by Mihail C. Roco, Aug. 17, 2017, https: / / www.nsf.gov / crssprgm / nano / reports / NNI_17-0817_Progress%20In%20Convergence-Basic%20Concepts%20and%20Applications_%40MexicoCity_MC%20Roco_45min_web.pdf; “Markov Model for the Flow of Nanobots in the Human Circulatory System,” by Gómez et al., Sep. 17, 2021, https: / / www.ccs-labs.org / bib / torres-gomez2021markov / torres-gomez2021markov.pdf; “Nanoscience Literature for Earth and Environmental Science,” Carleton University, Minnesota, Feb. 29, 2024, https: / / serc.carleton.edu / msu_nanotech / nano_topics.html; “Cyborgs R Us: The Bio-Nano Panopticon of Injected Bodies?”, by Kyrie et al., 10-xx-2022, https: / / www.researchgate.net / publication / 362694274_Cyborgs_R_Us_The_Bio-Nano_Panopticon_of_Injected_Bodies; “Smart Cities & Biodigital Convergence,” by Love Billy, https: / / www.biodigcon.com / , “52 pages; IEC SEG 12 Webinar Bio-Digital Convergence Standardization,” Yu et al., Feb. 8, 2022, https: / / www.iec.ch / dyn / www / f?p=103:186:507817984673502::::FSP_ORG_ID,FSP_LANG_ID:27 561,25; “Syllogistic Reasoning Demystifies Evidence of COVID-19 Vaccine,” by Broudy et al., Dec. 11, 2021, https: / / ijvtpr.com / index.php / UVTPR / article / view / 32; “IEC SEG 12 Webinar Bio-Digital Convergence Standardization,” by Frangois Coallier, 12-2022, https: / / www.iec.ch / dyn / www / f?p=103:186:507817984673502::::FSP_ORG_ID,FSP_LANG_ID:27 561,25; “Externally Controllable Molecular Communication,” by Nakano et al., 12-xx-2014, https: / / eeexplore.ieee.org / document / 6948243; “Secure and Efficient Internet of Body using Electro-Quasistatic Human Body Communication,” Purdue University, No author, No date, https: / / engineering.purdue.edu / ˜shreyas / SparcLab / research.html; “MI-FI: Micro / Nanoscale Transceivers for Wireless Molecular Information Communications,” No author, No date, https: / / nwcl.ku.edu.tr / axa.html; “Application of Graphene in Tissue Engineering of the Nervous System,” by Ławkowska et al., Dec. 21, 2021, https: / / www.mdpi.com / 1422-0067 / 23 / 1 / 33; “Microbiome-Gut-Brain Axis as a Biomolecular Communication Network for the Internet of Bio-Nano Things,” by Akyidiz, et al., Sep. 19, 2019, https: / / ieeexplore.ieee.org / document / 8844707; “A Simulation Framework for Connecting In-Body Nano Communication with Out-of-Body Devices,” by Kuestner et al., Sep. 23, 2020, https: / / www2.tkn.tu-berlin.de / bib / kuestner2020simulation / kuestner2020simulation.pdf; “5G & Network Transformation Conference: Prof. Dr. Ian F. Akyildiz—Georgia Tech,” Oct. 18, 2018, https: / / rumble.com / v465fuc-january-10-2024.html; “Talk by Prof Ian F Akyildiz on 6G and Beyond The Future of Wireless Communications Systems,” Apr. 30, 2021, https: / / www.youtube.com / watchv=diW1n0S_aVg&pp=ygU2SUFOIEYgQUtZSUxESVogU0VSSUVTIEIOIENPTU1VTklDQVRJT05TIEFORCBORVRXT1JLSU5H; “Science and Society Meetings—XI, Prof. Dr. Ilhan Fuat Akyildiz,” Georgia University, Mar. 31, 2023, https: / / youtu.be / MQ3dgOOZyE0?si=hqSauWg6qgR97Lxe; “Fundamentals of Molecular Nano-Communication Networks,” Oct. 10, 2022, https: / / youtu.be / PGvukbpujeU?si=AZUWgcslcADefL7S; “Hydrogel Platform Enables Versatile Data Encryption And Decryption—The Next Programmable Human Machine Interface Is Smarter Than You Think,” by Ana Maria Mihalcea, MD, PhD, Feb. 4, 2024, https: / / open.substack.com / pub / anamihalceamdphd / p / hydrogel-platform-enables-versatile?r=ry4ij&utm_campaign=post&utm_medium=web; “Biodefense in the Age of Synthetic Biology,” xx-xx-2018, National Academy of Sciences Press, https: / / www.ncbi.nlm.nih.gov / books / NBK535877 / ; “Nano Machines For Ultimate Control Of False Memories,” by Hildegarde Staninger, Jan. 8, 2012, https: / / open.substack.com / pub / anamihalceamdphd / p / global-brain-chip-and-mesogens-nano?r=ry4ij&utm_campaign=post&utm_medium=web; “Digital Super Intelligence has fused with Biological Intelligence turning humans into Biorobots,” Jan. 3, 2021, https: / / youtu.be / ymGsNmfP8q0?si=BOxZXjp6RP8kxRI; “DARPA AVATAR PROJECT LINKS YOUR MIND TO A DIGITAL WORLD INSIDE A QUANTUM COMPUTER,” Sep. 20, 2019, https: / / youtu.be / Hn_kb6b6_F4?si=AI5XkEdiTyHyF1SV; “The Global Brain Hive Mind Artificial Intelligence Control Grid,” Feb. 22, 2020, https: / / youtu.be / 3QtD3Eh4OOQ?si=z33BJPuxwWytKlF2; “MK ULTRA 2020 REMOTE MIND CONTROL THROUGH AMAZON CIA CLOUD COMPUTING ELECTRONIC BRAIN LINK,” Aug. 11, 2019, https: / / youtu.be / 6L8pwVcNwQk?si=JPtBv1rZDCZSUWOd; “GRAPHENE-based PLASMONIC NANO ANTENNA for TERAHERTZ Band Communication,” by Prof. Ian D. Akyildiz, May 27, 2023, https: / / www.bitchute.com / video / yHploDrvLUMP / ; “COVID MRNAS ARE NOTHING MORE THAN SMALL SCALE BIO-NANO MACHINES—Lecture by Professor Ian Akyildiz From Georgia Institute Of Technology,” by Ana Maria Mihalcea, MD. Ph.D, May 27, 2023, https: / / open.substack.com / pub / anamihalceamdphd / p / covid-mrnas-are-nothing-more-than?r=ry4ij&utm_campaign=post&utm_medium=web; “The National Nanotechnology Initiative Supplement To The President's 2023 Budget,” 02-xx-2023, https: / / www.nano.gov / sites / default / files / pub_resource / NNI-FY23-Budget-Supplement.pdf; “What Did The National Nanotechnology Initiative Supplement To The Presidents 2023 Budget Say About Polymer Amyloid Spider Silk Production?, Could This Have Been Weaponized Against Humanity?,” by Ana Maria Mihalcea, MD. PhD, May 14, 2024, https: / / open.substack.com / pub / anamihalceamdphd / p / what-did-the-national-nanotechnology?r=ry4ij&utm_campaign=post&utm_medium=web; “What is WBAN or IEEE 802.15.6?,” by Editorial Team EverythingRF, Mar. 3, 2021, https: / / www.everythingrf.com / community / what-is-wban-or-ieee-802-15-6; “Pervasive Computing—What You Need To Know,” No Author, Oct. 17, 2018, https: / / pervasivecomputinginfo.blogspot.com / ; “Enabling Covert Body Area Network using Electro-Quasistatic Human Body Communication, Scientific Reports,” Das et al., Feb. 27, 2020, https: / / www.nature.com / articles / s41598-018-38303-x; “Sensor Networks with IEEE 802.15.4 Systems,” Buratti et al., 2021, https: / / link.springer.com / book / 10.1007 / 978-3-642-17490-2; “Implementation of IoT and UAV Based WBAN for healthcare applications,” Ananthi et al, Oct. 1, 2021, https: / / ieeexplore.ieee.org / document / 9545052; “Human Interaction, Emerging Technologies and Future Systems V Proceedings . . . ,” by Ahram et al., Sep. 9, 2021, “Sensor Networks with IEEE 802.15.4 Systems,” by Buratti et al., 2021, https: / / link.springer.com / book / 10.1007 / 978-3-642-17490-2; “OSI Model—Wikipedia,” https: / / en.wikipedia.org / wiki / OSI_model; “Body Area Network—Wikipedia,” https: / / en.wikipedia.org / wiki / Body_area_network; “IEEE 802.15.5—Wikipedia,” https: / / en.wikipedia.org / wiki / IEEE_802.15.4; “Electroporation—Wikipedia,” https: / / en.wikipedia.org / wiki / Electroporation; “Wireless Energy and Information Transfer in WBAN: A Comprehensive State-of-the-Art Review,” by Zhumayeva, et al., Nov. 21, 2023, https: / / www.sciencedirect.com / science / article / pii / S1110016823010086; “Biofield Science and Healing: History, Terminology, and Concepts,” by Rubik et al., https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC4654789 / ; “How to Block Microwave Mind-Programming Signals,” Jul. 14, 2004, https: / / montalk.net / conspiracy / 55 / how-to-block-microwave-mind-programming-signals; “Maria Zeee: Nanobots Inside People Programming Humanity,” by Maria Zeee, May 14, 2024, https: / / madmaxworld.tv / watch?id=6643f3e2684fe5289a959215; “Are Programmable Nanotechnology Biosensing Mesogen “Computer Chip” Devices Being Self Assembled In C19 Uninjected Blood? How Dangerous Is Self Spreading Nanotechnology?,” by Ana Maria Mihalcea, MD. PhD, May 13, 2024, https: / / open.substack.com / pub / anamihalceamdphd / p / are-programmable-nanotechnology-biosensing?r=ry4ij&utm_campaign=post&utm_medium=web; “What is in the so-called COVID-19 “vaccines” ?Evidence of a Global Crime Against Humanity,” Dr. Ana Marie Mihalcea interview with Dr. David Hughes, https: / / rumble.com / v1sm3bm-what-is-in-the-so-called-covid-19-vaccines-evidence-of-a-global-crime-again.html; “Interview 763 with researcher and clinical scientists Dr. Robert O Young,” by Jesse Hal, May 15, 2024, https: / / www.youtube.com / live / RwBwJMIKEdo?si=Lnh0Oujl_nFYGJoJ; “Technical Presentation: WBAN on a 6gloPAN and your electromagnetic body part,” by Sabrina Wallace, Sep. 6, 2022, https: / / odysee.com / @psinergy:f / trim.D5E8F851-4FF8-483C-B72A-7590D29617E2:4; and other related videos https: / / odysee.com / @psinergy:f. As concerns the presence of nanometals and other materials in many vaccines, see: “New Quality-Control Investigations on Vaccines: Micro- and Nanocontamination,” by Gatti et al., Jan. 23, 2017, https: / / medcraveonline.com / UW / new-quality-control-investigations-on-vaccines-micro--and-nanocontamination.html. Several individuals have noticed unusual levels of prolonged electromagnetic radiation from NEXRAD microwave radar towers during the evening, e.g., Colonel Chris Sanders noticed radar reflectivity reaching 750,000 watts and then weird weather anomolies—these were turned on in the middle of the night; see, https: / / www.tiktok.com / @majornewsnetwork / video / 7367945295763672350, Facebook Post by German Torres, May 12, 2014, posted by TikTok@Godbeautifulgifts, https: / / www.facebook.com / german.towers / videos / 1890832918064620 / ?mibextid=v7YzmG.

[0037] In view of the ability of nanomaterials to be manipulated by electromagnetic radiation and wireless communication, some believe that the nanometals and chemicals which are being used in cloud seeding operations, and / or other unexplained chemtrails could possibly be hazardous to human physical and / or mental health because they can be inhaled, but also end up on the ground and so can get into the food supply and thereby the human body. In this regard, see, “What In The World Are They Spraying?,” May 20, 2011, https: / / youtu.be / rEUg8uLoZNY?si=0zlahGjlDevMEJju; “Why In The World Are They Spraying?,” Aug. 18, 2012, https: / / youtu.be / mEfJO0-cTis?si=tBiLCTL6iz5hJLPT; See U.S. Pat. No. 7,413,145 B2, by Hale et al., for Aerial Delivery System assigned to Evergreen International Aviation Inc. of McMinneville, Oregon, and notice that this airlines has a history of working for the CIA as disclosed here: “Evergreen International Airlines—Wikipedia,” https: / / en.wikipedia.org / wiki / Evergreen_International_Airlines; Citizens “Seeking Answers to Aluminum Concerns,” MtShasta News, Mar. 25, 2009, and “Geoengineering 11 Years Ago, by Spiritual Battlecry, No Date, https: / / www.facebook.com / reel / 1123413948991467?fs=e&s=TleQ9V&mibextid=0NULKw; and see the website “Geoengineering Watch,” https: / / www.geoengineeringwatch.org / ; “Weather as a Force Multiplier Owning the Weather in 2025,” House et al., xx-xx-1996, https: / / open.substack.com / pub / anamihalceamdphd / p / mission-accomplished-military-report?r=ry4ij&utm_campaign=post&utm_medium=web; “Mission Accomplished: Military Report From 1996 ‘Weather As A Force Multiplier: Owning The Weather In 2025’—Is Spraying Poison In The Air For Military Advantage A Good Idea?”, by Ana Maria Mihalcea, MD, PhD, Feb. 2, 2024, https: / / open.substack.com / pub / anamihalceamdphd / p / mission-accomplished-military-report?r=ry4ij&utm_campaign=post&utm_medium=web; the book entitled “Geoengineered Transhumanism,” by Elana Freeland, Oct. 10, 2021, https: / / www.amazon.com / Geoengineered-Transhumanism-Environment-Electromagnetics-Nanotechnology / dp / 0578927055; the website: “Geoengineering Watch|Exposing the Climate Engineering Cover-Up; and, The Dimming, Full Length Climate Engineering Documentary (Geoengineering Watch),” Mar. 10, 2021, https: / / youtu.be / rf78rEA)vhY?si=WBsFPNHKI5OZ-9aF; and the Geoengineering Monitor Website: https: / / www.geoengineeringmonitor.org / .

[0038] Yuval Noah Harari, who is an advisor to Klaus Schwab of the World Economic Forum (WEF) has stated:

[0039] “Humans are now hackable animals. The whole idea that humans have this ‘soul” or “spirit,’ and nobody knows what's happening inside them and they have free will—that's over.” By hacking organisms, elites may gain the power to re-engineer the future of life itself. Because once you can hack something you can usually engineer it. In the past, many tyrants and governments wanted to do it but nobody had enough computer power and data to hack millions of people. Neither the Gestapo nor the KGB could do it. But soon, at least some corporations and governments will be able to systematically hack all the people.”In this regard, see the following video entitled: “Free Will? That's Over, says Klaus Schwab's Top Advisor Yuval Noah Harari,” by VT.com, Jan. 22, 2022, https: / / valuetainment.com / free-will-thats-over-says-klaus-schwabs-top-advisor-yuval-noah-harari / . For insights regarding his vision of the future see “Hatari: What Do We Do With the Useless Eaters?,” by Shifted Paradigm, Apr. 15, 2020, https: / / youtu.be / Ex3_brOUdpA?si=FMsqW8Co1c-9Ca-T, and in particular, the last 10 seconds, and also see: Yuval Noah Harari Reveals the Real Dangers Ahead|The TED Interview, Aug. 9, 2022, where he states: “We just don't need the vast majority of the population.” https: / / www.youtube.com / watch?v=w7DohVZSYo&pp=ygUcaHR0cHM6Ly95b3V0dS5iZS93N0R vaFZaUzVZbw%3D%3DF; and, Just a Casual Conversation at WEF . . . , by MacNeil4Freedom, https: / / www.facebook.com / share / r / 1A64a6GWp3 / ?mibextid=N9fs7i. For insights into Klaus Schwab's undemocratic political methodology and vision of the future, e.g., see “Klaus Schwab Talking About Penetrating Justin Trudeau's Cabinet (and others), at the John F. Kennedy School of Government, at Havard University,” by Eikichi Onizuka, Feb. 19, 2022, https: / / youtu.be / NhHmy9AQLBA?si=sJRUDL1FqwtIrxQS; The End of Humanity—As Planned By Global Leaders, by StopWorldControl, 04-xx-2024, https: / / rumble.com / v4q7hcq-the-end-of-humanity-as-planned-by-the-global-leaders.html; Excerpt from an interview on Suisse Radio Television with English translation, by Jessica Nocar, Jan. 10, 2016, https: / / x.com / jessynocar / status / 1538140205550551040?s=46&t=W1BatXsyDXjdeQJc1u3vyg, and the full interview in French, “L'interview de Klaus Schwab,” by TRS Radio—Television Suisse, Jan. 10, 2016, https: / / youtu.be / UceylPPiIM?si=0dOWPSbAk1-ToZ9r; “Address by Mr. Klaus Schwab, Executive Chairman, World Economic Forum,” by United Nations Envoy on Technology, Jul. 8, 2020, https: / / youtu.be / MN--v9V21Cl?si=NX5fesWoNhXH-kaW; “The Final Report of Policy Lab Fundamental Rights in AI; Digital Societies: Towards An International Accord,” by UN 100 Remaking The World The Age of Global Enlightenment, May 31, 2021, https: / / un100.net / books-un / policy-lab-fundamental-rights-in-ai-digital-societies-towards-an-international-accord / , and in particular on the same webpage see the “CdM-BGF-Policy-Lab-2021-Final-Report-Annex.”“Bill Gates predicts mRNA will be a game changer for vaccines over next 5 years,” USA Today, Jan. 27, 2021, https: / / www.usatoday.com / videos / news / health / 2021 / 01 / 27 / bill-gates-explains-magic-mrna-vaccines-multitude-diseases / 4276472001 / , and he coincidentally also believes in human population control and BioDigital engineering, e.g., see: “Bill Gates—The Banned Video,” by StopWorld Control on Rumble, 2022, https: / / rumble.com / v1o6jmf-bill-gates-the-banned-video.html.

[0040] The question is how would this be effectively accomplished? Historically, the primary causes of depopulation have been human choice, but more suddenly and also dramatically the use of war, disease, and famine as took place during the genocide of the native American Indians. Biological warfare is nothing new. Blankets infected with smallpox were sometimes given to Native Americans. A bounty was placed on Buffalo skins which resulted in their near extinction (between 30-60 million buffalo were killed leaving only about 300), and so the food supply of the plains Indians was wiped out. Native Americans were placed on reservations or what most people would call internment or prison camps. Today, some would suggested that we are the next “American Indians,” and the reservations of the future are instead being called “Smart Cities” or “15 Minute Cities” by members of the World Economic Forum, e.g., see, “Governing Smart Cities: Policy Benchmarks for Ethical and Responsible Smart City Development, White Paper,” by the WEF, July 2021, https: / / www3.weforum.org / docs / WEF_Governing_Smart_Cities_2021.pdf.

[0041] At this time, the World Health Organization (WHO) is pushing for a Pandemic Preparedness Treaty that would give to this organization extraordinary powers during a pandemic and that would effectively bypass democratically elected governments and national sovereignty. Klaus Schwab and WEF members are supporting the Pandemic Preparedness Treaty, e.g., see WHO Pandemic Treaty: What Is It And How Will It Save Lives In The Future,” by the WEF, May 26, 2023, https: / / www.weforum.org / agenda / 2023 / 05 / who-pandemic-treaty-what-how-work / . For those individuals who are familiar with 20th century European history, the Pandemic Preparedness Treaty bears resemblance to the 1933 Enabling Act which similarly gave to the Chancellor, Adoft Hitler, the power to bypass the system of check and balances in the German government and to make and enforce laws in a national emergency without the involvement of the Reichstag or Weimar President Paul von Hindenburg, and thereby led to the rise of Nazi Germany, e.g., see “Enabling Act,” on Wikepedia, https: / / en.wikipedia.org / wiki / Enabling_Act_of_1933. In response, Senator Ron Johnson of Wisconsin, has introduced legislation entitled the “No WHO Pandemic Preparedness Treaty Without Senate Approval Act” to protect American sovereignty so that the Pandemic Preparedness Treaty would have to be approved by members of the U.S. Senate, e.g., see “Sen. Johnson Introduces Legislation to Protect American Sovereignty Against World Health Organization,” Feb. 17, 2024, https: / / www.ronjohnson.senate.gov / 2022 / 5 / sen-johnson-introduces-legislation-to-protect-american-sovereignty-against-world-health-organization.

[0042] Members of the public and their medical doctors are becoming increasingly aware of the many adverse events and health issues relating to the COVID-19 “vaccines.” In 2020, an anonymous letter allegedly made by two Moderna whistleblowers appeared on Twitter which read as follows:

[0043] I am an industrial engineer at Moderna and the other one of us is a process development engineer. I'm sure the same thing is happening with Pfizer-BioNtech. It was hard to put things together based on the small quantities of additions happening in manual step (highly unorthodox for a continuous process production). The explanation we got was highly sensitive trade secret adjuvants being added. Digging in deeper showed how sensitive it actually was.

[0044] Most people's understanding of this novel vaccine type is that it works as follows:1.Make mRNA coding for S protein2.Make lipid nanoparticle delivery system3.ProfitHow it actually works from what we've uncovered:1.Make mRNA coding for S protein2.Make mRNA coding for mutant versions of CYP19A1 and CDKN1B in smaller amounts3. Make sure that while delivery system for (1) mostly ends up in liver, most of (2) ends up in the gonads4. Make sure form and quantity of additive upregulating LINE-1 reverse transcription activity makes it hard to detect among legit adjuvants5. Effects from (2) integrated by (4) are recessive, mildly oncogenic effects in vaccine recipients unlikely to be noticed for many years6. (5) recessive but since most of population vaccinated, in next generation female offspring have premature ovarian failure

[0046] (6) coincides with poor people being obsoleted by AI and robotics, so we didn't have to dig for motivation. We've taken precautions but fear for our safety. So far I don't think we've raised suspicion, but can't be sure. Not sure what to do. Avoiding taking the vaccine makes us prime suspects for this leak.Whether this letter was a hoax or an actual leak by a whistleblower is unknown. What is most concerning is that there have since been many reported cases of women who received the COVID “vaccines” experiencing issues with their reproductive systems, and also what are now being called turbocancers, and a rise in excess deaths. Accordingly, it may be a good for medical researchers at the Mayo Clinic or elsewhere to conduct experiments with mice or rats, and determine if any of the COVID-19 “vaccines” do in fact cause recessive genes to express themselves in the next generation and then cause cancer or autoimmune disease.

[0047] The following ten-part series provides information and insights regarding the COVID-19 “Vaccines,” and links to other relevant articles and videos: “Part 1: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, Mar. 14, 2022, https: / / vaxxter.com / part-1a-a-primer-understanding-the-mechanisms-of-the-experimental-genetic-technology-known-as-the-covid-19-vaccines / ; “Part 2: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, Mar. 14, 2022, https: / / vaxxter.com / part-2-a-primer-understanding-the-mechanisms-of-the-experimental-genetic-technology-known-as-the-covid-19-vaccines / ; “Part 3: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, Apr. 9, 2022, https: / / vaxxter.com / part-3-a-primer-understanding-the-experimental-genetic-technology-referred-to-a-vaccine / ; “Part 4: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, May 10, 2022, https: / / vaxxter.com / part-4-a-primer-understanding-the-mechanisms-of-the-covid-19-vaccines / ; “Part 5: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, May 11, 2022, https: / / vaxxter.com / part-5-a-primer-understanding-the-mechanisms-of-the-experimental-genetic-technology-referred-to-as-covid-19-vaccines / ; “Part 6: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, Oct. 18, 2022, https: / / vaxxter.com / part-6-understanding-the-mechanisms-of-the-covid-19-vaccines / ; “Part 7: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, Nov. 30, 2022, https: / / vaxxter.com / part-7-a-primer-understanding-the-mechanisms-of-the-covid-19-vaccines / ; “Part 8: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, Dec. 3, 2022, https: / / vaxxter.com / part-8-a-primer-understanding-the-mechanisms-of-the-experimental-genetic-technology-referred-to-as-covid-19-vaccines / ; “Part 9: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, Dec. 14, 2022, https: / / vaxxter.com / part-9-a-primer-understanding-the-mechanisms-of-the-experimental-genetic-technology-referred-to-as-covid-19-vaccines / ; “Part 10: A Primer: Understanding The Mechanisms Of The Experimental Genetic Technology Referred to As COVID-19 Vaccines,” by Maryam Henein, Jan. 11, 2023, https: / / vaxxter.com / part-10-a-primer-understanding-the-mechanisms-of-the-experimental-genetic-technology-referred-to-as-covid-19-vaccines / .

[0048] In view of the information provided herein, members of the medical profession need to be aware of the possible ramifications of their unwittingly or not being used to inject so-called “vaccines” which are experimental forms of gene therapy.

[0049] With regards to the so-called “vaccines” and onset of cancer, see, e.g., “Oncogenesis and Autoimmunity as a Result of mRNA COVID-19 Vaccination,” by Kyriakopoulos et al., Apr. 23, 2024, https: / / d197for5662m48.cloudfront.net / documents / publicationstatus / 205375 / preprint_pdf / 3baa7e98c64d866054cdd37d173c7e11.pdf; “Japan's Most Senior Oncologist, Prof. Fukushima Condemns mRNA Vaccines as ‘Evil Practices of Science,’” by Aussie17, Apr. 28, 2024, interview, https: / / www.aussie17.com / p / japans-most-senior-oncologist-prof; “Syllogistic Reasoning Demystifies Evidence of COVID-19 Vaccine,” by Broudy et al., Dec. 11, 2021, https: / / ijvtpr.com / index.php / IJVTPR / article / view / 32; “Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan,” by Gibo et al., Apr. 8, 2024, https: / / zenodo.org / records / 8352450 / files / Increased%20Age-adjusted%20Cancer%20Mortality%20after%20the%203rd%20mRNA-Lipid%20Nanoparticle%20Vaccine%20Dose%20during%20the%20COVID-19%20Pandemic%20in%20.apan.pdf?download=1; “SARS-CoV-2 Vaccination and the Multi-Hit Hypothesis of Oncogenesis,” by Angues et al., Dec. 17, 2023, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC10792266 / ; “New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?,” by Rapti et al., Sep. 25, 2022, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC9611551 / ; On the increase in incidence and rapid progression of cancers, “Professor of Oncology Angus Dalgleish,” by Jean Emsallem, no date, LinkedIn, https: / / www.linkedin.com / feed / update / urn:li:activity:7100592880070574080?utm_source=share&utm_medium=member_ios; “Inventor of mRNA Technology: Vaccine Causes Lipid Nanoparticles to Accumulate in ‘High Concentrations’ in Ovaries,” by Megan Redshaw, Jun. 17, 2021, https: / / childrenshealthdefense.org / defender / mrna-technology-covid-vaccine-lipid-nanoparticles-accumulate-ovaries / ; “EXCLUSIVE REPORT: Forced retraction of Covid vaccine cancer-risk study, scientist allegies,” by Rebeka Barnett, Jun. 2, 2024, https: / / petermcculloughmd.substack.com / cp / 145213644; “SARS-CoV-2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro,” by Hui Jiang and Ya-Fang Mei, 10-xx-2021, https: / / news.rebekahbarnett.com.au / api / v1 / file / 7d2efe23-9df8-4394-bb31-263d000e0981.pdf; “Two New Studies Suggest mRNA Covid Vaccines Can Contribute To Cancer Formation,” by Rebekah Barnett, Apr. 16, 2024, https: / / news.rebekahbarnett.com.au / p / two-new-papers-suggest-mrna-vaccines; “SARS-CoV-2 spike S2 subunit inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells,” by Zhang and El-Deiry, Apr. 15, 2024, https: / / www.biorxiv.org / content / 10.1101 / 2024.04.12.589252v1; “S2 Subunit of SARS-nCoV-2 Interacts with Tumor Suppressor Protein p53 and BRCA: an In Silico Study,” by Singh et al., Translational Oncology, Volume 13, Issue 10, 10-xx-2020, https: / / www.sciencedirect.com / science / article / pii / S1936523320303065?via%3Dihub; “S2 of SARS-2 spike buggers up p53,” by Jessica Rose, Apr. 16, 2024, https: / / jessicar.substack.com / p / s2-of-spike-buggers-up-p53. Again, Senator Ron Johnson of Wisconsin held a Congressional Hearing on Jan. 24, 2020 which included a panel of doctors, researchers, and practitioners and several individuals then expressed their concerns that the COVID-19 so-called “vaccines” can possibly comprise the human immune system and its ability to eliminate of cancer cells, e.g., see the testimony beginning at 4:58 minutes in the Congressional Hearing on the website: https: / / youtu.be / asw_FBipVpg. DNA fragments have also been found in some of the COVID-19 “vaccines,” e.g., see “Cancer Genomics Expert Dr. Phillip Buckhaults Testifies to the SC Senate on the DNA Contamination Found in mRNA COVID Vaccines,” by Chief Nerd, Sep. 17, 2023, https: / / twitter.com / thechiefnerd / status / 1703544942004478251?s=46&t=W1BatXsyDXjdeQJc1u3vyg; and, “DNA fragments detected in monovalent and bivalent Pfizer / BioNTech and Moderna modRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events,” by Speicher et al., 10-xx-2023, https: / / www.researchgate.net / publication / 374870815_Speicher_DJ_et_al_DNA_fragments_detected_in_COVID-19_vaccines_in_Canada_DNA_fragments_detected_in_monovalent_and_bivalent.

[0050] Another possible danger which is possibly associated with some of the COVID-19 so-called “vaccines” is a phenomenon known as Antibody Dependent Enhancement (ADE), e.g., see https: / / en.wikipedia.org / wiki / Antibody-dependent_enhancement. In this regard, see the following articles and / or videos: “Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs,” by Seneff et al., 06-xx-2022, https: / / doi.org / 10.1016 / j.fct.2022.113008, and “Response to Barriere et al,” by Seneff et al., 06-xx-2022, https: / / doi.org / 10.1016 / j.fct.2022.113008; “Replication Derived mRNA: Implications for Cell Biology and Future Disease,” by McKernan et al., Nov. 25, 2021, https: / / doi.org / 10.31219 / osf.io%2Fbcsa6; “Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity,” by Lyons-Weiler, 03-xx-2020, https: / / www.sciencedirect.com / science / article / pii / S2589909020300186 / pdfft?md5=cc82211933974423b63c0bedea8d901e&pid=1-s2.0-S2589909020300186-main.pdf; “COVID Shots to “Decimate World Population, Warns Dr. Sucharit Bhakdi,” by Alex Newman, Apr. 6, 2021, https: / / thenewamerican.com / covid-shots-to-decimate-world-population-warns-dr-bhakdi / ; “A Review: Antibody-dependent enhancement in COVID 19: The not so friendly side of antibodies,” by Sanchez-Zuno et al, Oct. 10, 2021, https: / / doi.org / 10.1177 / 20587384211050199; “6 Big Differences Between Natural Vs. Vaccine-Induced Immunity,” by Rob Verkerk Ph.D., Feb. 4, 2022, https: / / childrenshealthdefense.org / defender / differences-natural-vaccine-induced-immunity / ; “The CDC Finally Admits That Natural Immunity to SARS-CoV-2 Is Superior to the Immunity Induced by COVID-19 Vaccines,” by Jeremy Hammon, Feb. 10, 2022, https: / / www.jeremyrhammond.com / 2022 / 02 / 10 / the-cdc-finally-admits-that-natural-immunity-to-sars-cov-2-is-superior-to-the-immunity-induced-by-covid-19-vaccines / ?feed_id=23; “Autoimmune inflammatory reactions triggered by the COVID-19 genetic vaccines in terminally differentiated tissues,” by Polykretis, Autoimmunity, 2023, VOL. 56, NO. 1, 2259123, Sep. 14, 2023, https: / / doi.org / 10.1080 / 08916934.2023.2259123; “Expert Dr. Sucharit Bhakdi, Why The Injections Are No Good;” Mar. 24, 2022, https: / / drtrozzi.org / 2022 / 03 / 26 / top-virologist-and-immunologist-dr-sucharit-bhakdi / ; “Del's Football Analogy goes Viral,” The Highwire With Del Bigtree, Jan. 7, 2021, https: / / thehighwire.com / videos / dels-; and, “Vaccine Immune Confusion with Geert Vanden Bossche and Dr Rennebohm,” Jun. 8, 2023, https: / / youtu.be / DPnPVOtt98M?si=g8tmX0isjSJ-8Wdyfootball-analogy-goes-viral / ; “The mRNA-LNP vaccines—the good, the bad and the ugly?,” by Igyártó and Qin, Feb. 8, 2024, https: / / www.ncbi.nlm.nih.gov / pmc / articles / pmid / 38390323 / ; “Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses—are we our own worst enemy?,” by Wong et al., Nov. 26, 2021, https: / / www.nature.com / articles / s41577-021-00656-2, “Innate and adaptive immune mechanisms of COVID-19 vaccines. Serious adverse events associated with SARS-CoV-2 vaccination: A systematic review,” by Rocío Morlanes Pallás, in Vacunas, Volume 25, Issue 2, April-June 2024, Pages 285.e1-285.e94, https: / / www.sciencedirect.com / science / article / pii / S2445146024000293, and also see: “Myocarditis Up 2800%: Army Veteran Pam Long Lists Alarming Numbers From the DMED Data Base, Myocarditis—Up 2800%, Cancers—Up 300% to 900%, Infertility (Both, Genders)—Up 500%, Miscarriages—Up 300%, Neurological Disorders—Up 1000%, Demyelinating Disorders—Up 1000%, Multiple Sclerosis (MS)—Up 600%, Guillain-Barré Syndrome—Up 500%, HIV—Up 500%, HIV—Up 500%. Pulmonary Embolisms—Up 400%,” by Pam Long, Jun. 4, 2024, https: / / x.com / toobaffled / status / 1797955858611261605.

[0051] The spike protein has been associated with many different kinds of adverse events, e.g., see: “‘Spikeopathy’: COVID-19 Spike Protein is Pathogenic, from Both Virus and Vaccine mRNA,” by Parry et al., Biomedicines. 11 (8): 2287, Aug. 17, 2023, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC10452662 / ; “The novel coronavirus' spike protein plays additional key role in illness,” Lie et al., Salk News, Apr. 30, 2021, https: / / www.salk.edu / news-release / the-novel-coronavirus-spike-protein-plays-additional-key-role-in-illness / ; “SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2,” by Lei, et al., https: / / www.ncbi.nlm.nih.gov / pmc / articles / pmid / 33784827 / ; “SARS-CoV-2 Spike Targets USP33-IRF9 Axis via Exosomal miR-148a to Activate Human Microglia,” by Mishra et al., https: / / www.ncbi.nlm.nih.gov / pubmed / 33936086; “Amyloidogenesis of SARS-CoV-2 Spike Protein,” by Nystram et al., May 17, 2022, https: / / www.ncbi.nlm.nih.gov / pmc / articles / pmid / 35579205 / ; “Replication Derived mRNA: Implications for Cell Biology and Future Disease,” by McKernan et al., Nov. 25, 2021, https: / / doi.org / 10.31219 / osf.io%2Fbcsa6; “Spike Proteins of SARS-CoV and SARS-CoV-2 Utilize Different Mechanisms to Bind With Human ACE2,” Xie, et al., Dec. 9, 2020, https: / / pubmed.ncbi.nlm.nih.gov / 33363207 / ; and, “MIT Professor provides future mRNA warning,” by Retsef Levi, Jason Olborne, World Series News Underground TV, Aug. 31, 2023, https: / / fb.watch / rtSDDFmPP0 / ?mibextid=v7YzmG. Further, the lipid nanoparticle using in some of the COVID-19 “vaccines” has its been found to be inflammatory, e.g., “The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory,” by Ndeupen et al., Dec. 17, 2021, https: / / www.cell.com / action / showPdf?pii=S2589-0042%2821%2901450-4. Further, the spike protein and COVID-19 so-called “vaccines” have also been linked to problems associated with the female reproduction system, e.g., see the article entitled: “Anti-COVID-19 Vaccination Alters the Menstrual Cycle and Dose Accumulation Enhances the Effect,” Meníndez et al., Jun. 8, 2024, https: / / lnkd.in / gJDEyzfd.

[0052] During the past two years, there has been a rise in myocarditis as discussed in the following videos and papers: “Myocarditis Paper (and interview with Dr. Peter McCullough),” by Dr. John Campbell, Feb. 6, 2024, https: / / youtu.be / 5BhC0BCYQwo?si=m4sB-nfdMaMJwkHj; “Autopsy findings in cases of fatal COVID-19 vaccine-induced myocarditis,” by Hulscher et al., Jan. 14, 2024, https: / / pubmed.ncbi.nlm.nih.gov / 38221509 / ; “Understanding COVID-19-Related Myocarditis: Pathophysiology, Diagnosis, and Treatment Strategies,” by Shu et al., Apr. 14, 2023, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC10364646 / : “Heart failure in Navy Pilots is up 973%. and myocarditis rising 151%. How could this be? And why is the response deafening silence?” by Macie, USN, May 28, 2024, https: / / fb.watch / rW86dlj-7i / ; “The US Military Has Its Own Version of VAERS, And The Results Are Frightening,” by Fed Up Texas Chick, Jan. 24, 2022, https: / / vaxxter.com / the-us-military-has-its-own-version-of-vaers-and-the-results-are-frightening / .

[0053] In this regard, there have been an unusually high number of athletes who have suffered health emergencies, as discussed in the following articles: “At least 69 Athletes Collapse In One Month, Many Dead,” by Bruce Foster, Nov. 26, 2021, https: / / dpbh.nv.gov / uploadedFiles / dpbhnvgov / content / Boards / BOH / Meetings / 2021 / Public%20Comments%20324%20to%20328.pdf; “Report: 75 European Fully Vaccinated Athletes Have Died Or Became Seriously Ill From “Sudden” Heart Attacks In The Past 5 Months,” https: / / newzworldtoday.com / report-75-european-fully-vaccinated-athletes-have-died-or-became-seriously-ill-from-sudden-heart-attacks-in-the-past-5-months / . Some medical doctors and researchers think the COVID-19 so-called “vaccines” are possibly responsible for these and other health emergencies. Besides numerous high-profile cases involving the sudden death of athletes, many other individuals who have received one of the Covid-19 so-called “vaccines” have later died from blood clots.

[0054] However, the blood clots are abnormal and not composed of red blood cells, but instead of white blood cells, platelets, and other matter. In this regard, see the following video entitled “Died Suddenly,” by Stew Peters Network, Nov. 29, 2023, https: / / rumble.com / v1wac7i-world-premier-died-suddenly.html. Dr. Bryan Artis and Mike Adams who has an ISO lab have stated that several labs in China, France, and Italy have detected snake venom and / or other peptide toxins in victims of COVID-19: e.g., see “Dr. Jane Ruby Show: Ardis and Adams Blow Open Truth On Mass Genocide,” by Stew Peters Network, 2022, https: / / rumble.com / v1rlnyo-dr.-jane-ruby-show-ardis-and-adams-blow-open-truth-on-mass-genocide.html, and, “Dr. Jane Ruby Show: Ardis and Adams Blow Open Truth On Mass Genocide,” by Survive The News, “EXCLUSIVE: Self-assembling vaccine clot biostructures harvest conductive metals from your blood—preliminary ICP-MS analysis results released,” by Mike Adams, Jul. 22, 2022, https: / / www.newstarget.com / 2022-07-22-vaccine-clot-biostructures-harvest-conductive-metals-from-blood.html. According to Dr. Bryan Artis and Mike Adams synthetic snake venom peptides were possibly used to cleave normal RNA and insert the mRNA segment in making and using the COVID-19 so-called “vaccines.” In the video provided below, Mike Adams shows how he typically prepares organic matter for mass spectroscopy analysis, and in this case the sample is a white blood clot that has been taken from a deceased individual who had taken one of the Covid-19 mRNA so-called “vaccines.”“Mike Adams carries out an lab analysis of a blood ‘clot’ found in a deceased vaccinated person,” by ApplesIsland, Jul. 29, 2022, https: / / www.bitchute.com / video / YAoeEIPKR6Dt / . It can be clearly seen that when a portion of the white blood clot is added to nitric acid some of the sample oxidizes and turns black in an exothermic reaction. Adams states that organic matter normally does not do this. What does do this is a form of inorganic matter, e.g., aluminum does this when it is placed in nitric acid as shown in the following video and demonstration: https: / / youtu.be / T1SdumDd-0s. Here is the chemical formula that is associated with this exothermic reaction: Aluminium+nitric acid=aluminium nitrate+hydrogen, that is, Al+HNO3═Al NO3+H, e.g., see https: / / pubchem.ncbi.nlm.nih.gov / compound / Aluminium-nitrate. Mike Adams and Harrison Smith have also discussed finding other unusual things in people's bloodstream, e.g., see “Microscopic Video of Engineered Biostructures Removed From Blood Vessels,” Forbidden Knowledge TV, Jun. 13, 2022, https: / / forbiddenknowledgetv.net / microscopic-video-of-engineered-bio-structures-removed-from-blood-vessels / : “Exclusive Horrific Images: Circuits In Covid Jab Internet Router Causes Circuits to Self Assemble,” Stew Peters Network, 2022, https: / / rumble.com / v1g4del-exclusive-horrific-images-circuits-in-covid-jab-internet-router-causes-circ.html. The COVID-19 so-called “vaccines” have also been linked to progression of Alzheimer's, e.g., see “Association Between COVID-19 Vaccination and Development of Alzheimer's Disease,” by Peter McCullough, Jun. 25, 2024, https: / / petermcculloughmd.substack.com / p / association-between-covid-19-vaccination, and, “A potential association between COVID-19 vaccination and development of alzheimer's disease,” by Roh et al., May 28, 2024, https: / / pubmed.ncbi.nlm.nih.gov / 38806183 / . See also, “SARS-CoV-2 Spike Protein Persists in the Skull-Meninges-Brain Axis and Causes Neurological Damage,” by Hulscher, Dec. 2, 2024, https: / / substack.com / app-link / post?publication_id=1119676&post_id=152452405&utm_source=post-email-title&utm_campaign=email-post-title&isFreemail=true&r=ry4ij&token=eyJ1c2VyX2lkljo0Njk0MTc4NywicG9zdF9pZCI6MTUyNDUy NDA1LCJpYXQjOjE3MzMxNjAwOTAsImV4cCl6MTczNTc1MjA5MCwiaXNzljoicHViLTExMTk2NzYiL CJzdWliOiJwb3N0LXJlYWN0aW9uln0.Wb8Ycg8_7SuFqdD2moy3ygL06g0Kz353aieQSavW8l4.

[0055] The number of deaths from COVID-19 and month in which they occurred in the United States is shown in graphs provided in: “US COVID-19 cases and deaths by state|USAFacts,” 07-xx-2023, published online: https: / / usafacts.org / visualizations / coronavirus-covid-19-spread-map / . As discussed in the article: “The First Authorized COVID-19 Vaccine in the U.S. Is Here_TIME,” by Alice Park, Dec. 11, 2020, https: / / time.com / 5920134 / first-authorized-covid-19-vaccine-us / , the first COVID-19 vaccines began to be administered in the United States in December, 2020, and this is when the largest spike in deaths from COVID-19 occurred. Further, the Supplementary Table: “Timeline of Booster, Second Booster, and Additional Dose COVID-19 Authorizations and Recommendations—United States, August, 2021-May, 2022.” published online: https: / / stacks.cdc.gov / view / cdc / 120701 / cdc_120701_DS1.pdf, shows that the next large spike in deaths from COVID-19 occurred after the COVID-19 boosters were made available in August, 2021. In 2020, the flu disease burden was estimated by the CDC to be 35,000,000, but in 2021 it was somehow only 9,400,000, and then it was back up to 31,000,00 in 2022, as shown on the website: “Disease Burden of Flu|CDC,” Feb. 28, 2024, https: / / www.cdc.gov / flu / about / burden / index.html. What the data shows is that for every person who may have been saved by the COVID-19 so-called vaccines, two people were killed, e.g., see the audio / video recording of the “FDA's Vaccines and Related Biological Products Advisory Committee—Sep. 17, 2021,” at 4 hours 21 minutes, the presenter goes over the facts: the Covid shots killed 2 people for each life saved, https: / / youtube.com / watch? / V=WFpf7-6t34M+authuser=0. It was later announced that “The U.S. Government Will No Longer Pay For COVID Vaccines,” Aug. 19, 2022, https: / / www.advisory.com / daily-briefing / 2022 / 08 / 19 / covid-costs, and the CDC stopped collecting daily COVID-19 data in May, 2023. Suddenly, the drive for vaccination was over, and people could go to shopping malls and out to music concerts again.

[0056] Edward Dowd is a former analyst for the Blackrock Investment firm who is studying the emerging data on excess mortality. He has written a book entitled: “Cause Unknown:” The Epidemic of Sudden Deaths in 2020 2021,” and he observed that the sudden death epidemic has not stopped. See the video entitled “Hell On Earth May Have Already Started,” Connor Boyle interview with Edward Dowd, Oct. 3, 2022, https: / / fb.watch / gxLojBY9bT / , and the data on excess mortality which is provided on his website: theyliedpeopledied.com / . According to the insurance data and actuary tables which Mr. Dowd has studied all-cause mortality in 2021 and 2022 was between 20-40 percent higher than average, and the upward trend of regarding disabilities and all-cause mortality continues to increase. In this regard, see the article entitled: “A Systematic REVIEW of Autopsy findings in deaths after covid-19 vaccination,” by Hulscher et al., Jun. 21, 2024, https: / / www.sciencedirect.com / science / article / pii / S0379073824001968. As a result, the States of Texas, Florida, Kansas and others have filed lawsuits against Pfizer, Inc., e.g., see the State of Kansas vs. Pfizer Inc., Complaint, by KRIS W. KOBACH, Attorney General, Jun. 17, 2024, https: / / tmsnrt.rs / 3xjKgIg.

[0057] Millions of individuals around the world have now taken the COVID-19 so-called “vaccines” and boosters. Because there is reason to believe that some or all of them possibly include substances which can pose health risks, there is need for a structure, device, method, and technique for removing foreign substances from the blood of individuals who have received one or more of the COVID-19 shots, or who otherwise have undesired matter, e.g., metals such as aluminum, magnesium, gold, silver, iron oxide, titanium, titanium oxide, and / or other matter such as graphene oxide, barium, barium-strontium-titanate, fluoride, lithium, silicon dioxide, strontium, nanostructures, nanobots, pathogens, or toxins in their bloodstreams, and who need or wish to reduce their risk of suffering health problems now and in the future. Medical professionals need to be made aware that fluoride has now been linked to an increased risk of cancer, and also impaired cognitive function, e.g., see the following articles and videos: “Developmental fluoride neurotoxicity: an updated review,” by Philippe Grandjean, Dec. 19, 2019, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC6923889 / ; and see the video interview with Dean Burk captured by the Internet Archive Wayback Machine on May 17, 2023, https: / / web.archive.org / web / 20230601000000 / https: / / video.xx.fbcdn.net / v / t42.1790-2 / 345341691_554631986836709_9036859584582935712_n.mp4?_nc_cat=108&ccb=1-7&_nc_sid=985c63&efg=eyJybHliOjMwMCwicmxhljo1MTsnZbmNvZGVfdGFnljoic3ZIX3Nkln0%3D&_nc_ohc=VVjf5P2dWCgAX_C14ml&rl=300&vabr=101&_nc_ht=scontent-mad2-1.xx&oh=00_AfD5pv9gA8tNw1LYRZpAfFnUp0vpNSUIae8vGMMPhpCJ9A&oe=64691139; and also the testimony of Dean Burk in Congress which can be found in the publication entitled: “The National Cancer Program: Fluoridation of Public Drinking Water,” United States. Congress. House. Committee on Government Operations. Intergovernmental Relations and Human Resources Subcommittee, January, 1977, U.S. Government Printing Office, Google Play Book, https: / / play.google.com / books / reader?id=b98kAAAAMAAJ&pg=GBS.PP1&hl=en; and see the book entitled “The Fluoride Deception,” by Christopher Bryson, published by Seven Stories Press on Mar. 7, 2006, Fluoride Action Network website: https: / / fluoridealert.org / content / fluoride-deception / ; and the video entitled: “The Fluoride Deception: an interview with Christopher Bryson,” posted by fluoride alert on Jun. 22, 2011, https: / / youtu.be / Ly_QP4rGczo?si=Mi3mCIM2uy95weW-; and, see the outcome of the related lawsuit: The EPA'S Final Witnesses Concede Fluoride's Harm, Admit to Flaws In Key Study As Trial Closes, by Brenda Baletti, Ph.D, Feb. 12, 2024, https: / / fluoridealert.org / news / epas-final-witnesses-concede-fluorides-harm-admit-to-flaws-in-key-study-as-trial-closes / .

[0058] The blood supply in the United States and around the World is now believed by some individuals to be contaminated with undesired matter, including but not limited to the spike protein, mRNA, and / or the COVID-19 virus. In this regard, a bill has been introduced in the State of Illinois requiring donated blood to be tested and screened for mRNA vaccines, e.g., see HB4243—Illinois General Assembly, https: / / www.ilga.gov / legislation / 103 / HB / 10300HB4243.htm, and also see the article entitled: “Transfusions of Blood Products Derived from Genetic Vaccine Recipients: Safety Concerns and Proposals for Specific Measures,” by Ueda et al., Mar. 29, 2024, https: / / www.preprints.org / manuscript / 202403.0881 / v2 / download. Accordingly, the present disclosure is directed to structures, devices, methods, and techniques for removing or disabling undesired foreign matter, such as metals, graphene oxide, nanostructures, pathogens, and toxins from human blood or blood portions.SUMMARY

[0059] A first aspect of the present disclosure is a filter device for separating and removing undesired mater from blood or a component of blood including a chamber having a top side, a bottom side, a lateral side and a central axis; the chamber including a cavity; an outside height dimension between the top side and the bottom side of the chamber, and maximum width dimension; an inlet disposed on the top side and an outlet disposed on the bottom side; a filter disposed in the cavity; the filter including at least one of a mesh, a screen, and a filter media capable of capturing, trapping, or adhering the undesired matter being disposed on a plane which is orientated perpendicular to the central axis, whereby the blood or component of blood can be filtered in the chamber between the inlet and the outlet.

[0060] Optionally, the outside height dimension is equal to or greater than the maximum width dimension.

[0061] Optionally, the lateral side is curved.

[0062] Optionally, the filter device has a cylindrical shape.

[0063] Optionally, the inlet and the outlet of are removable.

[0064] Optionally, the inlet is configured to be aligned with the outlet and also about the central axis.

[0065] Optionally, the at least one of the mesh, the screen, and the filter media forms a layer, and the filter includes a plurality of layers.

[0066] Optionally, the at least one of the mesh, the screen, and the filter media further includes a border.

[0067] Optionally, the at least one of the mesh, the screen, and the filter media includes a plurality of wires.

[0068] Optionally, the at least one of the mesh, the screen, and the filter media includes a convoluted configuration.

[0069] Optionally, the plurality of layers are configured in a nested configuration.

[0070] Optionally, the filter device further includes a magnet device disposed proximate to the filter for providing an electromagnetic field.

[0071] Optionally, the magnet device includes at least one permanent magnet or electromagnet disposed proximate to at least one of the top side and the bottom side of the chamber, whereby the undesired matter can be captured, trapped, or adsorbed in the filter.

[0072] Optionally, the magnet device includes at least one permanent magnet or electromagnet disposed proximate to the lateral side of the chamber, whereby the undesired matter can be captured, trapped or adsorbed in the filter.

[0073] Optionally, the magnetic device includes a first magnet having a first positive pole and a first negative pole, and a second magnet having a second positive pole and a second negative pole, the first magnet being configured relative to the second magnet such that the first positive pole of the first magnet is disposed opposite the second negative pole of the second magnet.

[0074] Optionally, the magnet device has an electromagnetic field which is in the range between 0.01-1.0 Tesla.

[0075] Optionally, the magnet device includes an electromagnet including a coiled wire.

[0076] Optionally, the magnet device includes an electromagnet including a wire coiled around a conductive core.

[0077] Optionally, the chamber further includes a support structure for removably securing the magnet device.

[0078] Optionally, the filter is configured to have an electrical charge.

[0079] Optionally, the filter includes a plurality of magnetic beads.

[0080] Optionally, the filter includes a screen or pore size smaller than about 1.5 microns, or 15 microns, or 30 microns.

[0081] Optionally, the undesired matter includes at least one of a metal, graphene oxide, graphene hydroxide, magnetic graphene oxide, an electronic chip or other electronic device, a pathogen, and a toxin.

[0082] A second aspect of the present disclosure includes a filter device for separating and removing undesired matter from blood or a component of blood including: a chamber having a top side, a bottom side, a lateral side, and a central axis; the chamber including a cavity; an outside height dimension between the top side the bottom side of the chamber, a maximum width dimension; an inlet disposed on the top side and an outlet disposed on the bottom side; a filter disposed in the cavity; the filter including at least one of a mesh, a screen, and a filter media capable of capturing, trapping, or adsorbing the undesired matter; the at least one of the mesh, the screen, and the filter media being disposed concentrically about the central axis, whereby the blood or component of blood can be filtered in the chamber between the inlet and the outlet.

[0083] Optionally, the lateral side is curved.

[0084] Optionally, the filter device has a cylindrical shape.

[0085] Optionally, the inlet and the outlet of are removable.

[0086] Optionally, the inlet is configured to be aligned with the outlet and also about the central axis.

[0087] A third aspect of the present disclosure includes a filter device for separating and removing undesired matter from blood or a component of blood including: a chamber having a top side, a bottom side, a lateral side, and a central axis; the chamber including a cavity; an outside height dimension between the top side and the bottom side of the chamber, a maximum width dimension; an inlet disposed on the top side and an outlet disposed on the bottom side; the inlet being in fluid communication with at least one channel which is in fluid communication with the cavity; the chamber including a perforated tube orientated parallel to and about the central axis; the perforated tube being in fluid communication with the outlet; a filter disposed in the cavity of the chamber; the filter including at least one of a mesh, a screen, and a filter media capable of capturing, trapping, or adsorbing the undesired matter; the at least one of the mesh, the screen, and the filter media being disposed concentrically about and parallel to the central axis; whereby the blood or component of blood can be filtered in the chamber between the inlet and the outlet.

[0088] Optionally, the lateral side is curved.

[0089] Optionally, the filter device has a cylindrical shape.

[0090] Optionally, the inlet and the outlet of are removable.

[0091] Optionally, the inlet is configured to be aligned with the outlet and also about the central axis.

[0092] A fourth aspect of the present disclosure includes a filter device for separating and removing undesired matter from blood or a component of blood including: a chamber having a top side, a bottom side, a curved lateral side, and a cylindrical shape; the chamber including a cavity; an outside height dimension between the top side and the bottom side of the chamber, a maximum width dimension; an inlet disposed on the top side and an outlet disposed on the bottom side; the inlet configured to be aligned with the outlet and about the central axis; the chamber including a first wall having a first outside surface and a first inside surface and having a first radius; the chamber including a second wall having a second outside surface and a second inside surface and having a second radius; the second wall being concentric to the first wall and the second radius being less than the first radius; the second wall defining a first space in the cavity of the chamber between the first inside surface of the first wall and the second outside surface of the second wall; the second wall defining a second space in the cavity of the chamber between opposite portions of the second inside wall; a filter including at least one of a mesh, a screen, and a filter media capable of capturing, trapping, or adsorbing the undesired matter disposed in the cavity of the chamber in the second space; and, a magnetic device disposed in the cavity of the chamber in the first space, whereby the magnetic device can impart an electromagnetic field upon the filter and the undesired matter, whereby the blood or component of blood can be filtered in the chamber between the inlet and the outlet.

[0093] A fifth aspect of the present disclosure includes a filter device for separating and removing undesired matter from blood or a component of blood including: a chamber having a top side, a bottom side, and a lateral side; the chamber including a cavity; an outside height dimension between the top side and the bottom side of the chamber, a maximum width dimension; the chamber including an inlet and an outlet; the chamber including a spiral channel which descends from proximate to the top side to proximate to the bottom side; a filter including at least one of a mesh, a screen, and a filter media capable of capturing, trapping, or adsorbing the undesired matter disposed within the spiral channel, whereby the length of the flow path of the blood or blood component is greater than the outside height dimension, and the blood or component of blood can be filtered in the chamber between the inlet and the outlet.

[0094] Optionally, the spiral channel descends from proximate to the top side to proximate to the bottom side in a plurality of portions which alternate in slope in the range between 0 / 1 and 10 / 1.

[0095] Optionally, the lateral side is curved.

[0096] Optionally, the filter device has a cylindrical shape.

[0097] Optionally, the inlet and the outlet of are removable.

[0098] Optionally, the filter device has a central axis.

[0099] Optionally, the inlet is configured to be aligned with the outlet and also about the central axis.

[0100] A sixth aspect of the present disclosure includes a filter device for separating and removing undesired matter from blood or a component of blood including: a chamber having a top side, a bottom side, and a lateral side; the chamber including a cavity; an outside height dimension between the top side and the bottom side of the chamber, a maximum width dimension; an inlet disposed on the top side and an outlet disposed on the bottom side; the chamber including a plurality of baffles defining a plurality of channels and openings; each of the plurality of channels being in fluid communication with each other of the plurality of channels through the openings; one or more filters including at least one of a mesh, a screen, and a filter medium disposed within the plurality of channels; whereby the length of the flow path of the blood or blood component is greater than the outside height dimension and the blood or component of blood can be filtered in the chamber between the inlet and the outlet.

[0101] Optionally, the lateral side is curved.

[0102] Optionally, the filter device has a cylindrical shape.

[0103] Optionally, the inlet and the outlet of are removable.

[0104] Optionally, the filter device has a central axis.

[0105] Optionally, the inlet is configured to be aligned with the outlet and also about the central axis.

[0106] A seventh aspect of the present disclosure includes a method of treating an individual having undesired matter dispersed in their blood, the method including the steps of: inserting a first needle into a first vein or artery of the individual at a first puncture site and connecting the first needle to tubing, a stop valve, a filter device, an air bubble eliminator device, and to a second needle which is inserted into a second vein or artery of the individual at a second puncture site; and, manipulating the stop valve to initiate the flow of blood from the first puncture site through the filter device and reinfusing filtered blood through the second puncture site.

[0107] Optionally, the method further includes a magnet device including at least one permanent magnet or electromagnet for providing an electromagnetic field disposed proximate to the filter.

[0108] Optionally, the magnet device includes a first magnet having a first positive pole and also a first negative pole, and a second magnet having a second positive pole and also a second negative pole, the first magnet being configured relative to the second magnet such that the first positive pole of the first magnet is disposed opposite the second negative pole of the second magnet.

[0109] Optionally, the electromagnetic field of the magnet device is in the range between 0.01-1.0 Tesla.

[0110] Optionally, the magnet device further includes at least one selection control for controlling at least one of the following electrical or electromagnetic variables: the voltage and current, the frequency and wavelength, the waveform, the polarity, the source of electrical power being either AC versus DC, and an on and off switch.

[0111] Optionally, the filter device is configured to have an electrical charge.

[0112] Optionally, the filter device further includes a plurality of magnetic beads, whereby the undesired matter is separated from the blood and captured, trapped, or adsorbed in the filter device.

[0113] Optionally, the undesired matter includes at least one of a metal, graphene oxide, graphene hydroxide, magnetic graphene oxide, an electronic chip or other electronic device, a pathogen, a bacterium, a cancerous cell, a virus, a spike protein, a blood cell infected with a virus, a COVID-19 virus, and a toxin.

[0114] Optionally, the flow of blood is performed at one of the following rates: 0.1-10 L / hr, 1-10 L / hr, 3-10 L / hr, or 5-10 L / hr.

[0115] Optionally, the flow of blood and reinfusion is performed in a continuous mode, or a cyclic mode.

[0116] Optionally, the filter includes a screen or pore size smaller than 1.5 microns, or 15 microns, or 30 microns.

[0117] Optionally, the inlet of the filter device and the outlet of the filter device are removable.

[0118] An eighth aspect of the present disclosure is a method of treating an individual having undesired matter dispersed in their blood, the method including the steps of: inserting a first needle into a first vein or artery of the individual at a first puncture site and connecting the first needle to tubing, a stop valve, a filter device, a pump, an air bubble eliminator, and to a second needle which is inserted into a second vein or artery of the individual at a second puncture site; and, manipulating the stop valve to initiate the flow of blood from the first puncture site through the filter device and reinfusing filtered blood through the second puncture site.

[0119] Optionally, the method further includes connecting and using at least one analyte sensor between the first needle and the filter device.

[0120] Optionally, the method further includes connecting and using a blood or blood portion dispersion device including a window between the first needle and the filter device.

[0121] Optionally, the method further includes deploying and using at least one optical device between the first needle and the filter device.

[0122] Optionally, the method further includes deploying and using a first blood or blood component conditioning device between the first needle and the filter device.

[0123] Optionally, the method further includes deploying and using a second blood or blood component conditioning device proximate to the filter device.

[0124] Optionally, the second blood or blood component conditioning device includes a magnet device including at least one permanent magnet or electromagnet for providing an electromagnetic field.

[0125] Optionally, the magnet device includes a first magnet having a first positive pole and a first negative pole, and a second magnet having a second positive pole and a second negative pole, the first magnet being configured relative to the second magnet such that the first positive pole of the first magnet is disposed opposite the second negative pole of the second magnet.

[0126] Optionally, the electromagnetic field of the magnetic device is in the range between 0.01-1.0 Tesla.

[0127] Optionally, the method further includes deploying and using a third blood or blood component conditioning device between the filter device and the second needle.

[0128] Optionally, the method further includes deploying and using a computer or other electronic medical device including a monitor and having a wired or wireless connection to at least one of a stop valve, an air bubble eliminator, a filter, a pump, an analyte monitoring device, an optical device, and a blood or blood component conditioning device.

[0129] Optionally, the method further includes an optical device which is at least one of a microscope, a stereo microscope, and an electron microscope.

[0130] Optionally, the blood or blood component conditioning device includes at least one selection control for controlling at least one of the following electrical or electromagnetic variables: the voltage and current, the frequency and wavelength, the waveform, the polarity of at least one electromagnet, the source of electrical power being either AC versus DC, and an on and off switch.

[0131] Optionally, the filter device is configured to have an electrical charge whereby the undesired matter can be separated and removed from the blood and be captured, trapped, or adsorbed in the filter device.

[0132] Optionally, the filter device further includes a plurality of magnetic beads whereby the undesired matter can be separated and removed from the blood and captured, trapped, or adsorbed in the filter device.

[0133] Optionally, the undesired matter includes at least one of a metal, graphene oxide, graphene hydroxide, magnetic graphene oxide, an electronic chip or other electronic device, a pathogen, a bacterium, a cancerous cell, a virus, a spike protein, a blood cell infected with a virus, a COVID-19 virus, and a toxin.

[0134] Optionally, the flow of blood is performed at one of the following rates: 0.1-10 L / hr, 1-10 L / hr, 3-10 L / hr, or 5-10 L / hr.

[0135] Optionally, the flow of blood and reinfusion is performed in a continuous mode, or a cyclic mode.

[0136] Optionally, the filter includes a screen or pore size smaller than 1.5 microns, or 15 microns, or 30 microns.

[0137] Optionally, the inlet of the filter device and the outlet of the filter device are removable.

[0138] Optionally, the pump is a portion of medical device selected from the group of medical devices consisting of an apheresis device, a plasmapheresis device, an extracorporeal blood purification device, a hemofiltration device, a continuous veno-venous hemofiltration device, a hemodiafiltration device, an ultrafiltration device, and a hemodialysis or dialysis device.

[0139] Optionally, the filter is a portion of a medical device selected from the group of medical devices consisting of an apheresis device, a plasmapheresis device, an extracorporeal blood purification device, a hemofiltration device, a continuous veno-venous hemofiltration device, a hemodiafiltration device, an ultrafiltration device, and a hemodialysis or dialysis device.

[0140] Optionally, the method further includes using a blood or blood component conditioning device which is an ultrasound device for providing vibration excitation.

[0141] Optionally, the vibration excitation is selected in the range between 5-10 MHz.

[0142] Optionally, the method further includes using a blood or blood component conditioning device which is a source of ultraviolet light.

[0143] Optionally, the ultraviolet light has a wavelength in the range between 10-400 nanometers.

[0144] A ninth aspect of the present disclosure is a method of treating human blood or a blood portion which includes undesired matter, the method including the steps of: causing the human blood or the blood portion to be passed at least through one of an air bubble eliminator, a blood dispersion device, and a filter device, and also in proximity and functional relation to a blood conditioning device which includes at least one of a magnet device or other source for providing at least one electromagnetic field, an ultrasound device for providing vibration excitation, and an ultraviolet light device for providing ultraviolet light, and exposing the blood or blood portion to at least one of an electromagnetic field, an ultrasound vibration excitation, and an ultraviolet light, and then collecting and storing the blood or blood portion which has been so treated.BRIEF DESCRIPTION OF THE DRAWINGS

[0145] FIG. 1 is a side cross sectional view of a filter device.

[0146] FIG. 2 is a side cross sectional view of an alternative embodiment of a filter device including a magnetic device.

[0147] FIG. 3 is a top view of a screen portion of a filter for use in a filter device.

[0148] FIG. 4 is a top view of an alternative embodiment of a filter for use in a filter device.

[0149] FIG. 5 is a top perspective view of the alternate embodiment of a filter for use in a filter device.

[0150] FIG. 6 is a side cross sectional view of an alternative filter device including an alternative magnetic device.

[0151] FIG. 7 is a top perspective view of an alternative embodiment of a filter for use in a filter device.

[0152] FIG. 8 is a top view of a portion of an alternative embodiment of a filter for use in a filter device.

[0153] FIG. 9 is a side cross-sectional view of an alternative embodiment of a filter device.

[0154] FIG. 10 is a top view of the filter shown in FIG. 7.

[0155] FIG. 11 is a cross-section view taken along line 11-11 of the blood dispersion device shown in FIG. 16.

[0156] FIG. 12 is a cross-sectional view taken along line 12-12 of an alternative embodiment of the filter device shown in FIG. 15.

[0157] FIG. 13 is a perspective view of an alternative electromagnet disposed around a tube.

[0158] FIG. 14 is a side view of an alternative electromagnet disposed around a filter device.

[0159] FIG. 15 is a side cross-sectional view of an alternative embodiment of a filter device including an alternative electromagnet device.

[0160] FIG. 16 is a top view of a blood dispersion device.

[0161] FIG. 17 is a side view of a T-shaped alternative embodiment of a filter device.

[0162] FIG. 18 is a side view of a L-shaped alternative embodiment of a filter device.

[0163] FIG. 19 is a side view of three components of a kit for making a blood infusion or transfusion.

[0164] FIG. 20 is a side cross-sectional view of an alternative embodiment of a filter device which includes a plurality of internal baffles and openings.

[0165] FIG. 21 is a side cross-sectional view of an alternative embodiment of a filter device which includes a spiral structure.

[0166] FIG. 22 is a side cross sectional view of a filter device generally similar to the filter device shown in FIG. 1, but which further includes a removable top side and seal.

[0167] FIG. 23 is a top view of an alternative T-shaped embodiment of a filter device which includes four quadrant portions.

[0168] FIG. 24 is a side cross sectional view taken along line 24-24 of the alternative T-shaped embodiment of a filter device shown in FIG. 23.

[0169] FIG. 25 shows an extracorporeal blood filtering device and method which can include in complete combination or various alternative partial combinations, a first needle disposed at a first puncture site, tubing, a valve or roller clamp, a filter device, an air bubble eliminator device, and a second needle disposed at a second puncture site on the body of an individual and patient.

[0170] FIG. 26 shows an alternative embodiment of an extracorporeal blood filtering device and method which can include in complete combination or various alternative partial combinations, a first needle disposed at a first puncture site, tubing, a valve or roller clamp, a filter device, an air bubble eliminator device, a second needle disposed at a second puncture site on the body of an individual and patient, and also a conditioning device, a plurality of wires, and a computer or other medical device which includes a monitor screen and a plurality of selection controls including a keyboard.

[0171] FIG. 27 shows an alternative embodiment of an extracorporeal blood filtering device and method which can include in complete combination or various alternative partial combinations, a first needle disposed at a first puncture site, tubing, a stop valve, a filter device, a pump device, an air bubble eliminator device, a second needle disposed at a second puncture site on the body of an individual and patient, and also a conditioning device, a plurality of wires, and a computer or other medical device including a monitor screen and a plurality of selection controls including a keyboard.

[0172] FIG. 28 shows an alternative embodiment of an extracorporeal blood filtering device and method which can include in complete combination or various alternative partial combinations, a first needle disposed at a first puncture site, tubing, a valve or roller clamp, a filter device, a pump device, an air bubble eliminator device, at least one analyte sensor device, a second needle disposed at a second puncture site on the body of an individual and patient, and also a conditioning device, a plurality of wires, and a computer or other medical device including a monitor screen and a plurality of selection controls including a keyboard.

[0173] FIG. 29 shows an alternative embodiment of an extracorporeal blood filtering device and method which can include in complete combination or various alternative partial combinations, a first needle disposed at a first puncture site, tubing, a valve or roller clamp, a filter device, a pump device, an air bubble eliminator device, a second needle disposed at a second puncture site on the body of an individual and patient, a first conditioning device, a second conditioning device, a third conditioning device, a first analyte sensor device, a second analyte sensor device, a possible third analyte sensor device, a plurality of wires, and a computer or other medical device including a monitor screen and plurality of selection controls including a keyboard.

[0174] FIG. 30 shows an alternative embodiment of an extracorporeal blood filtering device and method which can include in complete combination or various alternative partial combinations, a first needle disposed at a first puncture site, tubing, a valve or roller clamp, a filter device, a pump device, an air bubble eliminator device, a second needle disposed at a second puncture site on the body of an individual and patient, a first conditioning device, a second conditioning device, a third conditioning device, a first analyte sensor device, a second analyte sensor device, a third analyte sensor device, a first blood dispersion device, a second blood dispersion device, a first optical monitor, a second optical monitor, a possible third optical monitor, a plurality of wires, and a computer or other medical device including a monitor screen and a plurality of selection controls including a keyboard.

[0175] FIG. 31 shows a first bag 95a or container which contains blood or a blood portion which is to be treated, and also its collection in a second bag 95b or container which contains the blood or blood portion which has been treated.

[0176] FIG. 32 shows an alternative embodiment of a blood dispersion device which is wider than the blood dispersion device shown in FIG. 16.DETAILED DESCRIPTIONHuman Blood

[0177] Human blood includes four main components: plasma, red blood cells, white blood cells, and platelets. In this regard, the composition of human blood is about 45% blood cells and platelets, and about 55% plasma. An average man has about 12 pints of blood, and average woman about 9 pints of blood. With regards to the size and scale used to discuss blood and its various components one micron (μm) equals 1000 nanometers (nm) and the average size of red blood cells is normally in the range between 6-9 microns or 6,000-9,000 nm. The average size of small white blood cells is in the range between 7-8 microns or 7,000-8,000 nm, whereas the average size of most white blood cells is in the range between 10-15 microns or 10,000-15,000 nm, but a few white blood cells are as large as 15-30 microns or 20,000-30,000 nm. The average size of platelets is typically between 1.5-4 microns or 1,500-4,000 nm. For reference purposes, the size of a hydrogen atom is 0.1 nm; the size of a silicon atom is about 0.2 nm; the size of a DNA molecule is about 1 nm; the size of the COVID-19 virus is between 60-140 nm and it is negatively charged, and, the width of a human hair is about 80-100 microns or 80,000-100,000 nm.Graphene

[0178] Materials in the graphene family such as graphene oxide, graphene hydroxide, magnetic graphene oxide can be made one molecule layer thick which is approximately between 1-10 nm, but their length or sheet and particle size of can be anywhere between several nanometers to microns. These particles are typically electrically conductive and have a negative charge. At this time, the brand and specific type and size of the graphene particles which have apparently been included in the COVID-19 so-called “vaccines” are not known because the pharmaceutical companies did not list the substances as ingredients, and have denied that such particles have been included. However, more than one researcher has found evidence of foreign particles which belong to the graphene family in the so-called “vaccines.” It is not known whether all of the pharmaceutical companies used foreign particles of the same graphene family or different types and sizes of these particles in their so-called “vaccines.” Metals and other electrically conductive or magnetic particles, and including those in the graphene family such as graphene oxide or graphene hydroxide can sometimes be attracted to one another and then congregate, aggregate, and / or self-assemble. Such particles are responsive to electromagnetic radiation, magnetic fields, and including cell phones using 4G and 5G, and they can possibly constitute antennas on the micron and nanometer scales. Accordingly, the particle size of graphene oxide or other like substances in human blood could potentially be anywhere in the range between 1-10 nm to one or more microns. Because these substances can congregate, aggregate, and self-assemble there is also a potential for obstruction and clogging to take place within the circulatory system and elsewhere in the human body. The single molecule thick structure of graphene oxide combined with the strength and hardness of the material can possibly also provide a hazard with regards to the particles cutting and causing hemorrhaging and blood clots to form within the human body. The potential risk can possibly be increased for those athletes who typically exercise at elevated heart rates such as runners and soccer players, but also for individuals having pre-existing heart and circulatory system issues. Moreover, there are also potential risks which can be associated with the effects of electronic devices such as cell phones and heart pacemakers being placed in close proximity to an individual having metal or other electrically conductive foreign particles such as graphene oxide in their bloodstream. Some individuals believe that graphene oxide can possibly be broken down in the human body and eliminated by eating certain foods and / or taking certain substances. However, insofar as graphene oxide is stronger than steel and harder than diamond, and in some sense, resembles a sheet of glass on a micron or nanometer scale, the idea of breaking a sheet of glass into smaller pieces which could possibly then potentially travel more easily and become lodged in more vulnerable places may not be prudent in view of some of the aforementioned risk factors. In summary, there is a need for targeting, separating, and removing foreign and undesired matter which could include, but not be limited to members of the graphene family from the blood of potentially millions of people in the United States, and also all around the world.Extracorporeal Blood Filtering Device

[0179] This disclosure is written with the recognition that the same medical practices, equipment and supplies are not necessarily available to everyone all around the world. Further, depending upon which so-called “vaccines” have been administered, and how many booster shots have been taken, different individuals around the world could have different amounts or types of foreign matter, such as metals, or materials of the graphene family, or other kinds of undesired matter in their bloodstream and bodies. Other forms of undesired matter could possibly also include at least one marker, tracker, antenna, electronic chip and / or other electronic devices, a metal, a nanometal, graphene oxide, graphene hydroxide, magnetic graphene oxide, a pathogen, a bacterium, a cancerous cell, a virus, a spike protein, a blood cell infected with a virus, a COVID-19 virus, and a toxin. For this reason, this application will disclose several different methods, techniques, and processes for possibly removing undesired matter from a fluid, blood portion or blood of individuals and patients.

[0180] Before any of the procedures and techniques discussed below would be conducted, a typical medical practice would be to first remove, observe, analyze and test a small sample of an individual and patient's 28 blood 10 in order to ascertain the presence of undesired matter 9, and also screen for other pre-existing health conditions. At that time, a medical practitioner would be able determine the individual or patient's 28 ABO blood group system blood type, Rh factor and establish a baseline reference point with regards to their blood 10 profile and general health. In this regard, the removal, examination, and possible filtering treatment and return of human blood 10 to an individual and patient 28 is and should be performed by a trained medical doctor, nurse, paramedics, phlebotomists, dialysis technicians, or qualified nursing staff.

[0181] Several different alternative methods, techniques, and processes for possibly removing undesired matter from a fluid, blood portion or blood 10 of individuals and patients 28 will be disclosed and discussed with reference to drawing FIGS. 25-30 because the same medical expertise, methods, techniques, processes, equipment and supplies are not available to everyone all around the world. Some of these alternative methods, techniques, and processes would require fewer medical personnel and also less medical equipment, and so could be faster to perform and also less expensive than others.Conventional Blood Infusion and / or Transfusion

[0182] Common medical practice for the purpose of making a blood infusion and / or transfusion is to first locate one or more veins or arteries, and apply a tourniquet 3-4 inches above the desired puncture site 27a, sanitize the area where a needle 8a would be inserted using alcohol wipes, and then insert and secure the needle 8a. The size needle 8a which is typically used is 18 gauge, and made of a stainless-steel material. As shown in FIG. 19, the needle 8a can be connected to a straight union 86 made of a thermoplastic material such as an acrylic, a low-density polyethylene (LDPE), an acrylonitrile butadiene styrene (ABS), a polyvinyl chloride (PVC), a polyamide / Nylon (PA), a polypropylene (PP) which can be connected to a natural or latex rubber fitting 87 which in turn is connected to flexible tubing 7 which can be made of a clear thermoplastic material such as PVC. During a conventional blood infusion and / or transfusion procedure, a line including the aforementioned needle 8a, union 86, natural or latex rubber fitting 87, and tubing 7 is typically connected to the outlet 32c of a drip chamber 89. The drip chamber 89 is at least partially transparent and includes a flexible portion which can be used to manually pump a fluid therethrough in order to flush and at least partially fill the drip chamber 89. The drip chamber 89 includes an inlet 31c, an outlet 32c, and can and typically does include an integral valve 30 for venting air and also controlling the flow of a fluid, blood portion or blood 10. The drip chamber 89 also further includes a conventional filter 90 for removing possible blood clots and typically has a particle filtration size in the range between 170-260 microns. The inlet 31c of the drip chamber 89 can be and typically is connected by tubing 7 to the outlet 32y of a Y shaped union 84 which can be made and configured as a piece of Y tubing which includes three connectors 88 such as luer connectors 94 for joining and making fluid communication with three different lines of tubing 7. In this regard, one branch of the Y shaped union 84 can be and typically is connected by tubing 7 to the outlet 32b of a bag 92 of 0.9% saline solution which can be hung overhead and used to flush out the tubing 7 and any other devices which are going to be used in the procedure, and also possibly in order dilute the contents of a second bag 95 which can possibly include, e.g., whole blood, red blood cells, white blood cells, or plasma. Alternatively, when a bag 92 of 0.9% saline solution is not available, the individual and patient's 28 own blood 10 and / or the contents of the second bag 95 can be used to flush and / or fill the devices and lines that will be used during the blood infusion and / or transfusion procedure. The other branch of the Y shaped union 84 can be and typically is connected to a second bag 95 which can possibly include, e.g., whole blood, red blood cells, white blood cells, or plasma which is to be transfused. Three valves 30 in the form of roller clamps 85 which can be used to stop and / or control the rate of flow of these fluids are typically disposed on all of the tubes 7 leading to and from the Y shaped union 84, and a valve 30 or roller clamp 85 is also typically disposed on the tubing 7 which extends between the outlet 32c of the drip chamber 89 and the rubber or latex fitting 87, union 86 and needle 8a. When all of the above structures and connections have been made and the blood infusion and / or transfusion apparatus has been prepared, in a routine and non-emergency situation a medical professional will manipulate the valve(s) 30 and / or roller clamps 85 to initiate a blood infusion and / or transfusion of red blood cells, plasma, and / or platelets at a rate of 2 milliliters (mL) / kilogram (kg) / hour (hr) for the first 15 minutes, and then will typically increase the rate of flow to about 2-5 ml / kg / hr for red blood cells, and 4-10 ml / kg / hr for plasma, and or platelets.Extracorporeal Filtering of Blood

[0183] Common medical practice for the purpose of filtering and treating a blood portion and / or blood of an individual and patient is to first locate one or more veins or arteries, and apply a tourniquet 3-4 inches above the desired first puncture site 27a, sanitize the area where a first needle 8a would be inserted using alcohol wipes, and then insert and secure the first needle 8a. The size needle 8a which is typically used is 18 gauge and made of a stainless-steel material. The first needle 8a can be connected to a first straight union 86a made of a thermoplastic material such as an acrylic, a low density polyethylene (LDPE), an acrylonitrile butadiene styrene (ABS), a polyvinyl chloride (PVC), a polyamide / Nylon (PA), a polypropylene (PP) which can be connected to a first natural or latex rubber fitting 87a which in turn is connected to a piece of flexible tubing 7 which can be made of a clear thermoplastic material such as PVC. The tubing 7 can be and typically is connected to a Y shaped union 84 which can be configured as a piece of Y tubing which includes three connectors 88 such as luer connectors 94 for making fluid communication with three different lines and pieces of tubing 7. In this regard, one branch of the Y shaped union 84 can be connected using a piece of tubing 7 to the aforementioned tubing 7, rubber fitting 87 and union 86 structures which are connected to and in fluid communication with the first needle 8a. The other branch of the Y shaped union 84 can be possibly connected to a piece of tubing 7 which is connected to the outlet 32c of a drip chamber 89. The inlet 31c of the drip chamber 89 can be connected to the outlet 32b of a bag 92 of 0.9% saline solution which can be hung overhead and used to flush out the tubing 7 and any other devices which are going to be used in the procedure. The drip chamber 89 is at least partially transparent and includes a flexible portion which can be used to manually pump a fluid in order to flush and at least partially fill the drip chamber 89. The drip chamber 89 includes an inlet 31c, an outlet 32c, and can and typically does include an integral valve 30 for venting air and also controlling the flow of a liquid, blood portion or blood 10. The drip chamber 89 also further includes a conventional filter 90 for removing possible blood clots or other matter and typically has a particle filtration size in the range between 170-260 microns. Three valves 30 which can be in the form of roller clamps 85 can be used to stop and / or control the rate of flow of any given fluid are typically disposed on all of the tubes 7 leading to and from the Y shaped union 84, and including the tubing 7 which is disposed between the Y shaped union 84 and the rubber or latex fitting 87, union 86, and needle 8a. The outlet 32y of the Y shaped union 84 is typically connected to one end of piece of tubing 7 and the other end is connected to or otherwise placed in fluid communication with the inlet 31f of a filter device 4 which is configured to separate and remove undesired matter 9, such as a metal, a nanometal, members of the graphene family, trackers, chips and other electronic devices, a pathogen, a bacterium, a cancerous cell, a virus, a spike protein, a blood cell infected with a virus, a COVID-19 virus, and a toxin. The outlet 32f of the filter device 4 can be and typically is connected to a piece of tubing 7 which is connected to or otherwise placed in fluid communication with the inlet 31a an air bubble eliminator device 48. Another piece of tubing can be used to connect the outlet 32a of the air bubble eliminator device 48 to the second natural or latex rubber fitting 87b which is connected to a second union 86b which is connected to a second needle 8b that is inserted at a second puncture site 27b. Alternatively, when a bag 92 of 0.9% saline solution is not available, the individual and patient's 28 own blood 10 can be used to flush and fill the devices and lines that will be used during the procedure. In that case, the Y shaped union 84 can be eliminated and the tubing 7 connected to the first natural or latex fitting 87a and first union 8a and first needle 8a can instead be connected to or otherwise placed in fluid communication with the inlet 31f of the filter device 1. When all of the above structures and connections have been made and the extracorporeal blood filtering and transfusion apparatus has been prepared, in a routine and non-emergency situation a medical professional will manipulate the valve(s) 30 and / or roller clamps 85 to initiate a blood transfusion of red blood cells, plasma, and / or platelets at a rate of 2 milliliters (mL) / kilogram (kg) / hour (hr) for the first 15 minutes, and then will typically increase the rate of flow to about 2-5 ml / kg / hr for red blood cells, and 4-10 ml / kg / hr for plasma, and or platelets.

[0184] Henceforth in this application, the structures which are sometimes referred to in the medical field and which have been independently recited in the specification as being a needle 8a, a union 86a, and a natural rubber or latex fitting 87a will be simply referred to as a needle or first needle in the claims. Likewise, the structures which have been independently recited as being a needle 8b, a union 86b, and a natural rubber or latex fitting 87b will be simply referred to as a second needle in the claims. Further, the structures which have been independently recited as being a part of drip chamber 89 which typically includes a transparent portion, a flexible portion which can be manipulated as a hand pump, a conventional blood filter, and also a valve 30 will be simply be referred to as a drip chamber in the claims. In addition, the structures which are sometimes referred to in the medical field as being an air bubble eliminator, or an air bubble filter, or an air bubble trap will be referred to as simply an air bubble eliminator device 48 in the specification and air bubble eliminator device in the claims. Examples of commercially available air bubble eliminator devices include the GVS SpeedFLow® 0.2 μm filter made by GVS Filtration, Inc. of Bologna, Italy which is available from TrueCare Biomedix USA Inc., of South Miami, Florida, and the B. Braun 0.2 μm SUPOR® filter made by B. Braun Medical, Inc. of Bethlehem, Pennsylvania and B. Braun Melsunger AG, located in Melsungen, Germany, e.g., see the website: https: / / www.bbraun.com / en.html.

[0185] The extracorporeal blood filtering device 33a-f, and related methods, techniques and processes can include the devices, structures, methods and techniques which are disclosed in FIG. 19, FIGS. 25-30, and others discussed herein. As shown in FIG. 25, a first needle 8a can inserted into a vein or artery of an individual and patient's 28 arm 75 and be secured proximate to the first puncture site 27a. One end of a first piece of tubing 7a can be connected to the needle 8a and the other end can be connected to the inlet 31v of a valve 30 or roller clamp 85 which can stop or regulate the flow of an individual and patient's 28 blood 10. One end of a second piece of tubing 7b can be connected to the outlet 32v of the valve 30 and the other end can be connected to the inlet 31f of a filter device 1. One end of a third piece of tubing 7c can connected to the outlet 32f of the filter device 1 and the other end can be connected to the inlet 31a of an air bubble eliminator device 48. One end of a fourth piece of tubing 7d can be connected to the outlet 32a of the air bubble eliminator device 48 and the other end can be connected to a second needle 8b which is can be inserted and secured proximate a second puncture site 27b on the individual and patient 28. The second puncture site 27b can be located at a second vertical elevation on a different arm 75 or leg 76 of the individual and patient 28 that is below the first vertical elevation of the first puncture site 27a so that the individual and patient's 28 own heart, blood pressure and gravity can be used to move their blood 10 through the filter device 1 and back into their bloodstream.

[0186] As shown in FIG. 26, the next simplest and alternative extracorporeal blood filtering device 33b, and related method, technique and process can be the same as that which has been disclosed above, but further includes a blood or blood portion conditioning device 20, hereinafter referred to as “conditioning device 20” or “second conditioning device 20,” which can include a magnet device 11 that is disposed either inside or proximate to the filter device 1 and / or filter 4 for attracting, directing, or otherwise manipulating the foreign undesired matter 9 so that it can be captured, mechanically trapped and / or adsorbed by the filter 4. The conditioning device can be connected by wire or wirelessly to a computer 36 or other medical device having a monitor screen 37 and a keyboard 96, touch pad, and mouse.

[0187] As shown in FIG. 27, the next simplest and alternative extracorporeal blood filtering device 33c, and related method, technique and process can be the same as that which has been disclosed above, but further includes a blood pump 26 disposed between the filter device 1 and the air bubble eliminator device 48. Accordingly, as shown in FIG. 27, a first needle 8a can inserted into a vein or artery of an individual and patient's 28 arm 75 and be secured proximate to the first puncture site 27a. One end of a first piece of tubing 7a can be connected to the needle 8a and the other end can be connected to the inlet 31v of a valve 30 or roller clamp 85 which can stop or regulate the flow of an individual and patient's 28 blood 10. One end of a second piece of tubing 7b can be connected to the outlet 32v of the valve 30 and the other end can be connected to the inlet 31f of a filter device 1. One end of a third piece of tubing 7c can be connected to the outlet 32f of the filter device 1 and the other end can be connected to the inlet 21p of the blood pump 26. One end of a fourth piece of tubing 7d can be connected to the outlet 32b of the blood pump 26 and the other end can be connected to the inlet 31a of an air bubble eliminator device 48. One end of a fifth piece of tubing 7e can be connected to the outlet 32a of the air bubble eliminator device 48 and the other end can be connected to a second needle 8b which is can be inserted and secured proximate a second puncture site 27b on the individual and patient 28's arm 75 or leg 76. When a blood pump 26 is included, additional valves 30 or roller clamps 85 for stopping or regulating the individual and patient's blood 10 flow can be disposed before the inlet 31p and / or after the outlet 32p of the blood pump. The conditioning device 20 and blood pump 26 can be connected by wire or wirelessly to a computer 36 or other medical device having a monitor screen 37 and a keyboard 96, touch pad, and mouse.

[0188] As shown in FIG. 28, the next simplest and alternative extracorporeal blood filtering device 33d, method, technique and process can be the same as that which has been disclosed above, but further includes an first analyte sensor device 38a for detecting the undesired matter 9 before the inlet 31f of the filter device 1, a second analyte sensor device 38c after the outlet 32f of the filter device 1 disposed before the needle 8b located at the second puncture site 27b so the amount and degree of success in removing the undesired matter 9 can be measured and known. Further, a third analyte sensor device 38c can possibly be disposed inside or proximate to the filter 1 for research purposes. Accordingly, as shown in FIG. 28, a first needle 8a can inserted into a vein or artery of an individual and patient's 28 arm 75 and be secured proximate to the first puncture site 27a. One end of a first piece of tubing 7a can be connected to the needle 8a and the other end can be connected to the inlet 31v of a valve 30 or roller clamp 85 which can stop or regulate the flow of an individual and patient's 28 blood 10. One end of a second piece of tubing 7b can be connected to the outlet 32v of the valve 30 and the other end can be connected to the inlet 31s of the first analyte sensor 38a. One end of a third piece of tubing 7c can be connected to the outlet 32s of the first analyte sensor 38a and the other end can be connected to the inlet 31f of a filter device 1. One end of a fourth piece of tubing 7d can be connected to the outlet 32f of the filter device 1 and the other end can be connected to the inlet 32p of the blood pump 26. One end of a fifth piece of tubing 7d can be connected to the outlet 32b of the blood pump 26 and the other end can be connected to the inlet 31s of the second analyte sensor 38b. One end of a fifth piece of tubing 7e can be connected to the outlet 32s of the second analyte sensor 38b and the other end can be connected to the inlet 31a of the air bubble eliminator device 48. One end of a sixth piece of tubing 7f can be connected to the outlet 32a of the air bubble eliminator device 48 and the other end can be connected to a second needle 8b which is can be inserted and secured proximate a second puncture site 27b on the individual and patient 28's arm 75 or leg 76. Additional valves 30 or roller clamps 85 for stopping or regulating the individual and patient's 28 blood 10 flow can be disposed before the inlets 31s and also after the outlets 32s of the analyte sensor devices 38a-b. The conditioning device 20, analyte sensor devices 38a-c, and pump 26 can be connected by wire or wirelessly to a computer 36 or other medical device having a monitor screen 37 and a keyboard 96, touch pad, and mouse.

[0189] As shown in FIG. 29, the next simplest and alternative extracorporeal blood filtering device 33e, and related method, technique and process would be the same as that which has been just disclosed above, but can further include a first blood or blood portion conditioning device 5, hereinafter simply referred to as “conditioning device 5” or “first conditioning device 5” located between the first needle 8a and the inlet 31f of the filter device 1, and possibly also a third blood or blood portion conditioning device 25, hereinafter simply referred to as “conditioning device 25” or “third conditioning device 25,” located between the outlet 32f of the filter device 1 and the second needle 8b. The conditioning devices 5, 20 and 25, analyte sensor devices 38a-b, and pump 26 can be connected by wire or wirelessly to a computer 36 or other medical device having a monitor screen 37 and a keyboard 96, touch pad, and mouse.

[0190] As shown in FIG. 30, the next simplest and alternative extracorporeal blood filtering device 33f, and related method, technique and process would be the same as that which has been just disclosed above, but can further include a first blood dispersion device 49a disposed between the first needle 8a and the inlet 31f of the filter device 1, and possibly also a second blood dispersion device 49b disposed between the outlet 32f of the filter device 1 and the inlet 31p of the blood pump 26.

[0191] As shown in FIGS. 11, 16, and 32, a blood dispersion device 49a-b can include an inlet 31d which leads to a first funnel portion 50a, a middle portion 51 having a relatively thin vertical cross-section and inside dimension, a second funnel portion 50b, and an outlet 32d. The middle portion 51 having a relatively thin vertical cross-section and inside dimension can also further include a transparent window portion 52. The middle portion 51 leads to a second funnel portion 50b which then leads to an outlet 32d. In the embodiments shown in FIGS. 11, 16, and 32, the length of the middle portion 51 is oriented horizontally and disposed between the first funnel portion 50a and second funnel portion 50b. In these drawing figures the middle portion 51 is relatively short and nearly equal in length to the inlet 31d and outlet 32d portions of the blood dispersion device 49a-b, and this approximately represents the smallest length of a middle portion 51 which is practical for use. However, the middle portion 51 can alternatively be made to be longer, e.g., 2-10 times greater in length than what is shown in FIGS. 11, 16, and 32. The middle portion 51 is configured to provide a relatively flat and wide chamber 2a having a relatively thin vertical cross-section and inside dimension, but a relatively wide horizontal dimension between the inlet 31d and outlet 32d in which the blood or blood portion is caused to be more widely dispersed during flow as compared with its normal flow in conventional round plastic tubing, and thereby enables the blood or a blood portion to be more readily exposed to an electromagnetic field, and / or an ultrasound device, and / or ultraviolet light, and / or to be observed using a microscope, camera, or other imaging device, as discussed herein.

[0192] FIG. 32 shows an alternative embodiment of a blood dispersion device 49a which is wider than the blood dispersion device 49b shown in FIG. 16. In this regard, FIG. 16 shows a middle portion 51 which is relatively narrow in width. However, the middle portion 51 can alternatively be made to be wider, e.g., 2-10 times greater in width than what is shown in FIGS. 11, 16, and 32. Conventional surgical tubing has a round cross-section and is available, e.g., from Freudenberg Medical, and comes in many different sizes which have inner diameters in the range between 0.012 to 0.75 inches which corresponds to 0.31 to 19.05 mm. An inner diameter of 0.31 mm corresponds to 310 micrometers, also known as microns. It is a common medical practice to clean or prime tubing which is to be used in blood transfusion with saline solution. When blood clotting is a concern, it is known that doctors will sometimes use heparin which is an anticoagulant with their patients, and that tubing and other pieces of equipment used to conduct extracorporeal transfusions and / or infusions will sometimes be treated with heparin in order to prevent blood from clotting within the tubing and other pieces equipment, and also to prevent possible blood clots from being reinfused into a patient. As shown in FIG. 11, the relatively narrow gap 98 or vertical inside dimension of the middle portion 51 of a blood dispersion device 49 is typically equal to or less than ⅛ inch or 3.175 mm, or alternatively less than 1 / 16 inch or 1.588 mm which corresponds to 1588 microns, and an even smaller gap 98 or vertical inside dimension can be used depending upon the desired rate of blood or blood portion flow and / or the desired duration of its exposure to an electromagnetic field, and / or ultrasound vibration, and / or ultraviolet light. In some cases, the gap 98 or vertical inside dimension of the middle portion 51 to be less than or equal to 50 microns wide, or alternatively less than or equal to 30 microns wide, or alternatively in the range between 6-15 microns wide, or alternatively in the range between 1.5-10 microns wide. In this regard, a gap in the range between 6-15 microns wide can permit the relatively unobstructed passage and also the observation of platelets, red blood cells, and most white blood cells in an individual and patient's 28 blood 10.

[0193] As shown in FIG. 32, the blood dispersion device 49a can further include a plurality of splitters 82a in at least one of the funnel portion 50a, the middle portion 51, and the funnel portion 50b for dispersing and routing the blood or blood portion. In this regard, splitters 82 having different lengths can be disposed next to one another for the purpose of enhancing the speed of blood flow. An alternative blood dispersion device 49a-b, can also further include an integral stop valve for controlling the rate of flow of blood or a blood portion. The alternative extracorporeal blood filtering device 33d can include at least one optical monitor 24 disposed proximate to the window 52 of a blood dispersion device 49a-b. In this regard, a first optical monitor 24a can be disposed proximate to the window 52a portion of a first blood dispersion device 49a located between the first needle 8a and the inlet 31f of the filter device 1, a second optical monitor 24b can be disposed proximate to the filter device 1, and a third optical monitor 24c can be disposed proximate to a window 52b portion of a second blood dispersion device 49b located between the outlet 32f of the filter device 1 and the second needle 8b disposed at the second puncture site 27b. The optical monitor 24 can provide a microscopic view using a microscope, a stereo microscope, an electron microscope, a camera, or other optical device in order to provide for visual monitoring of an individual and patient's 28 blood portion and blood 10. The blood dispersion device 49a-b can be made, e.g., of glass, or of a thermoplastic material, natural rubber material, or silicone material which can permit exposure to wavelengths of electric fields, magnetic fields, and / or electromagnetic fields, and / or ultraviolet light, and / or ultrasound vibration. A blood dispersion device shown in FIGS. 11, 16, and 32. will typically be used once, and then disposed. However, not all parts of the world may have an adequate and ready supply of medical equipment. In the absence of a blood dispersion device 49a-b as shown and described in FIGS. 11, 16, and 32, it may be possible to alternatively use the drip chamber 89 in a transfusion kit 91 shown in FIG. 19 as a make-shift blood dispersion device. Alternatively, an open glass or plastic container can be used in order to disperse and better expose blood or a blood portion to a desired source of electric field, magnetic field, or electromagnetic fields, and / or ultraviolet light, and / or ultrasound for conditioning or treating blood or a blood portion. Alternatively, when no container is any kind is available to serve as a blood dispersion device, it is possible to wind a length of relatively clear plastic tubing 7 around an object to create a coil-like structure so that a relatively large quantity of blood or a blood portion which is then being caused to pass through the tubing 7 can be exposed to wavelengths of an electric field, magnetic field, and / or electromagnetic fields, and / or ultraviolet light, and / or ultrasound vibration and then for a sufficient length of time in order to disable or kill the spike protein and COVID-19 virus, or a different virus or pathogen. In this regard, if and when an artificial source of ultraviolet light is not available, it is possible to go outdoors and then use sunlight which provides ultraviolet light to expose blood or a blood portion which is contained within tubing, a glass or plastic container, and / or blood dispersion device.

[0194] As shown in FIG. 30, a first needle 8a can inserted into a vein or artery of an individual and patient's 28 arm 75 and be secured proximate to the first puncture site 27a. One end of a first piece of tubing 7a can be connected to the first needle 8a and the other end can be connected to the inlet 31v of a valve 30 or roller clamp 85 which can stop or regulate the flow of an individual and patient's 28 blood 10. One end of a second piece of tubing 7b can be connected to the outlet 32v of the valve 30 or roller clamp 85 and the other end can be connected to the inlet 31s of the first analyte sensor 38a. One end of a third piece of tubing 7c can be connected to the outlet 32s of the first analyte sensor 38a and the other end can be connected to the inlet 32d of the first blood dispersion device 49a. One end of a fourth piece of tubing 7d can be connection to the outlet 32d of the first blood dispersion device 49a and the other end to the inlet 31f of a filter device 1. One end of a fifth piece of tubing 7e can be connected to the outlet 32f of the filter device 1 and the other end can be connected to the inlet 31d of the second blood dispersion device 49b. One end of a sixth piece of tubing 7d can be connected to the outlet 32d of the second blood dispersion device 49b and the other end can be connected to the inlet 31p of the blood pump 26. One end of a seventh piece of tubing 7f can be connected to the outlet 32b of the blood pump 26 and the other end can be connected to the inlet 31s of the second analyte sensor 38b. One end of an eighth piece of tubing 7e can be connected to the outlet 32s of the second analyte sensor 38b and the other end can be connected to the inlet 31a of the air bubble eliminator device 48. One end of a ninth piece of tubing 7f can be connected to the outlet 32a of the air bubble eliminator device 48 and the other end can be connected to a second needle 8b which is can be inserted and secured proximate a second puncture site 27b on the individual and patient 28's arm 75 or leg 76. Additional valves 30 or roller clamps 85 for stopping or regulating the individual and patient's 28 blood 10 flow can be located before the inlets 31d and also after the outlets 32d of the blood dispersion devices 49a-b. Further, in order to not unduly restrict the flow of an individual and patient's blood 10, a blood dispersion device 49a or 49b can alternatively be connected to tubing and two Y or T junctions configured to create a parallel line to the main line which is used to transport the blood portion or blood 10 of an individual and patient 28. The conditioning devices 5, 20, and 25, analyte sensors 38a-c, optical monitors 24a-c, and pump can be connected by wire or wirelessly to a computer 36 or other medical device having a monitor screen 37 and a keyboard 96, touch pad, and mouse.

[0195] It can be readily understood by a person of ordinary skill in the art, and in particular, a medical doctor, that the relative position and location where the valves 30 and / or roller clamps 85, tubing 7, analyte sensors 38, blood dispersion devices 49, filter device 1, blood pump 26, air bubble eliminator device 48, optical monitors 24, blood conditioning devices 5, 20, and 25, wires 34 and computer 26 or other electronic medical device are disposed and located can possibly be modified and otherwise configured provided that such alternative configurations would not compromise the performance of an extracorporeal blood filtering device 33. For example, the order of the first analyte sensor 38a, the first valve 30 and / or roller clamp 85, and the first blood dispersion device 49a which are disposed between the first needle 8a and the filter device 1 could be changed. Likewise, the order of the second blood dispersion device 49b, the second analyte sensor 38b, and the pump 26 which are disposed between the filter device 1 and the second needle 8b could also be changed. Further, while some of the possible structures and configurations relating to the extracorporeal blood filtering devices 33a-f shown in FIGS. 25-30, and the methods, techniques and processes relating thereto have been discussed separately, it can be readily understood that depending on the condition of an individual and patient, and also the medical expertise and equipment which may be available, that some or all of the recited structures, configurations, methods, and technique can be selected and configured for use in various alternative partial combinations, or in a complete combination. In addition, the extracorporeal blood filtering devices 33a-f which have been disclosed in FIGS. 25-30 and discussed herein can be provided in various embodiments and in partial or complete combination in the form of prefabricated and ready-to-use medical kits which require little or no assembly. Moreover, depending on the condition of the individual and patient and also the medical expertise and equipment which is available, one or more of the device or structures which are typically included with the disclosed methods and techniques, such as a blood pump 26 or a filter device 1, can possibly be replaced and / or included within a more sophisticated medical device, such as one selected from the group of medical devices consisting of an apheresis device, a plasmapheresis device, an extracorporeal blood purification device, a hemofiltration device, a continuous veno-venous hemofiltration device, a hemodiafiltration device, an ultrafiltration device, and a hemodialysis or dialysis device.First Conditioning Device

[0196] As shown in FIG. 30, the extracorporeal blood filtering device 33f can include a first conditioning device 5 to introduce an electromagnetic field and gradient 45 that can impart an elevated electrical charge to or otherwise manipulate undesired matter 9 which is contained an individual or patient's 28 blood 10 after it has been removed from their body 6, but before it enters the inlet 31 of the filter device 1. For this purpose, the first conditioning device 5 can include at least one magnet device 11 such as a permanent magnet 12, a plurality of magnetic beads 13, or an electromagnet 14 which can be used to condition the undesired matter 9, which is typically negatively charged in the individual and patient's 28 blood 10, in order to facilitate its separation and removal. In this regard, a conditioning device 5 can include a variable control 15a for regulating the amount of voltage and current present in the electromagnet 14, and therefore the strength of the electromagnetic field that it will generate. Further, the conditioning device 5 can also include a variable control 15b for regulating the frequency and wavelength of the electromagnetic energy being generated. The conditioning device 5 can include a variable control 15c for selecting the type of waveform that will be produced, e.g., a square, saw, or sinusoidal wave form, and selecting whether the waveform is digital or analog. The conditioning device 5 can further include a variable control 15d for selecting and changing the magnetic poles of the electromagnet 14. In addition, the conditioning device 5 can include an AC versus DC variable control switch 15e for selecting either AC or DC as a source of power and / or for use in generating different types of waveforms. The conditioning device 5 can also include an on / off variable control switch 15f. The first conditioning device 5 can be disposed proximate to the narrow middle portion 51 of a first blood dispersion device 49a. The conditioning device 5 can also possibly include one or more gauges 22 and / or a conditioning device monitor screen 23 which can provide information and feedback with regards to the function of the variable controls 15a-f, and also regarding the nature and characteristics of the electromagnetic field and gradient 45 which is being produced. Alternatively, as shown in FIG. 30, the conditioning device 5 can be connected by wire 34 or wirelessly to a computer 36 or other medical device, and the one or more gauges 22 and monitor screens 23 can be displayed on at least one computer 36 monitor screen 37, and the variable controls 15a-f can be manipulated and controlled by using the computer's keyboard 96, touch pad or mouse. An alternative first conditioning device can be a nanoparticle removal chip configured to remove nanoparticles out of blood or a blood portion developed by Michael Heller at UC San Diego and manufactured by Biological Dynamics of La Jolla, California, e.g., see “Electric Fields Remove Nanoparticles From Blood With Ease,” by Liezel Labios, Nov. 20, 2015, https: / / today.ucsd.edu / story / electric_fields_remove_nanoparticles_from_blood_with_ease.Second Conditioning Device

[0197] As shown in FIG. 30, the extracorporeal blood filtering device 33f can include a second conditioning device 20 which can include a magnet device 11 such as a permanent magnet 12 or an electromagnet 14 which is configured to provide an electromagnetic field and gradient 45 in order to help separate and remove undesired matter 9 such as graphene oxide, graphene hydroxide, magnetic graphene oxide, or other metals, pathogens, and toxins from blood 10. A second conditioning device 20 can be used whether or not a first conditioning device 5 has been used in order to impart an elevated electrical charge to or otherwise manipulate the undesired matter 9 present in the blood 10 of an individual and patient 28 and which typically has a negative electrical charge. Accordingly, the second conditioning device 20 is typically configured to provide an electromagnetic field and gradient 45 proximate to a filter 4 which is contained in the cavity 3 of a chamber 2 of a filter device 1 in order to manipulate the negatively charged undesired matter 9 so that it can be more effectively captured, mechanically trapped and / or adsorbed in the filter 4. In this regard, the second conditioning device 20 can be used to cause the undesired matter 9 to go into resonance, freeze, slow, or otherwise attract, entrain or direct its movement and so help the undesired matter 9 to be filtered and removed from the blood 10 of an individual and patient 28. However, when a first conditioning device 5 and / or third conditioning device 25 are not also being used, a second conditioning device 20 including permanent magnets 12, a plurality of magnetic beads 13, or electromagnets 14 can also be used to impart a neutral or other normalizing electromagnetic field and gradient 45 and positive or negative charge or to otherwise manipulate the red blood cells, white blood cells, platelets, and other components of normal human blood 10 which approximately matches the condition of healthy blood 10 and can possibly be used to correct and improve the health of an individual and patient's 28 blood 10. A second conditioning device 20 can include a variable control 15a for regulating the amount of voltage and current 15 present in the electromagnet 14, and therefore the strength of the electromagnetic field and gradient 45 that it will generate. Further, the second conditioning device 20 can also include a variable control 15b for regulating the frequency and wavelength of the electromagnetic energy being generated. The second conditioning device 20 can include a variable control 15c for selecting the type of waveform that will be produced, e.g., a square, saw, or sinusoidal wave form, and selecting whether the waveform is digital or analog. The second conditioning device 20 can further include a variable control 15d for selecting and changing the magnetic poles of the electromagnet 14. In addition, the second conditioning device 5 can include an AC versus DC variable control switch 15e for selecting either AC or DC as a source of power and / or for use in generating different types of waveforms. The second conditioning device 20 can also include an on / off variable control switch 15f. The second conditioning device 20 can also include one or more gauges 22 and / or at least one conditioning device monitor 23 which can provide information and feedback with regards to the function of the variable controls 15a-f, and also regarding the nature and characteristics of the electromagnetic field and gradient 45 which is being produced. Alternatively, the second conditioning device 20 can be connected by wire 24 or wirelessly to a computer 36 including a monitor screen 37, and the one or more gauges 22 and conditioning device monitor screen 23 can be displayed on a computer 36 monitor screen 37, and the variable controls 15a-f can be manipulated and controlled by using the computer's keyboard 96, touch pad or mouse. An alternative second conditioning device can be a nanoparticle removal chip configured to remove nanoparticles out of blood or a blood portion developed by Michael Heller at UC San Diego and manufactured by Biological Dynamics of La Jolla, California, e.g., see “Electric Fields Remove Nanoparticles From Blood With Ease,” by Liezel Labios, Nov. 20, 2015, https: / / today.ucsd.edu / story / electricfields_remove_nanoparticles_from_blood_with_ease.Third Conditioning Device

[0198] As shown in FIG. 30, the extracorporeal blood filtering device 33f can include a third conditioning device 25 which can include a magnet device 11 such as a permanent magnet 12 or an electromagnet 14 which is configured to provide an electromagnetic field and gradient 45 so as to impart a neutral or normalizing electrical charge or to otherwise manipulate the fluid or blood 10 of an individual and patient 28 after the fluid or blood 10 has left the outlet 32f of the filter device 1. In particular, a third conditioning device 25 can be used when a first conditioning device 5 has been used in order to impart an elevated electrical charge to or otherwise manipulate the electromagnetic field and gradient 45 which has been imparted to undesired matter 9 in an individual or patient's 28 blood 10, and / or when a second conditioning device 20 has been used to impart an electrical charge to or otherwise manipulate the electromagnetic field and gradient 45 proximate to a filter device 1 including a filter 4 included in in order to help separate and remove undesired matter 9 such as at least one of a metal, nanometal, graphene oxide, graphene hydroxide, magnetic graphene oxide, an electronic chip or other electronic device, a pathogen, a bacterium, a cancerous cell, a virus, a spike protein, a blood cell infected with a virus, a COVID-19 virus, and a toxin from blood 10. In this regard, a third conditioning device 25 including permanent magnets 12, a plurality of magnetic beads 13, or electromagnets 14 can be used to impart either a neutral or a normalizing positive or negative charge and / or electromagnetic field and gradient 45 to the red blood cells, white blood cells, platelets, and other components of normal human blood 10 which approximately matches the condition of healthy blood 10, and in some cases can possibly correct and improve the status of a patient's blood 10. For example, the Ph of blood 10 could possibly be changed by the removal of negatively charged undesired matter 9, and also by the application of a normalizing electromagnetic filed and gradient 45 to an individual's blood 10. In this regard, a third conditioning device 25 can include a variable control 15a for regulating the amount of voltage and current 15 present in the electromagnet 14, and therefore the strength of the electromagnetic field that it will generate. Further, the third conditioning device 25 can also include a variable control 15b for regulating the frequency and wavelength of the electromagnetic energy being generated. The third conditioning device 25 can include a variable control 15c for selecting the type of waveform that will be produced, e.g., a square, saw, or sinusoidal wave form, and selecting whether the waveform is digital or analog. Further, the third conditioning device 25 can further include a variable control 15d for selecting and changing the magnetic poles of the electromagnet 14. In addition, the third conditioning device 25 can include an AC versus DC variable control switch 15f for selecting either AC or DC as a source of power and / or for use in generating different types of waveforms. The third conditioning device 25 can include an on / off variable control switch 15f. The third conditioning device 25 can also include one or more gauges 22 and at least one conditioning device monitor 23 which can provide information and feedback with regards to the function of the variable controls 15a-f and also regarding the nature and characteristics of the electromagnetic field and gradient 45 which is being produced. Alternatively, the third conditioning device 25 can be connected by wire 24 or wirelessly to a computer 36 including a monitor screen 37, and the one or more gauges 22 and conditioning device monitor screen 23 can be displayed on at least one computer 36 monitor screen 37, and the variable controls 15a-f can be manipulated and controlled by using the computer's keyboard 96, touch pad or mouse, as shown in FIG. 30. The third conditioning device 25 can be disposed proximate to the narrow middle portion 51 of a second blood dispersion device 49b. Alternatively, the first conditioning device 5, the second conditioning device 20, and the third conditioning device 25 can be configured as a single conditioning device 35 which has the capability of performing in partial or complete combination the desired or required functions of the first conditioning device 5, the second conditioning device 20, and the third conditioning device 25. An alternative third conditioning device can be a nanoparticle removal chip configured to remove nanoparticles out of blood or a blood portion developed by Michael Heller at UC San Diego and manufactured by Biological Dynamics of La Jolla, California, e.g., see “Electric Fields Remove Nanoparticles From Blood With Ease,” by Liezel Labios, Nov. 20, 2015, https: / / today.ucsd.edu / story / electric_fields_remove_nanoparticles_from_blood_with_ease.Analyte Sensor

[0199] As shown in FIG. 30, an electronic analyte sensor device 38 can be further included and used to identify and communicate the presence and levels of targeted undesired matter 9 which is possibly contained in the blood 10 of an individual and patient 28. In this regard, a first analyte sensor device 38a can be disposed between the location of the first needle 8a at the first puncture site 27a, and the inlet 31f of the filter device 1 in order to determine the presence and levels of undesired matter 9 in the unfiltered blood 10 of an individual and patient 28. In addition, a second analyte sensor device 38b can be disposed between the outlet 32f of the filter device 1 and the second needle 8b located at the second puncture site 27b in order to determine the presence and levels of undesired matter 9 in the filtered blood 10 of an individual and patient 28. For research purposes, a third analyte sensor device 38c shown using dashed lines can be disposed inside or proximate to a filter device 1 to monitor the presence and level of undesired matter 9 which is contained in the blood 10 of an individual and patient 28 while the blood 10 is being filtered by the filter device 1 and is also then possibly under the influence of the second conditioning device 20. The analyte sensor devices 38a, 38b can be connected by wire 34 or wirelessly to a computer 36 including a monitor screen 37, keyboard 96, touch pad, and mouse, or other medical device which includes controls for operating the analyte sensor devices 38a-c, and which uses a software application for comparing and monitoring the presence and levels of undesired matter 9 found by analyte sensors 38a-c in an individual and patient's blood 10.Optical Monitor Device

[0200] As shown in FIG. 30, an optical monitor 24 such as a camera device including a macro lens, a microscope, a stereo microscope, an electron microscope or other form of optical monitoring equipment can also be included and used to visually observe the content, structure, and behavior of undesired matter 9, red blood cells, white blood cells, platelets, and plasma in an individual and patient's 28 blood 10. For example, a first optical monitor 24a can be disposed between the location of the first needle 8a and puncture site 27a and the inlet 31f of the filter device 1 and proximate to a window 52 in the middle portion 51 of a first blood dispersion device 49a which is disposed in about the same location in order to observe and monitor the blood 10 of an individual and patient 28 before it is filtered by the filter device 1 and is then also possibly under the influence of a first conditioning device 5. A third optical monitor 24c can be disposed between the outlet 32f of the filter device and the location of the second needle 8b and puncture site 27b and proximate to a window 52 in the middle portion 51 of a second blood dispersion device 49b which is disposed in about the same location in order to observe and monitor the blood 10 of an individual and patient 28 after it has been filtered by the filter device 1 and is then also possibly under the influence of a third conditioning device 25. For research purposes, a second optical monitor 24b can possibly be disposed inside or proximate to a filter device 1 in order to observe and monitor the behavior of undesired matter 9 which is contained in the blood 10 of an individual and patient 28 while the blood 10 is being filtered by the filter device 1 and is also then possibly under the influence of a second conditioning device 20. In this regard, an optical monitor 24 can be connected by wires 34 or alternatively wirelessly to a computer 36 including a monitor screen 37, keyboard 96, touch pad, and mouse, or other medical device which includes at least one monitor screen 37 and one or more views for monitoring the blood 10 of an individual and patient 28.Computer Monitor and Control Device

[0201] As shown in FIG. 30, a computer 36 including a monitor screen 37, keyboard 96, touch pad, mouse, and other means for providing output such as a printer, a computer network, or other medical device can be placed in electronic communication by wire 34 or wirelessly with a plurality of optical monitors 24, and / or analyte sensor devices 38 so that blood 10 of an individual or patient 28 can be monitored in a plurality of locations, such as before the blood 10 enters the inlet 31f of a filter device 1, while the blood 10 is contained within the filter device 1, and after the blood 10 has left the outlet 32f of the filter device 1. Further, a computer 26 including a monitor screen 37, keyboard 96, touch pad, mouse, and other means for providing output such as a printer, a computer network, or other medical device can be placed in electronic communication by wire 34 or wirelessly with at least one of the first conditioning device 5, the second conditioning device 20, and the third conditioning device 25 in order to monitor and control the effects of the conditioning devices 5, 20, and 25 upon the undesired matter 9 and other structures contained in the blood portion or blood 10 of an individual or patient 28. In this regard, the computer 36 including a monitor screen 37, keyboard 96, touch pad, mouse, and other means for providing output such as a printer, a computer network, or other medical device can control and monitor the conditioning devices 5, 20, and 25, and this can include a variable control 15a for regulating the amount of voltage and current present in the electromagnet 14, and therefore the strength of the electromagnetic field that it will generate, a variable control 15b for regulating the frequency and wavelength of the electromagnetic energy being generated, a variable control 15c for selecting the type of waveform that will be produced, e.g., a square, saw, or sinusoidal wave form, and selecting whether the waveform is digital or analog, a variable control 15d for selecting and changing the magnetic poles of the electromagnet 14, a variable control switch 15e for selecting either AC or DC as a source of power and / or for use in generating different types of waveforms, and also an on / off variable control switch 15f. The computer 36 including a monitor screen 37, keyboard 96, touch pad, mouse, and other means for providing output such as a printer, or other medical device can provide information and feedback with regards to the function of the variable controls 15a-f and also regarding the nature and characteristics of the electromagnetic field and gradient 45 which is being produced. The computer 36 including a monitor screen 37, keyboard 96, touch pad, mouse, and other means for providing output such as a printer, computer network, or other medical device can be connected by wire or wirelessly to one or more magnetic devices 11, optical monitors 24, pump devices 26, analyte sensor devices 38, and / or to a medical device selected from the group of medical devices consisting of an apheresis device, a plasmapheresis device, an extracorporeal blood purification device, a hemofiltration device, a continuous veno-venous hemofiltration device, a hemodiafiltration device, an ultrafiltration device, and a hemodialysis or dialysis device.Filter Device

[0202] Many different kinds of devices and filters have been developed in order to remove and / or separate the four main constituent portions of human blood, but also to remove bacterial and viral pathogens, toxins, and other undesired matter from fluids, portions of blood, and blood. In medical practice, it is also known to add to human blood analgesics, chemical compositions, drugs, electrolytes, or other forms of matter, e.g., chemical markers, radioactive substances, and chelators. The latter are sometimes used in chelation therapy, which sometimes uses CaNa2EDTA (Calcium Disodium Ethylenediaminetetraacetate) to remove heavy metals from the bloodstream so that they can be excreted in order to correct an individual's levels and blood and thereby improve or restore heath. Activated charcoal, carbon 60, zeolite clinoptilolite, and selenium have sometimes also been used to help individuals with detoxification from heavy metals, or other toxins, e.g., see “Zeolite Clinoptilolite: Therapeutic Virtues of an Ancient Mineral,” by Mastinu et al., Apr. 17, 2019, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC6515299 / , and “Critical Review on Zeolite Clinoptilotite Safety and Medical Applications in Vivo,” by Pavelic et al., Nov. 27, 2018, https: / / www.ncbi.nlm.nih.gov / pmc / articles / pmid / 30538633 / .

[0203] Besides the metals aluminum and mercury which have been used as adjuvants and / or preservatives in some vaccines, other heavy metals such as antimony, arsenic, beryllium, cadmium, hexavalent chromium, cobalt, copper, lead, manganese, nickel, and silver, can sometimes be present in an individual's body in large enough quantities to be harmful and toxic. Electrically conductive metals, and also materials of the graphene family such as graphene oxide, graphene hydroxide, magnetic graphene oxide, but also many pathological or toxic forms of matter, diseased cells, cellular debris, and waste matter will typically exhibit a negative charge or isoelectric point in the range between 3.5 and 7 pH when present in a fluid, blood portion or blood 10 of an individual and patient 28. In this regard, the isoelectric point of most viruses are found in the Ph range between 1.9-8.4, and in particular in the Ph range between 3.5-7, as discussed in the article: “Isoelectric Points of Viruses,” by Michen et al., August, 2010, https: / / pubmed.ncbi.nlm.nih.gov / 20102425 / . As a result, undesired matter 9, e.g., bacteria, viruses, infected cells, cellular debris, waste products, and pathological or toxic forms of matter present in human blood 10 can be removed with the use of a magnetic device 11 which can provide an electromagnetic field and gradient 45 and filters 4 which incorporate materials which are or can be positively or negatively charged. For this reason, a magnetic device 11 which can be a permanent magnet device 12, a plurality of magnetic beads 13, or an electromagnet device 14 can be used to help separate and remove undesired matter 9 from a fluid, blood portion or blood 10 of an individual and patient 28, as will be discussed in greater detail below.

[0204] Conventional filter devices and filters are typically designed, configured and engineered to work and be effective in removing substances and matter from aqueous substances, organic substances, or a combination of both. For use in association with aqueous substances filters are typically made of hydrophilic materials such as cellulose / cellulose acetate (CA), or polyethersulfone (PES), whereas hydrophobic materials such as polypropylene (PP) or polytetrafluoroethylene (PTFE) are more commonly used to filter organic matter, but depending of the matter which is to be separated and the circumstances, one, the other, or combinations of different filters can be used to mixtures of aqueous and organic matter. Examples of non-electrically charged filters made by the 3M company of St. Paul, Minnesota include the 3M™ LifeASSURE™ line of PDA filters capsules and cartridges which feature a 0.2 micron / 200 nm, or a 0.1 micron / 100 nm particle rated membrane and include a double-asymmetric membrane layer filter construction. For more information, see the pdf document which can be obtained from the 3M website: https: / / www.3 m.com / . Other manufacturers of non-electrically charged filters include B. Braun Medical, Inc. of Bethlehem, Pennsylvania and B. Braun Melsunger AG, located in Melsungen, Germany, and also Corbetter Filtration Equipment Co., LTD, of Hangzhou, China. However, the 0.1 micron or 0.2 micron particle rated membrane size of the aforementioned 3M LifeASSURE™ line of PDA filters is too small to permit blood platelets which are commonly 1.5-4 microns, red blood cells which are commonly 6-9 microns in diameter, and most white blood cells which are commonly 7-15 microns to pass through their filter media, and so such a filter would trap just about everything normally contained in human blood except for plasma. Further, the size of graphene oxide, graphene hydroxide, or magnetic graphene oxide, and like foreign undesired matter 9 can be on the order of only about 1 nm in thickness, and commonly between 1-1000 nanometers or more in length and width, and so small pieces could possibly be able to pass through the 3M LifeASSURE™ filter membrane. Graphene oxide can also form in generally planar sheets, and these can also possibly congregate, aggregate, and self-assemble to form large clumps of undesired matter 9. An alternative blood conditioning device for possible use with or inside a filter device can be a nanoparticle removal chip configured to remove nanoparticles out of blood or a blood portion such as the one developed by Michael Heller at UC San Diego and manufactured by Biological Dynamics of La Jolla, California, e.g., see “Electric Fields Remove Nanoparticles From Blood With Ease”, by Liezel Labios, Nov. 20, 2015, https: / / today.ucsd.edu / story / electric_fields_remove_nanoparticles_from_blood_with_ease.

[0205] Examples of conventional electrically charged filters include the 3Mm Zeta Plus' ZB line and series filter capsules and cartridges. The ZB media incorporated into these 3M filters imparts a positive charge to the fiber matrix of the filter which can attract negatively charged matter, and as result the filters can use both mechanical entrapment and electrokinetic adsorption to remove undesired matter. In this regard, the ZB media and related filters are available in six grades which exhibit different levels of positive charge, and they also available in many different sizes. Further, many different filter particle rated membrane sizes are available in the range between 0.1-4 microns or 100-4000 nm. For more information, see the 3M website: https: / / www.3 m.com / 3M / en_US / p / d / b40070867 / and 3M literature 70-0203-0883-2. Another manufacturer of electrically charged filters is B. Braun Medical, Inc. of Bethlehem, Pennsylvania and B. Braun Melsunger AG, located in Melsungen, Germany which makes Intrapur® Plus filters with positively charged membranes. However, the 0.1-0.4 micron or 100-400 nanometer particle rated membrane size of the aforementioned 3Mm Zeta Plus™ ZB line and series filter capsules and cartridges is also too small to permit blood platelets which are commonly 1.5-4 microns, red blood cells which are commonly 6-9 microns in diameter, and white blood cells which are commonly 7-15 microns to pass through the filter media, and so such a filter would trap almost everything contained in human blood except for plasma. However, the size of graphene oxide, graphene hydroxide, or magnetic graphene oxide, and like undesired matter 9 can be on the order of only about 1 nm in thickness, and commonly between 1-1000 or more nanometers in length and width, and so small pieces could possibly be able to pass through such filter membranes unless their movement would be influenced by an electromagnetic field. Graphene oxide can also form in generally planar sheets, and these can congregate, aggregate, and self-assemble to form large clumps of undesired matter 9 when exposed to electromagnetic fields.

[0206] The news article entitled “New Filtration Material Could Remove Long-Lasting Chemicals From Water,” by David L. Chander, published on Sep. 6, 2024, MIT NEWS, https: / / news.mit.edu / 2024 / new-filtration-material-could-remove-long-lasting-water-chemicals-0906, and the related research paper entitled “Directed Assembly of Proteinaceous-Polysaccharide Nanofibrils to Fabricate Membranes for Emerging Contaminant Remediation,” by Zhang et al., Aug. 27, 2024, published in ACS Nano 2024, 18, 25205-25215, https: / / pubs.acs.org / doi / 10.1021 / acsnano.4c07409 discloses a filter material based on silk fibroin-cellulose nanocrystal (silk-CNC) nanofibrillar and nanoporous membranes for removing contaminants from water which is cationic, that is, has a negative charge, and is it both antimicrobial and antibacterial, and has demonstrated the ability to filter out PFAS contaminants and also heavy metals. This filtration material can be used as a filter in the filter devices disclosed in the drawing figures and which are discussed herein.

[0207] The following patents relate to filter devices for use in automobiles: U.S. Pat. Nos. 2,413,991, 2,966,990, 3,111,488, 3,232,437, 3,315,809, 3,465,883, 5,526,590, 5,548,893, 5,711,872, 5,888,383, 6,086,763, 6,221,242 B1, 6,381,983 B1, 6,554,139 B1, 6,568,539 B1, 6,595,372 B1, 7,413,089 B1, 7,597,292 B1, 8,439,204 B1, and all of these patents are hereby incorporated by reference herein.

[0208] FIG. 1 is a side cross sectional view of a filter device 1a which includes a wall 39 which can be made of a biocompatible material such as a medical grade metal, glass, or thermoplastic material, e.g., polyamides or nylon, polyethylene glycol, polyvinyl alcohol, polyethyleneimine, polyvinylamine, polyacrylates, polyesters, polycarbonates, polystyrenes, polypropylene, polydimethylsiloxane or silicone, ABS, urethanes, nylon, PTFE, and a thermoplastic elastomer such as Santoprene. The wall 39 include an outside wall surface 39o which is on the exterior 41 of the filter device 1a, and an inside wall surface 39i which is on the interior 42 of the filter device 1a. The filter device 1a can include an integral or removable inlet 31f and outlet 32f. The inlet 31f and outlet 32f can include barbs, threads, luer 94, or other types of male and female or hermathrodite structures for connecting and coupling the filter device 1a to tubes 7, and / or other structures or devices. The filter device 1a can have a top side 66, a bottom side 67, and one or more lateral side(s) 68 which can be straight or curved depending on whether the side 68 portion is configured to be cylindrical in shape and then possibly also have a radius oriented about a central axis 57, or instead be configured in a different geometric shape. As shown in FIG. 1, the filter device 1a is configured with the inlet 31f and outlet 32f being in alignment about a central axis 57 which can enhance the flow through of a liquid, blood portion and blood 10. The structure of the filter device 1a defines a chamber 2 which includes a cavity 3 which includes a void space when empty and which has a volume. The filter device 1a further includes a filter 4, such as one of the filters 4a-e shown in FIGS. 3, 4, 5, 7, 8, which is used to help separate and remove undesired matter 9 such as metals, graphene oxide, graphene hydroxide, magnetic graphene oxide, pathogens, and toxins from an individual and patient's 28 blood portion and blood 10. When a non-electrically charged and / or a positively electrically charged filter 4 is being used, it can be helpful to dispose a magnetic device 11 which can be a permanent magnet 12, or an electromagnet 14 which produces a magnetic field and gradient 45 that can impart an elevated electrical charge, and typically a positive charge proximate to the filter 4. In this regard, a filter 4 which already includes an internal structure and / or media which is and / or can be electrically charged is typically selected for use. In this regard, the filter structure and / or media is typically positively electrically charged. As shown in FIG. 1, the filter 4 can be permanently sealed and contained within the chamber 2 of the filter device 1a, or alternatively the filter 4 can be configured as a removable cartridge 55 and be replaced when a filter device 1t includes a screw-off or otherwise removable top portion 18 and seal 19, as shown in FIG. 22.

[0209] FIG. 2 is a side cross-sectional view of an alternative embodiment of a filter device 1b which includes a wall 39 which can be made of a biocompatible material which can be a medical grade metal, glass, or thermoplastic material, e.g., polyamides or nylon, polyethylene glycol, polyvinyl alcohol, polyethyleneimine, polyvinylamine, polyacrylates, polyesters, polycarbonates, polystyrenes, polypropylene, polydimethylsiloxane or silicone, ABS, urethanes, nylon, PTFE, and a thermoplastic elastomer such as Santoprene. The wall 39 includes an outside wall surface 39o which is on the exterior 41 of the filter device 1b, and an inside wall surface 39i which is on the interior 42 of the filter device 1b. The filter device 1b can include an integral or removable inlet 31f and outlet 32f. The inlet 31f and outlet 32f can include barbs, threads, luer 94, or other types of male and female or hermathrodite structures for connecting and coupling the filter device 1b to tubes 7, and / or other structures or devices. The filter device 1b can have a top side 66, a bottom side 67, and one or more lateral side(s) 68 which can be curved or straight depending on whether it is cylindrical in shape and then have a radius which is oriented about a central axis 57, or is configured in a different geometric shape. As shown in FIG. 2, the filter device 1b is configured with the inlet 31f and outlet 32f being in alignment which can enhance the flow through of a liquid, blood portion and blood 10. The structure of the filter device 1b defines a chamber 2 which includes a cavity 3 which includes a void space when empty and which has a volume. As shown in FIG. 2, the filter 4 can be permanently sealed and contained within the chamber 2 of the filter device 1b, or alternatively the filter 4 can be configured as a removable cartridge 55 and be replaced when a filter device 1t includes a screw-off or otherwise removable top portion 18 and seal 19, as shown in FIG. 22.

[0210] The filter device 1b includes a filter 4 such as filter 4a-b shown in FIGS. 3-4 which is used to help separate and remove undesired matter 9 from an individual and patient's 28 blood 10. When a non-electrically charged filter 4 is being used, it can be helpful to use a permanent magnet 12, a plurality of magnetic beads 13, or an electromagnet 14 which produces a magnetic field and gradient 45 that can impart a positive charge proximate to the filter 4. However, a filter 4 that includes an internal structure and / or media which is or can be electrically charged is typically selected for use. In this regard, the filter structure and / or media can be and is typically positively electrically charged. As shown, e.g., in FIGS. 3-4 a filter 4a-b can include a filter layer 56 including a screen 16 structure which is made of an electrically conductive metal, ceramic, or other composite material. As shown in FIG. 2, a plurality of twenty five filter layers 56 can be disposed, nested, or stacked next to one another and include a border 59, and the filter layers 56 can be orientated perpendicular to a central axis 57 associated with the configuration of the inlet 31f and outlet 32f and direction of flow of a liquid, blood portion and blood 10 to form a complex matrix or maze 69. As shown in FIG. 2, one or more magnet devices 11a-b can be removably or permanently secured proximate to the wall 39, and in particular, on the exterior 41 near the outside wall surface 39o of the filter device 1b. In this regard, the magnet devices 11a-b can be permanent magnets 12, a plurality of magnetic beads 13, or electromagnets 14. As shown in FIG. 2, when a plurality of magnet devices 11a-b are used, the magnet devices 11 are typically orientated so that their north and south poles are configured to face the oppositive poles of the magnetic device 11 which is disposed nearby, that is, the south pole S of magnet device 11a is disposed opposite to the north pole N of magnet device 11b. In other words, a first magnet device 11a having a first positive pole and first negative pole is typically configured such that the first positive pole is disposed proximate to the second negative pole of the second magnet device 11b, and / or the first negative pole is disposed proximate to the second positive pole. In FIG. 2, the magnet devices 11 are shown disposed proximate to the top side 66 and bottom side 67 of the filter device 1b. As shown in FIG. 2, the magnetic devices 11a and 11b can also be electrically connected by a conductive bridge 78.

[0211] FIG. 3 is a top view of a layer 56 of screen 16 for use in a filter 4a. A screen 16 can be configured in two superimposed, overlapping and joined perpendicular partial-layers or by two or more woven partial-layers of metal wire 34 or other electrically conductive material. A screen 16 can also be configured by knitting, or can alternatively be configured and made by 3D printing or other manufacturing processes, and can also be referred to as a mesh, net, or web. The layer 56 of screen 16 includes a border 59 which provides for a mating surface, seat, and / or seal between adjoining layers 56. The layer 56 can be an integral and permanent part of a filter device 1 such as filter device 1b shown in FIG. 2, or alternatively can be part of a removable and replaceable cartridge 55 when a filter device 1t includes a removable top portion 18 and seal 19, as shown in FIG. 22. While the drawing figures show various embodiments of screens 16, meshes, nets or webs for use in filters 4 which can be easily seen, it can and should be readily understood that regarding any or all of the different embodiments of a filter 4 the size of the screen 16, mesh, net, or web can typically be equal to or less than 2 mm or equal to or less than 1000 microns, or equal to or less than 270 microns, or equal to or less than 160 microns, or equal to or less than 50 microns, or equal to or less than 30 microns, or equal to 15 microns, but will typically be greater than the range between 1-15 microns when the passage of plasma, platelets, red blood cells, and white blood cells in a blood portion and blood 10 is desired or required. However, when filtering blood plasma containing undesired matter 9, e.g., a member of the graphene family such as graphene oxide, or a different pathogen or toxin that is typically smaller in size than 15 microns, the size of the particles which the filter 4 can effectively filter can be configured to be equal to or less than 15 microns, or be equal to or less than 2 microns, or be equal to or less than 1 micron, or be equal to or less than 0.2 microns, or be equal to or less than 0.1 micron and then be in the range between 1-100 nanometers.

[0212] FIG. 4 is a top view of an alternative embodiment of a layer 56 including a web-like screen 16 for use in a filter 4b. As shown, an alternative layer 56 can include a plurality of concentrically orientated rings 60 of metal wire or other electrically conductive material which are spaced about a central axis 57 and can be connected together by one or more cross braces 61. The alternative layer 56 can also be configured by superimposing wires 34, weaving, knitting, or be configured and made by 3D printing or other manufacturing processes, and can also be referred to as a mesh, net, or web. In FIG. 4, the alternative layer 56 of screen 16 includes a border 59 which provides for a mating surface, seat, and / or seal between the filter 4b and an inside wall portion 39i of the filter device 1b. The alternative layer 56 can be an integral and permanent part of a sealed filter device 1 such as filter device 1b shown in FIG. 2, or alternatively can be part of a replaceable cartridge 55 when a filter device it includes a removable top portion 18 and seal 19, as shown in FIG. 22.

[0213] FIG. 5 is a top perspective view of the alternative filter 4c which can include a plurality of circular and concentrically orientated layers 56 of metal wire or other electrically conductive material. The layers 56 are spaced around and about a central axis 57 and can be connected together by one or more cross braces 61. The screen 16 portions of the filter 4c can be configured and made by superimposing wires 34, weaving, knitting, or by using 3D printing or other manufacturing processes, and can also be referred to as a mesh, a net, or a web. Alternatively, the top end 62 and bottom end 63 of the layers 56 of screen 16 can also include a top seal 64 and bottom seal 65, as shown with the filter 4d shown in FIG. 7, which can provide a mating surface, seat, and / or seal between the filter 4c and an inside wall portion 39i of a filter device 1. In an alternative embodiment, the screens 16 used in filter 4c can further include or be connected to an additional filter media 21 for mechanically trapping and / or adsorbing undesired matter 9 from a liquid, blood portion and blood 10. The filter 4c can be an integral and permanent part of a sealed filter device 1 such as filter device 1c shown in FIG. 6, or can be a removable and replaceable cartridge 55 when a filter device 1t includes a removable top portion 18 and seal 19, as shown in FIG. 22.

[0214] FIG. 6 is a side view of an alternative filter device 1c which includes a wall 39 which can be made of a biocompatible material such as a medical grade metal, glass, or thermoplastic material, e.g., polyamides or nylon, polyethylene glycol, polyvinyl alcohol, polyethyleneimine, polyvinylamine, polyacrylates, polyesters, polycarbonates, polystyrenes, polypropylene, polydimethylsiloxane or silicone, ABS, urethanes, nylon, PTFE, and a thermoplastic elastomer such as Santoprene. As shown and previously discussed with regards to FIG. 1, the wall 39 includes an outside wall surface 39o which is on the exterior 41 of the filter device 1c, and an inside wall surface 39i which is on the interior 42 of the filter device 1c. The filter device 1c, further includes a ledge 70 and / or conductive bridge 78 which projects from the outside wall surface 39o of the chamber 2 on the exterior 41 of the filter device 1c which can serve as a support and / or bracket for securing removable magnetic devices 11a-b. Accordingly, the magnetic devices 11a-b can be placed in close proximity to a filter 4, such as filters 4a-e. The filter device 1c can include an integral or removable inlet 31f and outlet 32f. The inlet 31f and outlet 32f can include barbs, threads, luer 94, or other types of male and female or hermathrodite structures for connecting and coupling the filter device 1b to tubes 7, and / or other structures or devices. In FIG. 6, the inlet 31f and outlet 32f portions include male luer 94 style connectors for coupling with complimentary female luer style connectors which can be used to removably secure pieces of tubing 7 to the filter device 1c. The filter device 1c can have a top side 66, a bottom side 67, and one or more lateral side(s) 68 depending on whether the side 68 portion is configured as being circular in shape and has a radius oriented about a central axis 57, or other geometric shape. As shown in FIG. 6, the filter device 1c is configured with the inlet 31f and outlet 32f being in alignment which can enhance the flow through of a liquid, blood portion and blood 10. The structure of the filter device 1c defines a chamber 2 which includes a cavity 3 including a void space when empty and which has a volume. A filter 4, such as filter 4c shown in FIG. 5, filter 4d shown in FIG. 7, or filter 4e shown in FIG. 8 can be permanently sealed and contained within the chamber 2 of a filter device 1c, or alternatively can be configured as a removable cartridge 55 and be removed and replaced when a filter device it includes a screw-off or otherwise removable top portion 18 and seal 19, as shown in FIG. 22. FIG. 6 shows a filter 4 which generally resembles the filter 4c shown in FIG. 5, but which includes ten layers 56 that each include a screen 16 which are configured to be disposed and oriented parallel to a central axis 57 of the filter device 1c. The location of a central axis 57 has already been shown relative to the location of the inlet 31f and outlet 32f of filter device 1b shown in FIG. 2, and it is similarly located with respect to filter device 1c shown in FIG. 6.

[0215] The filter device 1c can include a filter 4c, 4d, or 4e which is used to help separate and remove undesired matter 9 from an individual and patient's 28 blood portion and blood 10. When a non-electrically charged filter 4 is being used, it can be helpful to use a magnetic device 11a-b, such as a permanent magnet 12, a plurality of magnetic beads 13, or an electromagnet 14 which produces an electromagnetic field and gradient 45 that imparts a positive charge proximate to the filter 4. However, a filter 4 such as 4c, 4d, or 4e which includes an internal structure and / or media which is or can be electrically charged is typically selected for use. In this regard, the filter structure and / or media is typically positively electrically charged. As shown in FIGS. 5, 7, and 8, a filter 4c, 4d, or 4e can include a plurality of circular concentrically orientated layers 56 or other geometric shapes including but not limited to a convoluted structure 80 or a zig-zag structure 81 and can include screens 16 made of metal wire 34 or other electrically conductive material which are spaced around and about a central axis 57 and which can possibly be connected together by one or more cross braces 61 or other means for making a permanent or removable connection. The screens 16 can also be configured by superimposing wires 34, weaving, knitting, or be configured and made by 3D printing or other manufacturing processes, and can also be referred to as a mesh, net, or web, and be made of an electrically conductive metal, ceramic, or other composite material. In an alternative embodiment, the screens 16 used in a filter 4c, 4d, or 4e can further include or be connected to an additional filter media 21 for mechanically trapping and / or adsorbing undesired matter 9 from a liquid, blood portion and blood 10. The alternative filter 4c, 4d, or 4e can be an integral component and be permanently sealed and contained within the chamber 2 of a filter device 1 such as filter device 1c shown in FIG. 6, or can alternatively be a removable and replaceable cartridge 55 and be replaced when a filter device 1 such as filter device it also includes a screw-off or otherwise removable top portion 18 and seal 19, as shown in FIG. 22.

[0216] As shown in FIGS. 5, 7 and 8, a plurality of filter layers 56 can be configured and disposed next to one another and the filter layers 56 can be orientated parallel to a central axis 57 associated with the configuration of the inlet 31f and outlet 32f, and also the direction of flow of a liquid, blood portion and blood 10 and then form a complex matrix or maze 69. As shown in FIGS. 5, 7, and 8, a filter 4c, 4d, or 4e can include a plurality of circular and / or concentrically orientated filter layers 56 including screens 16 of metal wire 34 or other electrically conductive material which are spaced about a central axis 57 and a connected together by one or more cross braces 61 or other means for making a connection, and can also possibly include a mechanically, chemically, and / or adhesively connected top seal 64 on the top end 62 and bottom seal 65 on the bottom end 63 as shown in FIGS. 7-8. Further, one or more magnet devices 11a-b can be removably or permanently secured proximate to the wall 39, and in particular, near the outside wall surface 39o of the filter device 1c. In this regard, the magnet devices 11a-b can be permanent magnets 12, a plurality of magnetic beads 13, or electromagnets 14. As shown in FIG. 6, when a plurality of magnet devices 11a-b are used with a filter device 1c which includes a filter 4c, 4d, or 4e, the magnet devices a-b are typically orientated so that their north and south poles are configured to face the oppositive poles of the magnetic device 11 which is disposed nearby, that is, the south pole S of magnet device 11a is disposed opposite to the north pole N of magnet device 11b. In other words, a first magnet device 11a having a first positive pole and first negative pole is typically configured such that the first positive pole is disposed proximate to the second negative pole of the second magnet device 11b, and / or the first negative pole is disposed proximate to the second positive pole. In FIG. 6, the magnet devices 11a-b are electromagnets 14 which are disposed proximate to the lateral side(s) 68 of the filter device 1c, and include conductive wire 34 disposed around a conductive core 46, and also male lead 53 and female lead 54 connectors.

[0217] FIG. 7 is a top perspective view of an alternative filter 4d which can include a plurality of convoluted 80 layers 56 including screens 16 of metal wire 34 or other electrically conductive material which project outwards around and about a central axis 57. The layers 56 can be configured so as to nest close to one another and be disposed inside of one another. The layers 56 can be connected together by one or more cross braces 61 and / or at the top end 62 and bottom end 63 by a top seal 64 and a bottom seal 65. The screens 16 can be configured by superimposing wires 34, weaving, knitting, or be configured and made by 3D printing or other manufacturing processes and can also be referred to as a mesh, net, or web. In FIG. 7, the top ends 62 and bottom ends 63 of the layers 56 of screen 16 include a top seal 64 and bottom seal 65 which provides for a mating surface, seat, and / or seal between the filter 4d and an inside wall surface 39i of a filter device 1 such as filter device 1c shown in FIG. 6. In an alternative embodiment, the screens 16 used in filter 4d can further include or be connected to an additional filter media 21 for mechanically trapping and / or adsorbing undesired matter 9 from a liquid, blood portion and blood 10. The alternative filter 4d can be an integral component and be permanently sealed and contained within the chamber 2 of a filter device 1 such as filter device 1c shown in FIG. 6, or can alternatively be a removable and replaceable cartridge 55 and be replaced when a filter device 1t also includes a screw-off or otherwise removable top portion 18 and seal 19 as shown in FIG. 22.

[0218] FIG. 8 is a top perspective view of an alternative filter 4e which can include a zig-zag structure 81 in a plurality of layers 56 including screens 16 of metal wire 34 or other electrically conductive material which project outwards around and about a central axis 57. The layers 56 can possibly be connected together by one or more cross braces 61, and / or at the top end 62 and bottom end 63 by a top seal 64 and a bottom seal 65. The layers 56 can be configured so as to nest close to one another and be disposed inside of one another. The screens 16 can also be configured by superimposing wires 34, weaving, knitting, and / or be configured and made by 3D printing or other manufacturing processes and can also be referred to as a mesh, net, or web. In FIG. 8, the top ends 62 and bottom ends 63 of the layers 56 of screen 16 include a top seal 64 and bottom seal 65 which provides for a mating surface, seat, and / or seal between the filter 4e and an inside wall surface 39i of a filter device 1b such as filter device 1c shown in FIG. 6. In an alternative embodiment, the screens 16 used in filter 4e can further include or be connected to an additional filter media 21 for mechanically trapping and / or adsorbing undesired matter 9 from a liquid, blood portion and blood 10. As also shown in FIG. 15, the filter 4e includes a splitter 82 which can cause a fluid, blood portion and blood 10 to be scattered and dispersed within the chamber 2 of a filter device 1 and structure of the filter 4e. The alternative filter 4e can be an integral component and be permanently sealed and contained within the chamber 2 of a filter device such as filter device 1c shown in FIG. 6, or can alternatively be a removable and replaceable cartridge 55 and be replaced when a filter device 1t also includes a screw-off or otherwise removable top portion 18 and seal 19, as shown in FIG. 22.

[0219] FIG. 9 is a side view of a filter device Id which includes a wall 39 which can be made of a biocompatible material which can be a medical grade metal, glass, or thermoplastic material, e.g., polyamides or nylon, polyethylene glycol, polyvinyl alcohol, polyethyleneimine, polyvinylamine, polyacrylates, polyesters, polycarbonates, polystyrenes, polypropylene, polydimethylsiloxane or silicone, ABS, urethanes, nylon, PTFE, and a thermoplastic elastomer such as Santoprene. The wall 39 includes an outside wall surface 39o which is on the exterior 41 of the filter device 1d, and an inside wall surface 39i which is on the interior 42 of the filter device 1d. The filter device 1d can include an integral or removable inlet 31f and outlet 32f. The inlet 31f and outlet 32f can include barbs, threads, luer 94, or other types of male and female or hermathrodite structures for connecting and coupling the filter device 1d to tubes 7, and / or other devices or structures. The filter device 1d can have a top side 66, a bottom side 67, and one or more lateral side(s) 68 depending on whether the side 68 portion is configured as being circular in shape and has a radius oriented about a central axis 37, or other geometric shape. As shown in FIG. 9, the filter device 1d is configured with the inlet 31f and outlet 32f being in alignment which can enhance the flow through of a liquid, blood portion and blood 10. The structure of the filter device 1d defines a chamber 2 which includes a cavity 3 which includes a void space when empty and which has a volume. The filter device 1d can include a filter 4, such as filters 4c-e which are shown in FIGS. 5, 7 and 8. In an alternative embodiment, the screens 16 used in filter 4 can further include or be connected to an additional filter media 21 for mechanically trapping and / or adsorbing undesired matter 9 from a liquid, blood portion and blood 10. The filter 4c-e can be permanently sealed and contained within the interior chamber 2 of the filter device Id shown in FIG. 9, or alternatively can be configured as a removable cartridge 55 and be removed when a filter device it also includes a screw-off or otherwise removable top portion 18 and seal 19, as shown in FIG. 22.

[0220] The filter device 1d can include a filter 4c-e which is used to help separate and remove undesired matter 9 from an individual and patient's 28 blood 10. When a non-electrically charged filter 4 is being used, it can be helpful to use a permanent magnet 12, a plurality of magnetic beads 13, or an electromagnet 14 which produces an electromagnetic field and gradient 45 that imparts a positive charge proximate to the filter 4c-e. However, a filter 4c-e which includes an internal structure and / or media that is or can be electrically charged is typically selected for use. In this regard, the filter structure and / or media is typically positively electrically charged. As shown in FIGS. 5, 7, and 8, the filters 4c-e can include a filter layer 56 including a screen 16 which is made of an electrically conductive metal, ceramic, or other composite material. As shown in FIGS. 5, 7, and 8, a plurality of filter layers 56 can be disposed next to one another, and the filter layers 56 can be orientated parallel to the central axis 57 associated with the configuration of the inlet 31f and outlet 32f and direction of flow of a liquid, blood portion and blood 10 to form a complex matrix or maze 69. As shown in FIGS. 2 and 6, it can be readily understood that one or more magnet devices 11a-b can also be removably or permanently secured proximate to the wall 39, and in particular, the outside wall surface 39o of the filter device 1d. In this regard, the magnet devices 11 can be permanent magnets 12, a plurality of magnetic beads 13, or electromagnets 14. As shown in FIGS. 2 and 6, when a plurality of magnet devices 11a-b are used, the magnet devices 11a-b are typically orientated so that their north and south poles are configured to face the oppositive poles of the magnetic device 11a-b which is disposed nearby, that is, the south pole S of magnet device 11a is disposed opposite to the north pole N of magnet device 11b. In other words, a first magnet device 11a having a first positive pole and first negative pole is typically configured such that the first positive pole is disposed proximate to the second negative pole of the second magnet device 11b, and / or the first negative pole is disposed proximate to the second positive pole. In FIG. 2, the magnet devices 11a-b are shown disposed proximate to the top side 66 and bottom side 67 of the filter device 1a, whereas in FIG. 6 the magnet devices 11a-b are shown disposed proximate to the lateral side(s) 68 of the filter device 1c. As shown in FIG. 9, the path of a liquid, blood portion and blood 10 which enters the inlet 31f is directed by channels 71 towards the lateral side(s) 68 on the interior 42 of the filter device 1d, and the liquid, blood portion and blood 10 can then pass through the screen 16 and / or other media 21 portion of the filter 4c-e and into the perforated collection tube 17 which is connected to and permits a liquid, blood portion and blood 10 to flow out of the outlet 32f.

[0221] FIG. 10 is a top view of the filter 4d shown in FIG. 7. In this regard, the filter 4d is configured to have a convoluted structure 80 and can include a screen 16 made of wire 34 and / or other filter media 21 which surrounds a central perforated collection tube 17, and the filter 4d can be contained in the chamber 2 of a filter device 1, such as filter device Id shown in FIG. 9. The filter 4d can alternatively further include a splitter 82 as shown in FIGS. 8 and 15. Alternatively, the filter 4d be configured as a removable and replaceable cartridge 55 and be removed when a filter device it is used which includes a screw-off or otherwise removable top portion 18 and seal 19, as shown in FIG. 22.

[0222] FIG. 11 is a cross-sectional view taken along a line 11-11 of the blood dispersion device 49 shown in FIG. 16. As shown, the blood dispersion device 49 includes a inlet 31d, a funnel portion 50a, a middle portion 51 which is narrow in cross-section and can include a window 52 for optical monitoring of the contents of the blood dispersion device 49 such as a liquid, blood portion and blood 10, a funnel portion 50b, and an outlet 32d. At least one valve 30 or roller clamp 85 for starting, stopping, or regulating the flow of a liquid, blood portion and blood 10 can be disposed before inlet 32d and also after outlet 32d, or alternatively, a valve 30 can be included in the blood dispersion device 49. Accordingly, a liquid, blood portion and blood 10 contained in the blood dispersion device 49 can be made to stop and then be relatively motionless in order to enable optimal monitoring. The blood dispersion device 49 can have a thin cross-section in the middle portion 51 which is configured to provide a gap for blood flow that is less than or equal to 50 microns wide, or alternatively less than or equal to 30 microns wide, or alternatively in the range between 6-15 microns wide, or alternatively in the range between 1.5-15 microns wide. In this regard, a gap in the range between 6-15 microns wide can permit the relatively unobstructed passage and also the observation of platelets, red blood cells, and most white blood cells in an individual and patient's 28 blood 10. Once again, with regards to the size and scale used to discuss blood and its various components one micron (μm) equals 1000 nanometers (nm) and the average size of red blood cells is normally in the range between 6-9 microns or 6,000-9,000 nm. The average size of small white blood cells is in the range between 7-8 microns or 7,000-8,000 nm, whereas the average size of most white blood cells is in the range between 10-15 microns or 10,000-15,000 microns, but a few white blood cells are as large as 15-30 microns or 20,000-30,000 nm. The average size of platelets is typically between 1.5-4 microns or 1,500-4,000 nm. In order to not undesirably slow the flow of an individual and patient's blood 10 through an extracorporeal filtering device 33, a blood dispersion device 49 can possibly be connected and reconnected using two Y or T shaped connectors 84 and tubing 7 in parallel to the main flow path of a liquid, blood portion and blood 10 in an extracorporeal blood filtering device 33.

[0223] FIG. 12 is a top cross-sectional view taken along line 12-12 of the filter device 1e shown in FIG. 15. In this regard, the filter device 1e includes a first wall 39a having an outside wall surface 39o on the exterior 41 of the filter device 1e, and an inside wall surface 39i on the interior 42 of the filter device 1e. The filter device 1e, further includes a second wall 39b having outside portion 43, and an inside portion 44. A filter 4 such as filter 4c-e can be disposed within the central space defined by the inside portion 44 of the second wall 39b of the filter device 1e, whereas one or more magnet devices 11a-d can be disposed in the space defined between the outside portion 43 of the second wall 39b, and the inside wall surface 39i of the first wall 39a. Accordingly, the one or more magnet devices 11a-d can be placed in close proximity to a filter 4, such as a filter 4c-e. The magnet devices 11a-d which can be one or more permanent magnets 12, magnetic beads 13, or one or more electromagnets 14 can be selected for use, and also removed and replaced for possible future use. Further, the type and strength of the permanent magnet 12, magnetic beads 13, or electromagnet 14 can be selected to optimize the function and process of removing undesired matter 9 from a liquid, blood portion and blood 10 of an individual and patient 28, such as from a separated portion of blood plasma.

[0224] The magnet devices 11a-e are typically configured to produce an electromagnetic field and gradient 45 in range between 0.01-1 Tesla. For reference purposes, 1 Tesla is equal to 10,000 Gauss, and also 1 Volt (V) per second / (meters) m2. Moreover, the Covid-19 virus is also negatively charged, and it is vulnerable to moderate electric fields. Electric field strengths between 106 and 107 Volts (V) Meter (m)−1 which are below the breakdown threshold of water are commonly used in industrial food processing to inactivate pathogens, and electric field strengths less than or equal to 104 Vm−1 can possibly be used without adverse effects as discussed in the article: “The SARS-CoV-2 Spike Protein is Vulnerable To Moderate Electric Fields,” by Arbeitman et al, Sep. 13, 2021, https: / / www.nature.com / articles / s41467-021-25478-7. The isoelectric point of most viruses are found in the Ph range between 1.9-8.4, and in particular in the Ph range between 3.5-7, as discussed in the article: “Isoelectric Points of Viruses,” by Michen et al., August, 2010, https: / / pubmed.ncbi.nlm.nih.gov / 20102425 / . Most bacteria pathogens have a negative electrical charge, and magnetic beads 13 or nanoparticles which have a positive electrical charge can be used to capture, separate and remove them, as discussed in the articles: “Using Positively Charged Nanoparticles to Capture Bacteria at Ultralow Concentration,” by Li Zhiming et al., Jun. 9, 2019, https: / / nanoscalereslett.springeropen.com / articles / 10.1186 / s11671-019-3005-z; and, “Electric Charge of Bacterial Antigens,” by Leo Olitzki, Apr. 1, 1932: https: / / www.jimmunol.org / content / 22 / 4 / 251.

[0225] Alternatively, it can be readily understood that a human donor can provide the source of blood or blood portion, and that the treated blood or blood portion can be collected in a second bag 95b or container and be stored. In either case, it is also possible for a sample of whole blood to be separated into its constituent parts and different blood portions, e.g., red blood cells, white blood cells, platelets, and serum. One or more of these different blood portions can be treated separately and then be either be reinfused in an individual, infused in a different individual when needed, or be stored for later use. In this regard, it may be possible to expose blood serum to one or more higher levels and / or different frequencies of electric, magnetic, and / or electromagnetic fields than can be used with red blood cells, white blood cells, or platelets without causing damage to biological structures.Ultrasound can Disable the Spike Protein

[0226] The SARS-CoV-2 spike protein is also vulnerable to ultrasound, e.g. see the article “A Potential treatment for COVID-19 Based On Modal Characteristics And Dynamic Responses Analysis of 2019-nCoV,” by Minghui Yao and Hongbo Wang, published by Springer Link in Nonlinear Dynamics online, Volume 106, pages 1425-1432, Oct. 21, 2020, https: / / link.springer.com / article / 10.1007 / s11071-020-06019-1. The two authors disclose that implementing a 360 degree sweep excitation using ultrasound with the vibration frequencies set in the range between 1.9×108 Hz to 2.0×108 Hz and the amplitude selected as being equal to or greater than 1.041×105 mm in order to safely disable and / or destroy the spike protein structures which are present in the COVID-19 virus(es) and thereby prevent them from infecting human cells. See also: “Collapsing COVID: MIT Says Ultrasound Can Damage Coronaviruses,” by Jennifer Chu, Mar. 16, 2021, https: / / news.mit.edu / 2021 / ultrasound-coronaviruses-damage-0316. These two articles were based on modeling of the COVID-19 virus and theoretical in nature, but also see the paper: “Ultrasound Treatment Inhibits SARS-CoV-2 In Vitro Infectivity,” by Flavio P. Veras et al., Nov. 21, 2022, https: / / www.biorxiv.org / content / 10.1101 / 2022.11.21.517338v2, based on actual in vivo tests on COVID-19 virus strains that were conducted in a laboratory. In brief, the Veras et al. found that ultrasound frequencies in the range of 5-10 MHz to be the most effective in stopping the virus from replicating and also killing the virus. As disclosed in the present application, when blood is drawn from an individual it can be caused to pass through a blood dispersion device and / or a filter device. Alternatively, and / or in addition to causing electric fields, magnetic fields, or electromagnetic fields to be made proximate to or inside of these blood dispersion and / or filter devices by using a blood conditioning device for the purpose of separating and removing undesired matter, e.g., metals, nanometals, graphene oxide, toxins, and pathogens including the COVID-19 virus from blood as disclosed in this application, it is also possible for an alternative blood conditional device to include or use an ultrasound device to provide vibration excitation in order to disable or destroy the spike protein in the COVID-19 virus, and / or other structures associated with viruses and pathogens. When the blood dispersion and / or filter devices and related structures and methods disclosed in this application are not available for use, it may still be possible to use ultrasound vibration excitation proximate to the arteries which pass through the wrist, or ankle areas of an individual's body for a sufficient period of time in order to expose their blood supply in vivo to ultrasound excitation in order to disable or destroy the spike protein of the COVID-19 virus, or other pathogen. This technique and method could be tested and evaluated in a laboratory setting with regards to its possible efficacy. They are many manufacturers of ultrasound devices for medical use including, e.g., Esaote, GE Healthcare, Cannon Medical Systems USA, Fujifil Holdings Corporation, Mindray, Siemans AG, Koninkliike Philips N.V., Parks Medical Electronics, Samsun, Sonosite, and Toshiba.

[0227] Alternatively, it can be readily understood that a human donor can provide the source of blood or blood portion, and that the blood or blood portion treated with ultrasound can be collected in a second bag 95b or container and be stored. In either case, it is also possible for a sample of whole blood to be separated into its constituent parts and different blood portions, e.g., red blood cells, white blood cells, platelets, and serum. One or more of these different blood portions can be treated separately and then be either be reinfused in an individual, infused in a different individual when needed, or be stored for later use. In this regard, it may be possible to expose blood serum to one or more higher levels and / or different frequencies of electric fields, magnetic fields, and / or electromagnetic fields, and / or ultrasound vibration excitation, than can be used with red blood cells, white blood cells, or platelets without causing damage to biological structures.Ultraviolet Light can Disable the Spike Protein and Kill the COVID-19 Virus, and / or Other Viruses During a Pandemic

[0228] The COVID-19 virus and its spike protein is also vulnerable to certain frequencies and wavelengths of light, and in particular, to ultraviolet light having a wavelength in the range between 10-400 nanometers, and in particular, to ultraviolet light having a wavelength of 222 nanometers as disclosed in the articles entitled: “Type of Ultraviolet Light Most Effective at Killing Coronavirus is Also the Safest to use Around People,” by Karl Linden, The Conversation, Oct. 26, 2021, https: / / theconversation.com / type-of-ultraviolet-light-most-effective-at-killing-coronavirus-is-also-the-safest-to-use-around-people-169602. In particular, see the paper entitled: “Ultraviolet Irradiation of Blood: The Cure That Time Forgot?,” by Michael Hamblin, Adv Exp Med Biol, 2017; 996: 295-309, Sep. 4, 2018, https: / / w.nchi.nlm.nih.gov / pmc / articles / PMC6122858 / ; and also the “Use of Ultraviolet Blood Irradiation Against Viral Infections”, by Boretti et al., Oct. 7, 2020, Clin Rev Allergy Immunol, 2021, 60(2): 259-270, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC7538853 / , which includes a discussion of the Knott Hemo Irradiator, designed in 1928, and provides many other supporting references. In this regard, before the creation of many of the antibiotic drugs which are commonly being used today, during the 1930's and 1940's the extracorporeal exposure of blood and blood components to ultraviolet light was successfully used in medical practice to kill viruses and restore health, but this knowledge and practice has been largely forgotten. Here are some key passages and excerpts from this article:

[0229] Viruses absorb much more energy than the red and white blood cells and get more damaged by UV light. The killed viral fragments create a vaccination-like response. This strengthens the immune system response to the specific pathogen. This may explain why treating only a small amount of blood with UBI may induce a significant immune system response . . . .

[0230] An approximately 5-7% of blood is necessary for the treatment with UV to have the optimum benefit . . . .

[0231] It is important to state the specific UBI technique developed by Knott.

[0232] This process involved removing approximately 3.5 mL / kg of venous blood, citrating it as an anticoagulant, and then passing it through a radiation chamber. The exposure time per unit of blood was selected at 10 s. The wavelength of light was set at 253.7 nm. The UVC was obtained by a quartz burner of mercury.

[0233] There are individuals in the medical community who are performing extracorporeal blood procedures today in which a patient's blood is removed, pumped and filtered using a filter which is typically used in dialysis, and the blood is then subjected to an ozone treatment and oxygenated, and then also exposed to UV light before being reinfused, e.g., see, “How to Activate your “Immortal Stem Cells” Through EBOO|Dr. Phillip Yoo|People Unlimited, by People's Unlimited Inc., Nov. 14, 2024, https: / / youtu.be / PdZWRDCybIQ, See 18:45-26:00 minutes; “EBOO Therapy_Revolutionary Blood Oxygenation Treatment Explained,” by NeuroLaunch editorial team, Oct. 1, 2024, https: / / neurolaunch.com / eboo-therapy / ; “Eboo Full Spectrum Uv—O3uv”, No Author, No Date, https: / / o3uv.com / products / eboo-full-spectrum; “Polychromatic Blood Therapy using the Hemealumen,” by Breiner Whole-Body Health Center, Mar. 22, 2029, https: / / youtu.be / 7qNsT2c2wbM?si=Vmbpdc3SJscPpzf2; “Hemealumen Polychromatic Device,” by aldmed.com, No Date, https: / / www.aldmed.com / ald-machines / hemealumen-polychromatic-device.html; Nipro “ELISIO™-H Dialyzer|Hollow Fiber Dialyzer|Nipro Medical,” by Nipro, No Date, https: / / nipro.com / products / renal / elisio-h-dialyzer / ; “ELISIO™-H Dialyzer,” by Nipro, No Date, https: / / nipro.com / products / renal / elisio-h-dialyzer / ; and the Masterflex®“Peristaltic Pump and Fluid Handling Solutions,” by VWR, No Date, https: / / us.vwr.com / cms / masterflex-fluid-handling-solutions.

[0234] During a pandemic associated with a large disease burden and what could be a potential or actual mass casualty event, it should be recognized that the number of hospital beds and trained medical doctors and nurses available may not be sufficient to provide medical attention to hundreds of thousands or tens of millions of people. Further, there would likely neither be a sufficient supply drugs or of advanced medical equipment available to large segments of the public in the United States and around the world. In this regard, if and when an artificial source of ultraviolet light is not available, it should be recognized that it would possible to go outdoors and then use sunlight which provides a source of ultraviolet light in order to expose and provide a treatment for blood or a blood portion contained within a blood dispersion device, a glass or plastic container, or tubing. The sun shines everywhere and is a ready source of ultraviolet UV-A and UV-B light, but not much UV-C light because the latter is substantially absorbed and / or blocked by the atmosphere. However, even on a cloudy day, ultraviolet UV-A and UV-B light is able to reach the earth's surface. Once again, a blood dispersion device as shown and discussed in FIGS. 11, 16, and 32 would be typically used only once, and then be disposed. However, it should be recognized that not all parts of the world may have an adequate and ready supply of needed and required medical equipment during a pandemic. In the absence of a blood dispersion device 49a-b as shown and discussed in FIGS. 11, 16, and 32, it may then be possible to alternatively use the drip chamber 89 in a transfusion kit 91 shown in FIG. 19 to serve as a make-shift blood dispersion device. Alternatively, an open glass or plastic container can be used in order to better expose blood or a blood portion to a desired source of electric, magnetic, or electromagnetic fields, and / or ultrasound vibration excitation, and / or ultraviolet light for conditioning or treating blood or a blood portion. Alternatively, when no container of any kind is available to serve as a blood dispersion device, it could be possible to wind a length of relatively clear plastic tubing 7 which does not include a substantial amount of blockers to UV light around an individual's arm 75, leg 76, or different object in order to create a coil-like structure so that a relatively large quantity of the blood or a blood portion which is being caused to pass through the tubing 7 can be exposed to wavelengths of electric, magnetic, and / or electromagnetic fields, and / or ultraviolet light, and / or ultrasound vibration for a sufficient length of time in order to disable or kill the spike protein and COVID-19 virus, and / or a different virus or pathogen. As discussed herein, a rate of blood flow of 100 mL / min is typically such that about 45-57 minutes will be required for the amount of blood to be recirculated from a first puncture site 27a to second puncture site 27b in an individual who weights between 150-180 pounds and who typically has a blood volume in the range between 4,500-5,700 mL. Accordingly, one or more hours of exposure to sunlight of an individual's blood which is being caused to pass from a first puncture site 27a through tubing 7, and / or a container or other makeshift device for exposing the blood to sunlight, and / or a blood dispersion device as shown in FIGS. 11, 16, and 32, and then be reinfused at a second puncture site 27b could be desired and performed by a qualified medical professional. In this regard, it is possible for an alternative blood conditional device to include or use a source of ultraviolet light in order to disable or destroy the spike protein in the COVID-19 virus, and / or to disable or kill other viruses and pathogens.Ultraviolet Light, Vitamin D, and Other Anti-Viral Substances and / or Methodologies and Related Procedures

[0235] Ultraviolet light type UV-A is in the range of 315-400 nanometers, type UV-B is in the range of 280-315 nanometers, and they can be associated with suntanning and the production of Vitamin D. The following video has a good discussion and shows in a series of graphs how important Vitamin D is with regards to immunity, and how and why people with darker skin, the elderly, and also obese individuals are more vulnerable to viruses and including COVID-19: see, “The Second Pandemic,” Dr. John Campbell with Dr. David Grimes,” Jan. 15, 2024, https: / / youtu.be / sp21CPCVNAw?si=59jkLbR9iKPnKB0P. One of the important points discussed is that when people get older, their skin does not produce much Vitamin D, and so most elderly people have a vitamin D deficiency which impairs their immune system. The late Dr. Zelenko read Ralf S. Baric's paper entitled: “Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture,” Velthuis et al., Nov. 4, 2010, PLoS Pathog. 2010 November; 6(11): e1001176, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC2973827 / , and then made a product which includes Vitamin D and Zinc, e.g., see the website: Z-Stack_Immune Support Vitamins_Immune System Booster_Z-Stack®, by Dr. Vladimir Zelenko, https: / / zstacklife.com / products / z-stack. Also see the article: “COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng / mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis,” by Borsche et al., Oct. 11, 2021, Nutrients 2021, 13(10), 3596; https: / / doi.org / 10.3390 / nu13103596.

[0236] Besides the merits of Vitamin D, it is also known that the Vitamin C contained in citrus fruits such a lemons, and bromelain which is present in pineapples can serve to reduce inflammation. Other foods or substances that are widely believed to boost immunity and / or have anti-bacterial, anti-viral, or other health benefits include: garlic, onions, turmeric, ginger, honey, oregano, mint, walnuts, olive oil, coconut oil, and zinc. Activated charcoal, carbon 60, zeolite clinoptilolite, and selenium are known to help regarding detoxification from heavy metals or other toxins. In the absence of activated charcoal, it is known to provide burnt toast to individuals who have food poisoning, or a stomach flu virus, and to follow up with natural yogurt to help restore their gut biome.

[0237] Dr. Peter McCullough has developed a protocol for detoxing from the spike protein and COVID-19 infections, and suggests taking Bromelain, Nattokinase, Curcumin which is contained in Turmeric, Hydroxychloroquine, and Colchicine, and also suggests that the following compounds may assist in spike protein detoxification and deregulation: N-Acetylcysteine (NAC), Glutathione, Ivermectin, Quercetin, Anigen, Nicotine, Emodin, Fisetin, Rutin, and Silymarin, e.g., see: “Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination, Nov. 21, 2023, Hulscher N, Procter B C, Wynn C, McCullough P A. Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination. Cureus. 2023 Nov. 21; 15(11): e49204. doi: 10.7759 / cureus.49204; PMID: 38024037; PMCID: PMC10663976, https: / / pubme3d.nchi.nim.nib.gov / 3824037 / ; “Base Spike Protein Detoxification Explained on FlashPoint,” by McCullough, Sep. 2, 2023, https: / / petermcculloughmd.substack.com / p / base-spike-protein-detoxification.

[0238] Further, Dr. Peter McCullough, Nicolas Hulscher, and Diane Marotta have recently suggested ways to possibly selectively deactivate the mRNA which is present in the COVID-19 vaccines, e.g., see “BREAKING Publication—Strategic Deactivation of mRNA COVID-19 Vaccines: New Applications for siRNA and RIBOTAC Therapy,: by Hulscher, McCullough, and Marotta, May 30, 2024, https: / / pctermeculloughmd.substack.com / p / rreaking-publliatiori-stategic-deactivation)?utm_source=profile&utm_medium=reader2, and, Hulscher, N., McCullough, P. A., & Marotta, D. E. (2024, May 30). “Strategic Deactivation of mRNA COVID-19 Vaccines: New Applications for RIBOTACs and siRNA Therapy,” https: / / osf.io / preprints / osf / qxbgu; and also see: “Irreversible Inactivation of SARS-CoV-2 by Lectin Engagement with Two Glycan Clusters on the Spike Protein,” by Nangarlia et al., Biochemistry, 2023 Jul. 18; 62(14):2115-2127. doi:10.1021 / acs.biochem.3c00109, Jun. 21, 2023, https: / / www.ncbi.nlm.nih.gov / pmc / articles / pmid / 37341186 / . Once again, individuals who experience health problems and / or who are taking medications should always first consult with their doctors with regards to their diet and any possible contraindications relating to the information provided herein.

[0239] The red blood cell, white blood cell, and platelet structures and serum contained in whole blood and / or these blood portions can possibly be exposed to UV-A and / or UV-B ultraviolet light for minutes or even hours depending on the light intensity without causing any harm, but Type UV-C in the range between 100-280 nanometers and is typically used as a germicidal, e.g., to purify public drinking water, and many microorganisms and pathogens are known to be vulnerable to exposure to UV-C light having a wavelength of around 260 nanometers. A well-known aphorism in jurisprudence and also the medical field is that: “circumstances alter cases.” Accordingly, depending upon the circumstances, whole blood and / or blood portions are typically exposed to UV-C light relatively sparingly, and / or not at all. Nevertheless, UV-C light can possibly be used to kill viruses in human blood, a blood portion such as serum, and also liquids such as water. Again, see the techniques and methods disclosed in the article: “Ultraviolet Irradiation of Blood: The Cure That Time Forgot?,” by Michael Hamblin, Adv Exp Med Biol, 2017; 996: 295-309, Sep. 4, 2018, https: / / www.nchi.nim.nih.gov / pmc / articles / PMC6122858i; and the “Use of Ultraviolet Blood Irradiation Against Viral Infections,” by Boretti et al., Oct. 7, 2020, Clin Rev Allergy Immunol, 2021, 60(2): 259-270, https: / / www.ncbi.nlm.nih.gov / pmc / articles / PMC7538853 / .

[0240] As disclosed in the present application, when blood is drawn from an individual it can be caused to pass through a blood dispersion device and / or a filter device. Alternatively, and / or in addition to causing at least one electric field, magnetic field, and / or electromagnetic field to be activated near or inside of these blood dispersion and / or filter devices using a blood conditioning device for the purpose of separating and removing metals, graphene oxide, toxins, and pathogens including the COVID-19 virus from blood as disclosed in this application, and / or using ultrasound excitation to disable or destroy the spike protein in the COVID-19 virus, it is also possible for an alternative blood conditioning device to include an ultraviolet light device that provides a source of ultraviolet light having a wavelength in the range between 10-400 nanometers which can be used to disable or kill the spike protein and / or COVID-19 virus. In this regard, it is possible for an alternative blood conditional device to include or use a source of ultraviolet light in order to disable or destroy the spike protein in the COVID-19 virus, and / or to disable or kill other viruses and pathogens. There are many manufacturers of ultraviolet lights which are suitable for phototherapy, e.g., Far UV Technologies, Inc., American Ultraviolet, The LightSources Group, McKesson Medical-Surgical, and Medical Illumination. Further, photopheresis is an existing medical technique and procedure in which a patient's blood is removed, and a blood portion including white blood cells is separated and treated with at least one chemical and also exposed to ultraviolet light (UV-A), and then returned to the patient in order to help fight cancer or calm their immunity response. Makers of photopheresis equipment include Pit Medical Systems GmbH, and Therakos, Inc. It may be possible for some of their products to provide, or be easily modified in order to provide ultraviolet light in the UV-B and UV-C range of wavelengths.

[0241] Alternatively, it can be readily understood that a human donor can provide the source of blood or blood portion, and that the blood or blood portion treated with ultraviolet light can be collected in a second bag 95b or container and be stored. In either case, it is also possible for a sample of whole blood to be separated into its constituent parts and different blood portions, e.g., red blood cells, white blood cells, platelets, and serum. One or more of these different blood portions can be treated separately and then be either be reinfused in an individual, infused in a different individual when needed, or be stored for later use. In this regard, it may be possible to expose blood serum to one or more higher levels and / or different frequencies of electric, magnetic, and / or electromagnetic fields, ultrasound vibration excitation, and ultraviolet light than can be used with red blood cells, white blood cells, or platelets without causing damage to biological structures.

[0242] At least a portion of the blood supply in the United States and also around the world may be contaminated with undesired matter, and / or the spike protein and COVID-19 virus, or other pathogens. Accordingly, the blood dispersion devices, filter devices, and the blood conditioning devices which can provide and in partial or complete combination an electric field, a magnetic field, an electromagnetic filed, ultrasound vibration excitation, ultraviolet light, and the related devices, techniques, methods, and procedures disclosed herein can also be used in partial or complete combination to disable and / or destroy, and / or remove undesired matter, e.g., metals, nanometals, members of the graphene family, an electronic chip or other electronic device, a pathogen, a bacterium, a cancerous cell, a virus, a spike protein, a blood cell infected with a virus, a COVID-19 virus, and a toxin from blood or a blood portion. In this case, the blood or blood portion would either be taken from a human donor, or from a blood or blood portion which is in storage, and the blood or blood portion would be treated as disclosed herein and then be collected and stored.

[0243] In this regard, FIG. 31 shows a first bag 95a or container which contains blood or a blood portion which is to be treated, and also its collection in a second bag 95b or container which contains the blood or blood portion which has been treated. Alternatively, it can be readily understood that a human donor can provide the source of blood or blood portion, and that the treated blood or blood portion can be collected in a second bag 95b or container and be stored. In either case, it is also possible for a sample of whole blood to be separated into its constituent parts and different blood portions, e.g., red blood cells, white blood cells, platelets, and serum. One or more of these different blood portions can be treated separately and then be either be reinfused in an individual, infused in a different individual when needed, or be stored for later use. In this regard, it may be possible to expose blood serum to one or more higher levels and / or different frequencies of electric, magnetic, and / or electromagnetic fields, ultrasound vibration excitation, and ultraviolet light than can be used with red blood cells, white blood cells, or platelets without causing damage to biological structures.Magnets and Electromagnet Devices

[0244] FIG. 13 is a perspective view of an electromagnet 14 which includes a coil 47 made of electrically conductive wire 34 or other electrically conductive matter which includes a male lead 53 and also a female lead 54 for connecting to positive and negative electrical wires and a source of electric power. The source of electric power can be DC or AC and come from a conventional power grid, a battery, solar panels or other form of renewable energy, a power supply, a computer 36 or a medical device which is connected by a power supply cord 97 to a wall plug 93. The electromagnet 14 can be disposed and encircle a tube 7 for carrying a liquid, blood portion and blood 10. When supplied with electric current it can impart an electromagnetic field and gradient 45 to undesired matter 9, and / or other substances contained in a liquid, blood portion and blood 10 and thereby elevate or otherwise modify the electric charge and / or manipulate undesired matter 9 and other substances contained in a liquid, blood portion and blood 10.

[0245] FIG. 14 is a side perspective view of an electromagnet 14 which includes a coil 47 made of electrically conductive wire 34 or other electrically conductive matter which includes a male lead 53 and also a female lead 54 for connecting to positive and negative electrical wires and a source of electric power. The source of electric power can be DC or AC and come from a conventional power grid, a battery, solar panels or other form of renewable energy, a power supply, a computer or a medical device which is connected to a wall plug 93. The electromagnet 14 can be disposed so at to coil around and encircle a filter device 1, such as filter device 1a for filtering a liquid, blood portion and blood 10. When the electromagnet 14 is supplied with electric current it can impart an electromagnetic field and gradient 45 to a filter 4 such as filter 4a-e and also to undesired matter 9, and other substances contained in a liquid, blood portion and blood 10, and thereby elevate or otherwise modify the electric charge of undesired matter 9, and / or manipulate other substances contained in a liquid, blood portion and blood 10. In this regard, the electromagnet 14 can impart an electromagnetic field and gradient 45 and create or enhance the positive charge of a filter 4, and also serve to attract, entrain, mix, move, or otherwise cause undesired matter 9 in the liquid, blood portion and blood 10 which typically have a negative charge to become captured, mechanically trapped, adsorbed, or otherwise attached to a filter 4 contained within a filter device 1 such as filter device 1a.

[0246] FIG. 15 is a side view of a filter device 1e which includes magnet devices 11a-e. The magnetic devices 11a-e can be made of permanent magnets 12, a plurality of magnetic beads 13, or electromagnets 14. As shown in FIG. 6, the electromagnets can include a coil 47 made of electrically conductive wire 34 or other electrically conductive matter disposed around a conductive core 46 and which include a male lead 53 and also a female lead 54 for connecting to positive and negative electrical wires or other sources of electric power. The source of electric power can be DC or AC and come from a conventional power grid, a battery, solar panels or other form of renewable energy, a computer or medical device which is connected with a power supply cord 97 to an electric outlet 93. The filter device 1e shown FIG. 15 includes a filter 4e similar to the one shown in FIG. 8 which includes a splitter 82 that can cause a stream of fluid, blood portion, or blood 10 to be scattered widely and dispersed within the structure of the filter 4e contained in the chamber 2 of the filter device 1e. The magnetic devices 11a-d can impart a plurality of electromagnetic fields and gradients 45 to a filter 4e and also to undesired matter 9 and other substances contained in liquid, a blood portion and blood 10, and thereby elevate or otherwise manipulate the electric charge and movement of undesired matter 9, and other substances contained in a liquid, blood portion and blood 10. When the magnetic devices 11a-d are configured as a plurality of electromagnets 14a-d they can be provided with electrical power simultaneously and constantly, or sequentially, or variably and in different patterns, and the polarity of the electromagnets 14a-d can also possibly be alternated and changed. In this regard, the electromagnets 14a-d can impart an electromagnetic field and gradient 45 and then create or enhance the positive charge of a filter 4 such as filter 4e, and also serve to attract, entrain, mix, move, or otherwise cause undesired matter 9 in a liquid, blood portion and blood 10 which typically has a negative charge to become captured, mechanically trapped, adsorbed, or otherwise attached to a filter 4 such as filter 4e contained within a filter device 1e. Blood Dispersion Device

[0247] Once again, FIG. 11 is a cross-sectional view taken along a line 11-11 of the blood dispersion device 49 shown in FIG. 16. As shown, the blood dispersion device 49 includes a inlet 31d, a funnel portion 50a, a middle portion 51 which is narrow in cross-section and can include a window 52 for optical monitoring of the contents of the blood dispersion device 49 such as a liquid, blood portion and blood 10, a funnel portion 50b, and an outlet 32d. At least one valve 30 or roller clamp 85 for starting, stopping, or regulating the flow of a liquid, blood portion and blood 10 can be disposed before inlet 32d and also after outlet 32d, or alternatively, a valve 30 can be included in the blood dispersion device 49. Accordingly, a liquid, blood portion and blood 10 contained in the blood dispersion device 49 can be made to stop and then be relatively motionless in order to enable optimal monitoring. The blood dispersion device 49 can have a thin cross-section in the middle portion 51 which is configured to provide a gap for blood flow that is less than or equal to 50 microns wide, or alternatively less than or equal to 30 microns wide, or alternatively in the range between 6-15 microns wide, or alternatively in the range between 1.5-15 microns wide. In this regard, a gap in the range between 6-15 microns wide can permit the relatively unobstructed passage and also the observation of platelets, red blood cells, and most white blood cells in an individual and patient's 28 blood 10. Once again, with regards to the size and scale used to discuss blood and its various components one micron (μm) equals 1000 nanometers (nm) and the average size of red blood cells is normally in the range between 6-9 microns or 6,000-9,000 nm. The average size of small white blood cells is in the range between 7-8 microns or 7,000-8,000 nm, whereas the average size of most white blood cells is in the range between 10-15 microns or 10,000-15,000 microns, but a few white blood cells are as large as 15-30 microns or 20,000-30,000 nm. The average size of platelets is typically between 1.5-4 microns or 1,500-4,000 nm. In order to not undesirably slow the flow of an individual and patient's blood 10 through an extracorporeal filtering device 33, a blood dispersion device 49 can possibly be connected and reconnected using two Y or T shaped connectors 84 and tubing 7 in parallel to the main flow path of a liquid, blood portion and blood 10 in an extracorporeal blood filtering device 33.

[0248] FIG. 16 is a top view of a blood dispersion device 49 which can include an integral or removable inlet 31b and also outlet 32b. The inlet 31b and outlet 32b can include barbs, threads, luer 94, or other types of male and female or hermathrodite structures for connecting and coupling the blood dispersion device 49 to tubes 7, and / or other devices or structures. As shown in FIG. 16, the blood dispersion device 49 is configured with the inlet 31b and outlet 32b being in alignment about a central axis 57 which can enhance the flow through of a liquid, blood portion and blood 10. The blood dispersion device 49 includes a plurality of walls 39 which can be made of a biocompatible material which can be a medical grade metal, glass, or thermoplastic material, e.g., polyamides or nylon, polyethylene glycol, polyvinyl alcohol, polyethyleneimine, polyvinylamine, polyacrylates, polyesters, polycarbonates, polystyrenes, polypropylene, polydimethylsiloxane or silicone, ABS, urethanes, nylon, PTFE, and a thermoplastic elastomer such as Santoprene. The walls 39 include an outside wall surface 39o which is on the exterior 41 of the blood dispersion device 49, and an inside wall surface 39i which is on the interior 42 of the blood dispersion device 49. The structure of the blood dispersion device 49 defines a chamber 2 which includes a cavity 3 having void space when empty and which has a volume. The blood dispersion device 49 includes an inlet 31b which leads to a funnel portion 50a, a middle portion 51, and a funnel portion 50b which leads to an outlet 32b. The middle portion 51 can further include a window 52 for optical monitoring of the contents of the blood dispersion device 49. At least one valve 30 or roller clamp 85 for starting, stopping, or regulating the flow of a liquid, blood portion and blood 10 can be disposed before inlet 32d and also after outlet 32d, or alternatively, a valve 30 can be included in the blood dispersion device 49. The blood dispersion device 49 has a thin cross-section which is configured to provide a gap for blood flow that is less than or equal to 50 microns wide, or alternatively less than or equal to 30 microns wide, or alternatively in the range between 6-15 microns wide, or alternatively in the range between 1.5-10 microns wide. In this regard, a gap between 6-15 microns wide can permit the relatively unobstructed passage, and also the observation of red blood cells, white blood cells, and platelets in an individual and patient's 28 blood 10. Once again, with regards to the size and scale used to discuss blood and its various components one micron (μm) equals 1000 nanometers (nm) and the average size of red blood cells is normally in the range between 6-9 microns or 6,000-9,000 nm. The average size of small white blood cells is in the range between 7-8 microns or 7,000-8,000 nm, whereas the average size of most white blood cells is in the range between 10-15 microns or 10,000-15,000 microns, but a few white blood cells are as large as 15-30 microns or 20,000-30,000 nm. The average size of platelets is typically between 1.5-4 microns or 1,500-4,000 nm.Alternative Filter Structures

[0249] FIG. 17 is a side view of an alternative configuration of a T-shaped filter device if. The remaining structure and function of filter device if can be generally similar to that of filter devices 1a-e, which are shown in the other drawing figures and also discussed herein. However, the embodiment of a filter device if shown in FIG. 17 further includes a divider wall 79 which includes an opening 72 proximate to the bottom side 67 of the filter device if and this causes the flow of liquid, a blood portion or blood 10 to be directed downwards from the inlet 31f and upwards towards the outlet 32f.

[0250] FIG. 18 is a side view of an alternative configuration of a L-shaped filter device 1h. The remaining structure and function of filter device 1h can be generally similar to that of filter devices 1a-e, which are shown in the other drawing figures and also discussed herein.

[0251] FIG. 19 is a side view of three components of a kit 91 for making a blood infusion or transfusion. In this regard, the kit 91 can include at least one needle 8 which can also be identified as 8a which is connected with a thermoplastic union 86 to a rubber or latex fitting 87 which is connected to tubing 7. The flow of a liquid, blood portion and blood in the tubing 7 can be controlled by at least one roller clamp 85 and / or valve 30. The tubing 7 which is connected to the rubber or latex fitting 87, union 86 and needle 8 is connected to a drip chamber 89 which is made at least in part of a flexible and at least partially transparent thermoplastic material which includes a conventional blood filter 90 which typically has a particle filtration size between 170-260 microns. In order to perform a transfusion, the kit 91 would typically further include another roller clamp 85, additional tubing 7, and another rubber or latex fitting 87, union 86, and needle 8 which can also be identified as 8b.

[0252] FIG. 20 is a side view of an alternative filter device 1j which includes a wall 39 which can be made of a biocompatible material which can be a medical grade metal, glass, or thermoplastic material, e.g., polyamides or nylon, polyethylene glycol, polyvinyl alcohol, polyethyleneimine, polyvinylamine, polyacrylates, polyesters, polycarbonates, polystyrenes, polypropylene, polydimethylsiloxane or silicone, ABS, urethanes, nylon, PTFE, and a thermoplastic elastomer such as Santoprene. The wall 39 includes an outside wall surface 39o which is on the exterior 41 of the filter device 1j, and an inside wall surface 39i which is on the interior 42 of the filter device 1j. The filter device 1j can include a top side 66, a bottom side 67, and one or more lateral side(s) 68 depending on whether the side 68 portion is configured to be circular in shape and has a radius oriented about a central axis 57, or other geometric shape. The filter device 1j can include an integral or removable inlet 31f and outlet 32f. The inlet 31f and outlet 32f can include barbs, threads, luer 94, or other types of male and female or hermathrodite structures for connecting and coupling the filter device 1j to tubes 7, and / or other devices or structures. As shown in FIG. 20, the filter device 1j is not configured with the inlet 31f and outlet 32f being in direct alignment, but rather the flow of a liquid, blood portion and blood 10 is directed through a plurality of internal channels 71 and openings 72 and plurality of internal baffles 73 resembling a matrix or maze 69 which serves to increase the exposure of a liquid, blood portion and blood 10 to the filter 4g which can include microstructures or nanostructures and / or filter media for trapping and / or adsorbing the undesired matter 9 to be separated and removed from a liquid, blood portion and blood 10. Alternatively, the inlet 31f and outlet 32f can be aligned about a central axis 57, or be otherwise disposed in functional relation to the filter device 4j. In FIG. 20, a total of eight internal baffles 73 and also eight openings 72 are shown, but the number of internal baffles 73, internal channels 71 and openings 72 can be in the range between 1 and a trillion. In this regard, the internal baffles 73 can be made of a thermoplastic or other materials which have been previously recited. Alternatively, the internal baffles 73 or other portions of the filter 4g can be made of a nanomaterial such as graphene, or graphene oxide, or magnetic graphene oxide, or other material which has a chemical, biological, mechanical, electromagnetic or other affinity to the undesired matter 9 which is targeted to be separated and removed from a liquid, blood portion and blood 10. As graphene oxide is known to have a natural tendency to congregate or aggregate and self-assemble, the use of the same family of material or an identical material as the target can be seen in some sense as “fighting fire with fire.” Alternatively, the filter 4g can include a nanomaterial which can be made of a biological material. In this regard, a biological material can possibly include, but not be limited to portions of DNA, RNA, or other biological molecules, cell structures, cells, natural or synthetic substances or a drug, e.g., heparin which is an anticoagulant, and can possibly include natural or synthetic liver or kidney tissue made outside of the human body in a laboratory and production facility. The structure of the filter device 1j defines a chamber 2 which includes a plurality of internal channels 71, baffles 73, and openings 72 and has a cavity 3 including a void space when empty and has a volume. In particular, the filter device 1j can include a filter 4g which is used to help separate and remove targeted undesired matter 9 from an individual and patient's 28 blood portion or blood 10. When a non-electrically charged and / or a positively electrically charged filter 4g is being used, it can sometimes be helpful to dispose a magnetic device 11 which can be a permanent magnet 12, a plurality of magnetic beads 13, or an electromagnet 14 which produces an electromagnet field and gradient 45 that can impart an elevated electrical charge, and typically a positive charge proximate to the filter 4g. A filter 4g that already includes an internal structure and / or media which is and / or can be electrically charged is typically selected for use. In this regard, the filter 4g structure and / or media is typically positively electrically charged. The filter 4g can be permanently sealed and contained within the chamber 2 of the filter device 1j, or alternatively can be configured as a removable cartridge 55 and be inserted when a filter device 1t would include a screw-off or otherwise removable top portion 18 and seal 19, as shown in FIG. 22.

[0253] FIG. 21 is a side view of an alternative filter device 1k which includes a wall 39 which can be made of a biocompatible material which can be a medical grade metal, glass, or thermoplastic material, e.g., polyamides or nylon, polyethylene glycol, polyvinyl alcohol, polyethyleneimine, polyvinylamine, polyacrylates, polyesters, polycarbonates, polystyrenes, polypropylene, polydimethylsiloxane or silicone, ABS, urethanes, nylon, PTFE, and a thermoplastic elastomer such as Santoprene. The wall 39 includes an outside wall surface 39o which is on the exterior 41 of the filter device 1k, and an inside wall surface 39i which is on the interior 42 of the filter device 1k. The filter device 1k can have a top side 66, a bottom side 67, and one or more lateral side(s) 68 depending on whether the side 68 portion is configured to be circular in shape and has a radius oriented about a central axis 57, or other geometric shape. The filter device 1k can include an integral or removable inlet 31f and outlet 32f. The inlet 31f and outlet 32f can include barbs, threads, luer 94, or other types of male and female or hermathrodite structures for connecting and coupling the filter device 1k to tubes 7, and / or other devices or structures. As shown in FIG. 21, the filter device 1k can be configured with the inlet 31f and outlet 32f being in direct alignment, but the flow of a liquid, blood portion and blood 10 is directed through at least one internal channel 71 which has a spiral configuration 74 which serves to increase the exposure of a liquid, blood portion and blood 10 to the filter 4h which can include microstructures and / or filter media for trapping and / or adsorbing the targeted undesired matter 9 to be separated and removed from a liquid, blood portion and blood 10. Alternatively, the inlet 31f and outlet 32f can be offset as shown in FIG. 20, or be otherwise disposed in functional relation to the filter device 1k. In FIG. 21, a total of twelve descending internal channels 71 appear in the cross-sectional view, but they are part of a single internal channel 71 having a spiral configuration 74, or semi-spiral configuration which descends continuously, or alternatively, the channel 71 and spiral 74 structure can descend discontinuously and then include relatively flat, but also descending portions which have a slope in the range between 1 / 0 and 10 / 1. In this regard, the internal channel 71 can be made of thermoplastic and the other materials which have been previously recited, or alternatively of a nanomaterial such as graphene, or graphene oxide, or magnetic graphene oxide, or other material which has a chemical, biological, mechanical, electromagnetic or other affinity to the undesired matter 9 which is targeted to be separated and removed from a liquid, blood portion or blood 10. As graphene oxide is known to have a natural tendency to congregate or aggregate and self-assemble, the use of the same family of material or an identical material as the target can be seen in some sense as “fighting fire with fire.” Alternatively, the filter 4h can include a nanomaterial which can be made of a biological material. In this regard, a biological material can possibly include, but not be limited to portions of DNA, RNA, or other biological molecules, cell structures, cells, natural or synthetic substances or drugs, e.g., heparin which is an anticoagulant, and could include natural or synthetic liver or kidney tissue made outside of the human body in a laboratory and production facility. The structure of the filter device 1k defines a chamber 2 which is configured to include an internal channel 71 having a spiral configuration 74 and which includes a cavity 3 including a void space when empty and which has a volume. In particular, the filter device 1k can include a filter 4h which is used to help separate and remove undesired matter 9 from an individual and patient's 28 blood portion or blood 10. When a non-electrically charged and / or a positively electrically charged filter 4h is being used, it can sometimes be helpful to dispose a magnetic device 11 which can be a permanent magnet 12, magnetic beads 13, or an electromagnet 14 which produces an electromagnetic field and gradient 45 that imparts an elevated electrical charge, and typically a positive charge proximate to the filter 4h in order to manipulate the undesired matter 9 and cause it to be separated and removed from a fluid, blood portion or blood 10. In this regard, a filter 4h that already includes an internal structure and / or media which is and / or can be electrically charged is typically selected for use. In this regard, the filter structure and / or media is typically positively electrically charged. The filter 4h can be permanently sealed and contained within the chamber 2 of the filter device 1k, or alternatively can be configured as a removable cartridge 55 and be replaced when the filter device it includes a screw-off or otherwise removable top portion 18 and seal 19, as shown in FIG. 22.

[0254] FIG. 23 is a top view of an alternative configuration of a T-shaped filter device 1g which includes a divider wall 79, and also three baffles 73a-c which are configured to define four quadrant 83a-d portions of the chamber 2 of the filter device 1g. In this regard, the first baffle 73a includes an opening 72 disposed proximate to the bottom side 67 of the filter device 1g and this causes a liquid, blood portion or blood 10 in the first quadrant 83a to flow downwards from the inlet 31f and into the bottom of the second quadrant 83b. The liquid, blood portion or blood 10 can then flow upwards in the second quadrant 83b and through an opening 72 disposed proximate to the top side 66 of the filter device 1g and into the third quadrant 83c. A liquid, blood portion or blood 10 can then flow downwards in the third quadrant 83c and through an opening 72 which is disposed proximate to the bottom side 67 of the filter device 1g and into the fourth quadrant 83d. The liquid, blood portion or blood 10 can then flow upwards in the fourth quadrant 83d and exit through the outlet 32f which includes an opening 72. FIG. 24 is a cross-sectional view of the filter device 1g shown in FIG. 23 taken along line 24-24 and shows baffles 73b-d which include openings 72 for directing the flow of a liquid, blood portion and blood 10 through the quadrants 83a-d disposed between the inlet 31f and outlet 32f. Magnet Devices and Related Techniques and Methods

[0255] Given the possible need or desire to remove metals or other electrically conductive and charged forms of undesired matter 9 from blood 10 which could include, but not be limited to members of the graphene family such as graphene oxide, graphene hydroxide, magnetic graphene oxide, and nanometals, magnetic devices 11 which generate or impart electromagnetic fields and gradients 45 can be used to disable and / or destroy and / or separate and remove undesired matter 9 from the blood 10 of an individual and patient 28. A magnet device 11 can be either a permanent magnet device 12 or an electromagnet device 14. Permanent magnet devices 12 are made and generally available in the form of alnico magnets which typically include a composite of aluminum, nickel, and cobalt; ceramic magnets which typically include ferrite or iron oxide and barium or strontium carbonate; samarium cobalt (SmCo) magnets; neodymium iron boron (NeFeB) magnets; and, injection molded and / or flexible magnets. A permanent magnet device 12 can also be made and configured in the form of magnetic beads 13. Alternatively, a magnet device 11 can be an electromagnet device 14. In this regard, the electromagnet device 14 can possibly include a magnetic core 46 made of ferrite or other conductive material, and a coil 47 of wire 34 made of an electrically conductive metal such as steel, copper, silver, gold, aluminum, nickel, cobalt, or a conductive composite. However, a simple wire 34, and in particular, a coil 47 of wire 34 made of an electrically conductive metal will produce an electromagnetic field and gradient 45 when an electric current is caused to flow in such a wire 34 or coil 47. In accordance with the so-called “right hand rule,” the direction of the magnetic field will typically be perpendicular and clockwise relative to the direction of the movement or flow of the corresponding electric current.

[0256] As previously discussed, a magnet device 11 such as an electromagnet device 14 can be included in the second conditioning device 20, but also in the first conditioning device 5 and the third conditioning device 25. In this regard, the strength of an electromagnetic field and gradient 45 produced by the second conditioning device 20 and electromagnetic device 14 can be selectively increased or decreased as desired or required by manipulating a variable control 15a for voltage and current such as a variable resistor or potentiometer. Further, a variable control 15b for frequency and wavelength can be included and possibly be used to manipulate the frequency and wavelength of the electromagnetic field and gradient 45 being produced. In addition, the second conditioning device 20 can also include a variable control 15c for selecting the type of waveform being produced by the electromagnet device 14, e.g., a square wave, sinusoidal wave, sawtooth, or other waveform. Moreover, a variable control 15d for selecting whether a positive or negative magnetic pole and / or changing electromagnetic field and gradient 45 will be imparted to undesired matter 9 can also possibly be included with the second conditioning device 20 which includes an electromagnet device 14. Further, a variable control 15e for selecting between AC / DC can also be included in a second conditioning device 20 which includes an electromagnet device 14. A second conditioning device can also include a variable control 15f for selecting between power on / off. The magnetic device 11, which can be an electromagnetic device 14, the first conditioning device 5, second conditioning device 20 and third conditioning device and their variable controls 15a-f can be controlled by a computer 36 or medical device including a monitor screen 37, a keyboard 96, touch pad, and mouse. The magnetic device 11 which can be a permanent magnet 12 or electromagnet 14 is typically configured to produce an electromagnetic field and gradient 45 in range between 0.01-1 Tesla. Again, for reference purposes 1 Tesla is equal to 10,000 Gauss, and also 1 Volt (V) per second / (meters) m2.

[0257] Moreover, the Covid-19 virus is also negatively charged, and it is vulnerable to moderate electric fields. Electric field strengths between 106 and 107 Volts (V) Meter (m)−1 which are below the breakdown threshold of water are commonly used in industrial food processing to inactivate pathogens, and electric field strengths less than or equal to 104 Vm−1 can possibly be used without adverse effects as discussed in the article: “The SARS-CoV-2 Spike Protein is Vulnerable To Moderate Electric Fields,” by Arbeitman, Sep. 13, 2021, https: / / www.nature.com / articles / s41467-021-25478-7. The isoelectric point of most viruses are found in the Ph range between 1.9-8.4, and in particular in the Ph range between 3.5-7, as discussed in the article: “Isoelectric Points of Viruses,” August, 2010: https: / / pubmed.ncbi.nlm.nij.gov / 20102425 / . Most bacteria pathogens have a negative electrical charge, and magnetic beads 13 or nanoparticles which have a positive electrical charge can be used to capture, separate and remove them, as discussed in the articles “Using Positively Charged Nanoparticles to Capture Bacteria at Ultralow Concentration,” Jun. 9, 2019, https: / / nanoscalereslett.springeropen.com / articles / 10.1186 / s11671-019-3005-z, and “Electric Charge of Bacterial Antigens,” by Leo Olitzki, Apr. 1, 1932, https: / / www.jimmunol.org / content / 22 / 4 / 251.

[0258] The following U.S. patents disclose the use of magnets and electromagnetic fields having a gradient to separate and remove undesired matter from fluids and / or human blood, and some of these also make use of magnetic beads. U.S. Pat. No. 5,123,901 for “Method For Separating Pathogenic Or Toxic Agents From A Body Fluid And Return To Body” discloses using magnetic beads having a size in the range between 0.01-10 microns which also corresponds to a range between 100,000-1,000,000 paramagnetic beads per milliliter to remove the HIV-1 virus from human blood. U.S. Pat. No. 5,711,871 for “Magnetic Separation Apparatus” discloses such a device in FIG. 1, and also in the corresponding specification. U.S. Pat. No. 6,231,760 for “Apparatus For Mixing And Separation Employing Magnetic Particles,” discloses that configuring two magnets in an opposing relationship with their positive and negative poles each being close to one another causes there to be two areas having a high magnetic attraction, and a neutral center area. Further, this patent also discloses neodymium iron boron or samarium-cobalt magnetics characterized by a maximum energy product also known as BHmax of 25-45 MGOe, that is, megaGauss Oersted, which are made by International Magnaproducts, Inc. of Valparaiso, Indiana. In addition, this patent discloses sequential energization of electromagnets using simple binary on and off, but also analog energization with power being gradually increased and decreased, and then switching the polarity of magnets using 10-200 revolutions per minute to perform mixing. Moreover, this patent discloses using magnetic particles having a size range in diameter from 0.1 um to about 300 um, and a range in magnetic strength between about 200-5000 Gauss. U.S. Pat. No. 6,764,859 for “Device And Method For Mixing Magnetic Particles With A Fluid” discloses in Column 4, Lines 42-57 that having magnets face each other with similar poles helps to perform mixing. U.S. Pat. No. 7,699,979 for “Separation System And Efficient Capture Of Contaminants Using Magnetic Nanoparticles” discloses using magnetic nanoparticles and rotating magnetic fields to separate matter. This patent also suggests that a magnetic field having a strength of 1 Tesla which equals 10,000 Gauss is too high for use with human blood. U.S. Pat. No. 8,870,446 for “Device And Method For Manipulating And Mixing Magnetic Particles In A Liquid Medium,” and also U.S. Pat. No. 8,999,732 for “Method For Manipulating Magnetic Particles In A Liquid Medium” both disclose structures and methods of manipulating and mixing magnetic particles in a liquid. U.S. Pat. No. 9,150,631 for “Engineered Opsonin For Pathogen Detection And Treatment” discloses the use of magnetic beads made the following manufacturers: Dynal, Inc. which makes My One™ Dynabeads® located in Lake Success, New York; PerSeptive Diagnostics, Inc. located in Cambridge, Massachusetts; Invitrogen Corp. located in Carlsbad, California; Cortex Biochem, Inc. located in San Leandro, California; and, Bangs Laboratories located in Fishers, Indiana. U.S. Pat. No. 9,156,037 for “Microfluid Device And Uses Therefore” discloses using magnets to separate target components from fluid, and also the use of at least one collection channel, transfer channel, and removal channel. U.S. Pat. No. 9,389,225 for “Separating Target Analytes Using Alternating Magnetic Fields” discloses using alternating or shifting magnetic fields to separate magnetic and other matter from human blood. U.S. Pat. No. 10,265,457 for “Magnetic Filter Apparatus And Method,” discloses that the typical flow rate of blood to and from a human artery or vein for an adult is approximately between 40-400 milliliters (ml.) per minute (min.) with extracorporeal volume being about 8% of the total blood volume which in an adult having a body weight of 80 kilograms (kg) would be approximately 0.08×6.4 liters=512 ml.

[0259] The typical rates, volumes, and duration for routine (non-emergency) transfusions: are less than or equal to 100 mL / hour for all types of blood components or whole blood during the first 15 minutes; it typically takes 1.5-4 hours for a transfusion of one unit of red blood cells at a rate of 2-5 mL / kg / hour for adults, but equal to or less than 300 mL / hour with children; it typically takes 1 hour to transfuse 250-350 mL of platelets in adults at a rate of 4-8 mL / kg / hour; and, it typically takes 30-60 minutes to transfuse one unit or 200-250 mL of plasma in adults at a rate of 4-8 mL / kg / hour. An average adult who weighs between 150-180 pounds will typically have between 1.2-1.5 gallons which corresponds to about 4,500-5,700 mL of blood in their body. Accordingly, at a rate of 100 mL / minute, it will typically take 45 to 57 minutes for all or most of the blood in the human body to be passed through an extracorporeal tube and closed loop starting from a first puncture site 27a and ending at a second puncture site 27b where the blood would be reinfused.

[0260] U.S. Pat. No. 10,265,457 discloses the use of neodymium iron boron magnets having 45 Newtons (N) of pull at 30 mm and 200 N of pull at 10 mm being disposed proximate to a filter including a plurality of wire screens, a blood pump, an air detector device, and also an air bubble removal device. This patent is assigned to MediSieve, Ltd. located in London, United Kingdom which makes the MediSieve single-use disposable magnetic filter which includes at least one removable and reusable permanent magnet, and can also be used with magnetic beads in order to filter a patient's total blood volume in less than an hour. For more information, see https: / / www.medisieve.com. U.S. Pat. No. 10,274,495 for “System And Method For Separating Cells Incorporating Magnetic Separation” discloses structures and methods for separating cells and matter from blood. U.S. Pat. No. 10,828,414, for “Magnetic Filtration Devices and Methods Relating Thereto” discloses in Column 22, at Lines 31-39: “Longer magnets magnetized across their length in the reversed orientation with like polarities repelling each other and minimal spacing between magnets exhibited strong efficacy in producing suitable magnetic fields for filtration of magnetic particle bound therapeutic agents.” U.S. 20100331753 A1 for “Blood Purification Method And Apparatus For The Treatment Of Malaria” discloses the use of magnetic fields to purify the blood of patients having malaria. All of the patents and patent applications recited in this paragraph are hereby incorporated by reference herein.

[0261] U.S. Patents relating to magnetic mixing devices include: U.S. Pat. Nos. 3,995,835, 6,764,859, 9,636,689, U.S. 20040114458 A1, U.S. 20050286342 A1, U.S. 20070207272 A1, and all of these patents are hereby incorporated herein. In addition, U.S. Patents relating to magnetic separation of particles or other matter from a solid or a liquid include: U.S. Pat. Nos. 3,567,026, 3,676,337, 3,902,994, 3,985,646, 4,054,513, 4,526,681, 4,663,029, 5,137,629, 5,465,849, 5,691,208, 6,361,749, 6,688,473, and all of these patents are hereby incorporated herein.

[0262] U.S. Patents relating to the use of magnetic particles or beads some of which include or disclose medical devices and methods for separating pathogens or toxins from human blood include: U.S. Pat. Nos. 3,531,413, 3,970,518, 3,933,997, 4,018,886, 4,177,253, 4,230,685, 4,267,234, 4,452,773, 4,554,088, 4,628,037, 4,659,678, 4,677,055, 4,695,393, 4,770,183, 4,795,698, 4,895,650, 4,910,148, 5,110,624, 5,123,901, 5,186,827, 5,200,084, 5,238,819, 5,240,855, 5,336,760, 5,385,707, 5,543,158, 5,578,325, 5,674,173, 5,695,946, 5,939,319, 6,033,574, 6,045,925, 6,676,729, 6,878,445, 7,462,446, 8,768,501, JP 58193687, WO 091 / 02811.

[0263] Further, U.S. Patents relating to binding members which can be used in separating pathogens or toxins from human blood include: U.S. Pat. Nos. 4,159,804, 4,219,411, 4,452,773, 4,710,472, 4,795,698, 5,200,084, and all of these patents are hereby incorporated herein.

[0264] In addition, U.S. Patents relating to devices and methods for use in identifying or separating pathogens or toxins from human blood include: U.S. Pat. Nos. 5,123,901, 5,439,586, 5,711,871, 5,951,877, 5,980,479, 6,051,146, 6,071,422, 6,153,113, 6,231,760, 6,280,622, 6,616,623, 7,758,533, 7,601,133, 7,699,979, 8,557,518, 8,841,104, 8,870,446, 8,999,732, 9,150,631, 9,156,037, 9,347,595, 9,389,225, 9,428,547, 9,593,160, 10,265,457, 10,274,495, 10,828,414, U.S. 2010021989 A1, U.S. 20100331753 A1, U.S. 20120065482 A1, U.S. 20130217144 A1, WO 2002094351 A3 WO 2009097151 A1, and all of these patents are hereby incorporated herein.Air Bubble Eliminator Device

[0265] The structures which are sometimes referred to in the medical field as being an air bubble eliminator, or an air bubble filter, or an air bubble trap will be referred to as being an air bubble eliminator device 48 in the specification and air bubble eliminator device in the claims. Examples of commercially available air bubble eliminator devices include the GVS SpeedFLow® 0.2 μm (micron) filter made by GVS Filtration, Inc. of Bologna, Italy which is available from TrueCare Biomedix USA Inc., of South Miami, Florida, and the B. Braun 0.2 μm SUPOR® filter made by B. Braun Medical, Inc. of Bethlehem, Pennsylvania and B. Braun Melsunger AG, located in Melsungen, Germany.Magnetic Beads

[0266] As briefly discussed above, magnetic beads 13 and / or magnetic nanoparticles of different types and compositions have been used in combination with permanent magnets 12 and / or electromagnets 14 in order to mix substances in fluids or blood, but also to separate and remove specific elements, pathogens or toxins in human blood. Magnetic beads 13 can be included inside a filter 4, and / or within the filter media of a filter 4. In this regard, the magnetic beads 13 can be electromagnetically attached to a conductive metal screen 16 of a filter 4. Further, magnetic beads 13 can be disposed proximate to a filter 4 and / or filter device 1. Moreover, magnetic beads 13 and / or magnetic nanoparticles can be placed in fluid communication with a fluid, blood portion and blood 10 of an individual and patient 28. Magnetic beads 13 can be used to help separate and remove metals, materials belonging to the graphene family, nanostructures, trackers, chips and other electronic devices, and / or to otherwise filter and treat the fluid, blood portion and blood of an individual and patient 28. In this regard, BD BioSciences located in San Jose, California makes flow cytometers, cell sorters, and also provides a Covid-19 ebook for identifying and separating different substances in human blood. The following article discloses that magnetic beads can be used in a process for testing for Covid-19: “A Magnetofluidic Platform For SARS-CoV-2 Variant And Respiratory Pathogen Detection,” by Trick et al., May 11, 2021, https: / / pubmed.ncbi.nlm.nih.gov / 34013284 / . Manufacturers of magnetic beads 13 for possible use include the following companies: AMSBIO located in Abingdon, United Kingdom which makes MagSi magnetic beads; IBA Lifesciences GmbH located in Göttingen, Germany which makes MagStrep Type3 XT beads and also a magnetic separator; Audemars Microtec located in Lamone-Cadempino, Switzerland which makes microbeads, microcoils, micromagnets and other related microcomponents; Bang Laboratories located in Fishers, Indiana which makes magnetic beads and microspheres; Cortex Biochem, Inc. located in San Leandro, California; Cube Biotech GmbH of Monheim am Rhein, Germany which makes nanodisks and other products relating to protein testing and purification; Dynal, Inc. which makes My Onem Dynabeads® located in Lake Success, New York; Invitrogen Corp. located in Carlsbad, California; MilliporeSigma located in Burlington, Massachusetts which also makes many other medical related products; Miltenyi Bioted GmbJ of Cologne, Germany which has a location in Cambridge, Massachusetts; PerSeptive Diagnostics, Inc. located in Cambridge, Massachusetts; and, Thermo Fisher Scientific located in Waltham, Massachusetts and having a sales office in Coon Rapids, Minnesota which makes Dynabeads™ including Streptavidin Dynabeads™ M-280, DynaMags™, and other medical related products.Pump Device

[0267] FIG. 30 shows a pump device 26 which has an inlet 31p, an outlet 32p. With reference to current medical practice in the United States, a pump device 26 will typically either be a roller type pump device or a centrifugal type pump device. The pump device 26 can include a variable blood flow control 29 whether onboard or remotely for regulating the speed at which an individual or patient's 28 blood 10 flows in the path or loop beginning from the first needle 8a puncture site 27a on their body 6 which is used for the extraction of their blood 10 and to the second needle 8b disposed at the second puncture site 27b on their body 6 where the treated blood 10 is returned to the individual or patient 28. The inlet 31 of the pump device 26 can be connected to or in fluid communication with the outlet 32 of the filter device 1 by tubing 7, and a valve 30 or roller clamp 85 can also be included for stopping or regulating the flow of blood 10 between the outlet 32 of the filter device 1 and inlet 31 of the pump device 26. Further, the outlet 32 of the pump device 26 can be connected by tubing 7 and also possibly to a valve 30 or roller clamp 85 for stopping or regulating the flow of blood 10 between the pump device 26 and the second needle 8b disposed at a second puncture site 27b for returning the individual or patient's treated blood 10 to their body 6 and bloodstream. For information relating to the history and development of blood pumps including early pulsatile tube compression pumps, but also the modern roller pump and centrifugal pump devices which are being used today, see, e.g., the article “History of Extracorporeal Circulation: The Invention And Modification Of Blood Pumps”: https: / / pubmed.ncbi.nlm.nih.gov / 14653417 / . Once again, when medical equipment such as the pump device 26 is not available, as could be the case in some parts of the so-called third world, the use of a pump device 26 could possibly be omitted and the treatment procedure could simply use the individual's 28 normal blood pressure and also gravity, that is, provided that the first puncture site 27a used for extracting blood 10 would be disposed above the second puncture site 27b used for returning treated blood 10 to the body 6 of an individual and patient 28.

[0268] A pump device 26 can sometimes be already incorporated within and / or also be used in conjunction with other pieces of more sophisticated medical equipment for treating human blood. In this regard, depending upon the particular manufacturer and the model of medical equipment which is available for use and the particular need and requirement, one or more medical devices could be used for pumping blood and / or for also performing more complex tasks relating to extracorporeal blood purification (EBP), and such could include one or more of the following medical procedures: hemofiltration; continuous veno-venous hemofiltration; hemodiafiltration; ultrafiltration; hemodialysis / dialysis which typically uses dialysis filters which can remove molecules with molecular weights of 5,000-10,000 Dalton or more; and, plasmapheresis which typically uses plasma filters and / or centrifuge methods which can remove molecules with molecular weights of 1,000,000-5,000,000 Dalton or more. One makers of dialysis filters is the Nipro Medical Corporation which has an office in Bridgewater, New Jersey, and makes the “Nipro ELISIO™-H Dialyzer|Hollow Fiber Dialyzer|Nipro Medical,” by Nipro, No Date, https: / / nipro.com / products / renal / elisio-h-dialyzer / ; and also see “ELISIO™-H Dialyzer,” by Nipro, No Date, https: / / nipro.com / products / renal / elisio-h-dialyzer / .

[0269] Makers of blood pumps and related equipment include: Masterflex® Peristaltic Pump and Fluid Handling Solutions, distributed by Avantor™ of Visalia, CA, https: / / us.vwr.com / cms / masterflex-fluid-handling-solutions, Baxter International located in Deerfield, Illinois makes the AMIA with SHARESOURCE remote patient monitoring platform, HomeChoice™, HomeChoice PRO™, and THERANOVA™ renal care products and Artificial Kidney AK 98 hemodialysis machine, and many infusion pumps such as model BM-11; B. Braun Medical, Inc. located in Bethlehem, Pennsylvania makes the Outlook®, Infusomat®, Vista®, and Easypump® infusion blood pumps, the Dialog+® Evolution Hemodialysis System, and Plasmat™ Futura System for H.E.L.P.® LDL Apheresis therapy; Medtronic PLC. located in Mounds View, Minnesota makes the Biomedicus Bio-Console® 500 series, the Affinity™ CP, and the BPX-80 Bio Pump™ blood pumps; Thoratec Corporation / Abbott located in Pleasanton, California makes the Thoratec®, CentriMag®, and PediMag®, blood pumps; Terumo Corporation located in Somerset, New Jersey makes the Sams™, CAPIOX® SP, centrifugal blood pumps, Advanced Perfusion System 1 Roller Pump, and also CAPIOX®, Haemonetics®, LipiGuard®, Paul AutoVent SV™, and Pall LeukoGuard® filters, and CAPIOX® Bubble Traps; Qura Srl located in Mirandola, Italy makes centrifugal blood pumps, heat exchangers, and combinations thereof; Braile Biomedica, Ltd located in Sān Josè dio Rio Preto, Brazil makes the Centriflux® and Safira® centrifugal blood pumps and also blood filters; LivaNova, PLC. located in London, United Kingdom makes the Revolution® centrifugal blood pump and Intraoperative Autotransfusion System XTRA®; XENIOS AG / Fresenius Medical Care Company located in Heilbronn, Germany makes the Xenios® Diagonal pump, Xenios® Console for heart and lung support, and extracorporeal membrane oxygenation ECMO devices; Stockert Shiley had made roller blood pumps; and, Getinge AB located in Gothenburg, Sweden makes the Rotaflow RF-32 and RotaFlow II centrifugal blood pumps, Permanent Life Support (PLS) system, and Rotaflow Console. These and other products made by the aforementioned manufacturers can possibly be used in order to help remove metals and / or graphene oxide, graphene hydroxide, magnetic graphene oxide, or other undesired matter from the blood of individuals and patients.

[0270] Further, apheresis machines separate blood into its various components: red blood cells, white blood cells, platelets, and plasma. Examples of commercially available apheresis machines include: the thrombapheresis machine MAGELLAN® made by Arteriocyte Medical Systems located in Hopkinton, Massachusetts; the Bag-Extractor Bio15, Blood Component Extractor BIO45, and BagPRESS Bio45P made by Bioelecttronica located in Milan, Italy; the Benchtop Blood Component Extractor(s) TWIN6920 and ROBOTIC6960 made by BMS / Wuhan BMS Medicalteh Co., Ltd. located in Wuhan, China; the Plasmat Futura Apheresis System made by B. Braun located in Bethlehem, Pennsylvania; the Automatic Blood Component Extractor GIOTTO MONZA made by Delcon located in Grassobbio, Italy; the Automatic Blood Component Extractor DSEP series made by Demophorius Healthcare located in Limassol, Cyprus; the Erythropheresis Machine ALYS™ made by Fenwal™ located in Lake Zurich, Illinois; the Fractiomatic® Plus 2 Automated Blood Component Separator made by GRIFOLS located in Sant Cugat del Vallés, Spain; the plasmapheresis machine MCS+ 8150 made by ‘Haemonetics® located in Salt Lake City, Utah; the plasmapheresis machine XJ-II made by Haier Biomedical located in Sunbury Surrey, United Kingdom; the CF300 Plasma Adsorption Monitor made by INFOMED located in Geneva, Switzerland; the Autophereis-C Plasma Collection System, Aurora Plasma Collection System, and Alyx Apheresis Collection System made by Fresenius Kabi located in Lake Zurich, Illinois; the adsorption type plasma purification devices LIPOSORBER™ and Lixelle™ and the DX-21 apheresis machine made by Kaneka Medix Corporation located in Minato-Ku, Tokyo, Japan; the Automated Blood Component Extractor Luxomatic V2 made by LMB located in Schwaig, Germany; the leukapheresis machine LA25 and therapeutic apheresis machine AFTERSMART made by Medica located in Medolla, Italy; the ADAsorb® Therapeutic Apheresis System made by Medicap located in Ulrichstein, Germany; the transfusion apheresis machines TRIMA ACCEL® and Trim Accel® 7 made by Terumo located in Somerset, New Jersey; and, the plasmapheresis machine PCM made by Zhengyuan Technology Company, Ltd., (ZYT) located in China. Again, these and other products made by the aforementioned manufacturers can possibly be used in order to help remove undesired matter from the blood of individuals and patients.

[0271] In addition, when a medical practitioner is treating individuals and patients who are seriously ill and infected with the Covid-19 virus, other medical devices can possibly be used to remove the Covid-19 virus and / or cytokines from their bloodstream: e.g., the Extracorporeal Blood Purification (EBP) Device which can use the Oxiris® filter set and PrisMax® and Prismaflex® systems made by the Baxter Healthcare Corporation located in Deerfield, Illinois; the Seraph® 100 Microbind® Affinity Blood Filter and Extracorporeal Blood Purification (EBP) Device which us...

Claims

1. A method of treating an individual having undesired matter in their blood, the method comprising the steps of:inserting a first needle into a first vein or artery of said individual at a first puncture site on said individual and connecting said first needle to at least one piece of tubing;connecting said at least one piece of tubing to a filter device comprising a top side, a bottom side, at least one lateral side, an inlet, an outlet, and a chamber comprising at least one of a mesh, a screen, and a filter media which is capable of capturing, trapping, or adsorbing at least of portion of said undesired matter and disposing said filter device between said first puncture site and said second puncture site;connecting said at least one piece of tubing to a second needle;inserting said second needle into a second vein or artery of said individual at a second puncture site;initiating the flow of said blood from said first puncture site through said at least one piece of tubing and said filter device;providing a source of an electromagnetic field and applying said electromagnetic field proximate to said filter device causing said at least a portion of said undesired matter to be separated from said blood and to be captured, trapped, or adsorbed in said filter device; and,reinfusing said blood which has been filtered through said second puncture site.

2. The method of treating an individual having undesired matter in their blood according to claim 1, further comprising a step of disposing a magnet device to provide said electromagnetic field proximate to said filter device.

3. The method of treating an individual having undesired matter in their blood according to claim 1, further comprising a step of including a stop valve on said at least one piece of tubing and / or on said filter, and manipulating said stop valve to initiate said flow of said blood from said first puncture site through said at least one piece of tubing and said filter device and to said second puncture site.

4. The method of treating an individual having undesired matter in their blood according to claim 1, further comprising providing an air bubble eliminator device in communication with said at least one piece of tubing and / or said filter device between said first puncture site and said second puncture site such that any air bubbles are removed from said filtered blood.

5. The method of treating an individual having undesired matter in their blood according to claim 1, wherein said filter media comprises a plurality of magnetic beads.

6. The method of treating an individual having undesired matter in their blood according to claim 1, wherein said undesired matter comprises at least one of a metal, a nanometal, a graphene oxide, a graphene hydroxide, a magnetic graphene oxide, an electronic chip or other electronic device, a pathogen, a bacterium, an abnormal or cancerous cell, a virus, a spike protein, a blood cell infected with a virus, a COVID-19 virus, and a toxin.

7. The method of treating an individual having undesired matter in their blood according to claim 1, further comprises providing a blood dispersion device and causing said blood to be dispersed between said first puncture site and said second puncture site.

8. The method of treating an individual having undesired matter in their blood according to claim 1, further comprising providing a blood pump, and manipulating said blood pump to pump said blood between said first puncture site and said second puncture site.

9. The method of treating an individual having undesired matter in their blood according to claim 1, further comprising providing an analyte sensor, and causing said blood to be analyzed by said analyte sensor between said first puncture site and said second puncture site.

10. The method of treating an individual having undesired matter in their blood according to claim 1, further comprising providing an optical device and observing said blood between said first puncture site and said second puncture site.

11. The method of treating an individual having undesired matter in their blood according to claim 1, further comprising providing a blood conditioning device which is disposed between said first puncture site and said second puncture site.

12. The method of treating an individual having undesired matter in their blood according to claim 11, wherein said blood conditioning devices comprises an ultrasound device for implementing a vibration excitation to disable and / or destroy and / or remove said at least a portion of said undesired matter in said blood.

13. The method of treating an individual having undesired matter in their blood according to claim 12, wherein said vibration excitation is selected in the range between 5-10 MHz.

14. The method of treating an individual having undesired matter in their blood according to claim 11, wherein said blood conditioning device comprising an ultraviolet light device for exposing said blood to UV-A ultraviolet light having a wavelength in the range between 315-400 nanometers, and / or UV-B ultraviolet light having a wavelength in the range between 280-315 nanometers, and / or UV-C ultraviolet light having a wavelength in the range between 10-400 nanometers to disable and / or destroy and / or remove said at least a portion of said undesired matter in said blood.

15. The method of treating an individual having undesired matter in their blood according to claim 1, wherein said at least one piece of tubing is treated with heparin to prevent blood clotting.

16. A method of treating human blood or a blood portion which includes undesired matter, the method comprising the steps of: causing said human blood or said blood portion to be passed in proximity to a source of ultraviolet light comprising the sun, and exposing said blood or blood portion to said ultraviolet light, and collecting and storing said blood or said blood portion which has been treated.

17. The method of treating human blood or a blood portion which includes undesired matter according to claim 16, further providing a filter device comprising at least one of a mesh, a screen, and a filter media which is capable of capturing, trapping, or adsorbing at least of portion of said undesired matter, and causing said blood or said blood portion to be passed through said filter device before collecting and storing said blood or said blood portion which has been treated.

18. The method of treating human blood or a blood portion which includes undesired matter according to claim 17, further providing a source of an electromagnetic field and applying said electromagnetic field proximate to said filter device causing said at least a portion of said undesired matter to be separated from said blood and to be captured, trapped, or adsorbed in said filter device.

19. The method of treating human blood or a blood portion which includes undesired matter according to claim 16, further causing said human blood or said blood portion to be placed or passed in proximity to a source of ultrasound vibration excitation, and exposing said blood or said blood portion to said ultrasound vibration excitation, and collecting and storing said blood or said blood portion which has been treated.

20. A method of treating human blood or a blood portion which includes undesired matter, the method comprising the steps of:providing a filter device which is capable of capturing, trapping, or adsorbing at least of portion of said undesired matter and causing said blood or blood portion to pass through said filter device;providing a source of an electromagnetic field and applying said electromagnetic field proximate to said filter device causing said at least a portion of said undesired matter to be separated from said blood and to be captured, trapped, or adsorbed in said filter device; and,providing a source of ultraviolet light and causing said human blood or said blood portion to be exposed to said ultraviolet light; and,collecting and storing said blood or said blood portion which has been treated.

Images